UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2024

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to __________________

 

Commission File Number 001-40615

 

QUANTUM COMPUTING INC.

(Exact name of registrant as specified in its charter)

 

Delaware   82-4533053
(State or other jurisdiction of
incorporation or organization)
  (I.R.S Employer
Identification No.)
     
5 Marine View Plaza, Suite 214, Hoboken, NJ   07030
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (703) 436-2121

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.0001   QUBT   The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. 

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐  No .

 

The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2024 was $34,743,396 based on the closing price of $0.50 per share of Quantum Computing Inc. common stock on the Nasdaq Stock Market LLC on that date.

 

As of March 18, 2025, there were 137,244,545 shares of the registrant’s common stock issued and outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

None

 

 

 

 

 

 

TABLE OF CONTENTS

 

  PART I 1
     
ITEM 1. BUSINESS. 1
     
ITEM 1A. RISK FACTORS. 7
     
ITEM 1B. UNRESOLVED STAFF COMMENTS. 26
     
ITEM 1C. CYBERSECURITY. 26
     
ITEM 2. PROPERTIES. 27
     
ITEM 3. LEGAL PROCEEDINGS. 27
     
ITEM 4. MINE SAFETY DISCLOSURES. 28
     
  PART II 29
     
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. 29
     
ITEM 6. [RESERVED] 29
     
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 29
     
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. 36
     
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. 36
     
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. 36
     
ITEM 9A. CONTROLS AND PROCEDURES. 36
     
ITEM 9B. OTHER INFORMATION. 37
     
ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS. 37
     
  PART III 38
     
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. 38
     
ITEM 11. EXECUTIVE COMPENSATION. 43
     
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. 46
     
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. 48
     
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 48
     
  PART IV 49
     
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. 49

 

Introductory Comments

 

Throughout this Annual Report on Form 10-K, the terms “we,” “us,” “our,” “the Company,” “our Company,” “QCi” and “QUBT,” refer to Quantum Computing Inc., a Delaware corporation, and unless the context indicates otherwise, also includes our wholly-owned subsidiaries.

 

i

 

 

PART I

 

FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements.

 

These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Annual Report on Form 10-K. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Annual Report on Form 10-K to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of this Annual Report on Form 10-K as well as those discussed elsewhere in this Annual Report on Form 10-K. We qualify all of our forward-looking statements by these cautionary statements.

 

ITEM 1. BUSINESS.

 

The High-Performance Computing Landscape

 

There is a large and growing demand for ever-increasing computational performance in information processing and data storage. The recent emergence of artificial intelligence, large language models, and machine learning algorithms has added to the need for efficient processing of vast volumes of data. Classical computers that use silicon microprocessors are understood to have performance limitations in solving certain classes of computational problems, in particular, optimization problems. Solving large optimization problems requires complex calculations that cannot currently be performed in a reasonable amount of time using classical computing systems for problem sizes relevant to many industrial and real-world applications.

 

There is a growing belief among computer science experts that quantum computing, which uses quantum mechanics to solve problems faster than traditional computers, may offer a potential solution to the hard limits now being approached by classical computers. In addition to new computational methodologies using quantum mechanics, there is a corresponding emergence of new materials in microprocessors that may be able to overcome some of the limitations of the silicon based processors used in classical computers. One promising area is in the use of photonics, which uses particles of light for computation. We believe that these emerging approaches will create an opportunity for new materials and methods that can meet the growing demand for scalable performance and power efficiency. While it is difficult to determine the date that quantum computers will begin to have practical relevance, we believe that quantum computers with gradually increasing performance will be introduced by multiple vendors over the next five years.

 

The Company

 

Quantum Computing Inc. is an American company utilizing integrated photonics and non-linear quantum optics to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging and cybersecurity applications. Our vision is to lead the revolution in photonics and quantum computing with scalable, accessible, and affordable solutions for real-world problems. QCi’s products are designed to operate at room temperature and at very low power levels compared to other quantum systems currently available in the market, such as superconducting, ion-trap, or annealing architectures. Our acquisition of QPhoton, Inc. (the “QPhoton Merger”) in June 2022, enabled us to offer the aforementioned products, integrated with the Company’s software platform, Qatalyst, that existed before the QPhoton Merger.

 

1

 

 

QCi’s proprietary core technology rests in our ability to condition, manipulate, and measure single photons (particles of light). Specifically, our integrated photonics approach exploits the non-linear capabilities of photons (our “Core Photonics Technology”). Our Entropy Quantum Computer (“EQC”) is a quantum application of our Core Photonics Technology, designed to solve complex optimization problems. EQC is based on a patent-pending methodology that utilizes the energy in the environment to drive controlled feedback through energy loss in a photonic circuit architecture. The EQC’s use of the environment as an integral part of the system is in sharp contrast to competing quantum approaches, including the aforementioned superconducting, trapped-ion, and annealing architectures, which seek to establish stable quantum states by the complete elimination of environmental effects. As a result, the EQC consumes less power than these competing methods and operates at room temperature making it compatible with an ordinary server room environment. We anticipate that our EQC will enable us to develop and produce multiple generations of quantum machines with increasing computational power, scalability, and speed.

 

Our longer-term product development plan is to migrate product designs based on discrete components, including EQC’s current design, to a set of optical integrated circuits built on wafers using a crystalline material called lithium niobate (“Thin Film Lithium Niobate” or “TFLN”). The Company believes that TFLN is an excellent material for optical integrated circuit design, given its advantageous optical properties (both linear and non-linear) and its compatibility with silicon-based semiconductor fabrication methods. The Company is completing the buildout of a state-of-the-art TFLN chip manufacturing facility in a leased space within Arizona State University’s Research Park in Tempe, Arizona (the “AZ Chips Facility”).

 

In addition to our EQC technology, we have leveraged QCi’s core photonics technology to demonstrate powerful quantum sensing use cases in LIDAR (light detection and ranging) (a technology that uses pulsed laser light to measure distances to objects by calculating the time it takes for the reflected light to return), reservoir computing (a form of neural network that can be used in machine learning applications and quantum cyber authentication (a method for highly secure communication within a network). Several of these technologies are in the early stages of commercialization and several are available to customers through our research & development offerings.

 

Our Strategy

 

QCi’s strategy is to provide a range of accessible and affordable quantum machines to commercial and government markets, supported by professional services through our “Quantum Solutions” offering. Our proprietary technology is central to our strategy because we believe that it enables us to leverage the advantages of size, weight, power, and cost over competing cryogenic products. We further differentiate ourselves in the market by offering, in addition to cloud-based access to our quantum computers, on-premises installation of our EQC product, which is rack-mountable and compatible with standard server room infrastructure and requires no special cooling, shielding, or power considerations.

 

Further, our EQC development plan to gradually replace discrete optical components with photonic integrated circuits will provide us the ability to fabricate and sell a range of custom lithium niobate chips for use in our own product lines as well as TFLN Optical Chips, as defined below, for sale into existing commercial markets for optical devices.

 

Market Opportunity

 

The Company believes that quantum solutions have the potential to bring significant and increasing advances in the fields of medicine, engineering, autonomous vehicles, energy management, and cybersecurity and that the demand for quantum computing in these market sectors will likely outpace and outperform the general-purpose universal computing market in the near- to mid-term and into the foreseeable future. We believe that our core photonics technology applications offer practical, cost-effective solutions that can materially advance the adoption of quantum machines across several market segments including:

 

1.Quantum computing, including quantum optimization computing

 

2.Reservoir computing, including edge hardware devices

 

2

 

 

3.Remote sensing and imaging, including LiDAR and quantum photonic vibrometry

 

4.Cybersecurity, including authentication

 

While the current quantum computing market comprises a fraction of the broader high-performance computing market, we anticipate that quantum computers will unlock new applications that are unlikely to be addressable by existing high-performance computers comprised of leveraging classical processing units. Estimates of the size of the global high-performance computing industry vary, but according to Grand View Research, the high-performance computing market was valued at $39.1 billion in 2019 and is expected to reach a value of $53.6 billion by 2027, see Grand View Research - High Performance Computing Market Size Worth $53.6 Billion By 2027, https://www.grandviewresearch.com/press-release/global-high-performance-computing-hpc-market According to a report from Allied Market Research, the global enterprise quantum computing market size was valued at $1.3 billion in 2020 and is projected to reach $18.3 billion by 2030, growing at a compound annual growth rate of 29.7% from 2021 to 2030, according to a published report on the enterprise quantum computing market at https://www.alliedmarketresearch.com/enterprise-quantum-computing-market (Information contained on, or that can be accessed through, these websites is not incorporated by reference in this Annual Report, and you should not consider information on these websites to be part of this Annual Report).

 

As an early participant in this rapidly growing market, we believe we are well-positioned to capture a meaningful amount of this growth. We also believe that there is further potential upside from quantum computing and technology more broadly opening new markets not included in traditional high-performance computing market size estimates.

 

Additionally, we believe that our foundry services offering will address the growing TFLN market and photonic integrated circuit markets. A recent Market Research Reports: Document ID: LPI08232779; Published August 8, 2023 Thin Film Lithium Niobate Market Forecast 2023 – 2029,” indicates a significant potential market growth for TFLN devices. The study covers use applications and segments that forecast the global TFLN electro-optical modulator market, valued at $190.4 million in 2022, to grow an estimated $1,931.3 million by 2029 - a compound annual growth rate of 39 percent. The report further describes how such increase in demand is expected to be principally driven by the material advantages described above. Specifically, TFLN electro-optical modulators have the advantages of large bandwidth, low power consumption, and small size. Further, Mordor Intelligence published a market report, “Photonic Integrated Circuit Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)” forecasts that the photonic integrated circuit (PIC) market, currently valued at $15.1 billion, will grow at a compound annual growth rate of 20.5% to $38.4 billion in 2029. We believe that this suggests significant potential demand for QCi’s products and services.

 

Products and Products in Development 

 

The Company believes it is well-positioned in the marketplace due to its Core Photonics Technology in integrated photonics that allows QCi to offer a suite of quantum machines to the market today with a robust technology roadmap for the future. The QPhoton Merger substantially broadened the Company’s technology portfolio and enabled us to develop a group of closely related products to EQC, based on our underlying Core Photonics Technology.

 

TFLN Optical Chips

 

We believe that TFLN optical integrated circuits (“TFLN Optical Chips”) will ultimately provide the greatest scalability and performance advantages for quantum information processing, sensing, and imaging applications. While the Company is developing proprietary chip designs to for TFLN Optical Chips for exclusive use in our products for the aforementioned applications, the Company’s foundry services offering at our AZ Chips Facility will make available a range of custom TFLN chips (custom single photon detectors) for sale into existing commercial markets, including optical devices such as electro-optical modulators, periodically poled devices for frequency conversion and micro ring resonator cavities.

 

3

 

 

Entropy Quantum Computer

 

QCi launched a new EQC device during the first quarter of 2024 (Dirac-3) and plans to release a series of additional EQC products in the coming years that build and expand upon the same analog architecture. This planned evolution of technology and product enhancements will involve improving the size and capacity of the EQC machines, as well as speed, scalability, and performance fidelity. The EQC is available both as a cloud-based subscription service, similar to other quantum machines, as well as an affordable on-premises solution.

 

EQC is a full-stack system, incorporating QCi’s custom user interface software Qatalyst, which allows users to avoid the complexity of software development kits (“SDKs”) at the circuit level and has evolved from QCi’s primary SaaS offering to the software that powers our offerings. Operating on EQC, Qatalyst enables developers to create and execute quantum-ready applications using application programming interfaces. Users can then use these same interfaces on conventional computers to achieve optimization performance advantages using our cloud-based solution.

 

Reservoir Computer

 

Launched in June 2023, QCi’s first reservoir computing product is an edge device that used an integrated circuit that can be reprogrammed after manufacturing and optimized for recurrent neural network applications. An “edge device” allows the user to process, measure, and analyze data locally (at the user’s device) as opposed to over a network where data must be sent over the internet or through some cloud service. QCi’s Reservoir Computer (“RC”) is a standalone device that can be plugged into a local computer or server without having to connect over the internet. We believe that the RC’s hardware-based approach to reservoir computing has advantages over more traditional software approaches, including significantly faster processing speeds, 80% - 95% less energy consumption, portability (size of power bank), affordability, and requiring significantly shorter training time. Our benchmarking analyses further show that the RC is capable of delivering superior performance in time-dependent tasks, such as chaotic time series prediction, unstructured financial model prediction, natural language processing, and weather forecasting. To date, the market for reservoir computing has been limited due to computing cost and technical implementation complexities, which we designed the RC to address. We anticipate that future generations of the RC will introduce greater speed of performance and scalability, which will enable the RC to participate in large language model training and other applications. While technology challenges remain in scaling this technology, this is one of our focus areas to gain a significant share in the artificial intelligence / machine learning hardware market.

 

LiDAR and Quantum Photonic Vibrometer

 

QCi’s LiDAR uses patented methodologies that leverage the selective use of spatial-temporal modes to maximize the signal-to-noise ratio of weak information signals in a high-noise background. This technology allows QCi machines to see through dense fog and provide image fidelity at great distances with very high resolution in difficult environments such as snow, ice, and water. The practical benefits on payload and signal-to-noise enhancement can be used to produce LiDAR machines that are greatly enhanced in their ability to measure at improved resolution and distances from aircraft, drones, and even satellites.

 

Launched July 2023, QCi’s Quantum Photonic Vibrometer is a proprietary, powerful instrument for remote vibration detection, sensing, and inspection. We believe that this device offers significant advancements in sensitivity, speed, and resolution, capable of discerning for the first time, highly obscured and non-line-of-sight objects. The Quantum Photonic Vibrometer measures the vibration frequency of a remote target by utilizing fast-gated single photon counting to directly detect returning photons whose wavefunctions are dynamically modulated as they are reflected off the target. By counting photons at a megahertz rate, important properties such as material composition and mechanical integrity can be determined within seconds and, depending on detection distance, with microwatt to milliwatt optical power. Working at an eye-safe wavelength, the system can accurately characterize the vibration spectra of solid or liquid targets with vibration amplitude as small as 100 nanometers.

 

Quantum Networks and Quantum Authentication

 

QCi has developed a prototype system to address one of the major challenges in cybersecurity, the authentication of users on a network, which is currently facilitated by the distribution of “private keys” by a trusted third party. This approach is inherently insecure as keys are bundled and travel with the encrypted data, making it susceptible to harvest-and-decrypt-later vulnerability. QCi has developed a quantum authentication technology and methodology that eliminates the need for trust in third-party involvement in key distribution. Our approach uses a combination of a high-powered laser, and a patented detection methodology deeply rooted in the fundamental principles of quantum mechanics, resulting in what we believe will be an unbreakable basis for private network communication.

 

4

 

 

Competition

 

The quantum computing industry is highly competitive and rapidly evolving and will likely remain so for the foreseeable future. As this industry continues to grow and mature, we expect a continued influx of new competitors, products, hardware advances, and concepts to emerge that can dramatically transform the industry and our business. Due to the high price point of quantum computing hardware today, novel business models may emerge to adapt to customer preferences in the high-performance computing industry. Our ability to evolve and adapt rapidly over an extended period of time will be critical in remaining competitive. We perform a broad range of research and development efforts to identify and position for the changing demands of future customers and users, industry trends, and competitive forces.

 

According to research conducted by The Quantum Insider, there are over 700 companies and approximately 400 university academic groups working in various aspects of quantum technology, with approximately 400 of these having a pure-play focus on quantum computing.

 

These entities range in size from diversified global companies with significant research and development resources such as IBM, Google, Intel, Microsoft, Quantinuum (formerly Honeywell) and Amazon to recent market entrants such as D-Wave Quantum, Rigetti Computing, IonQ, PsiQuantum, Xanadu and Infleqtion (formerly ColdQuanta), as well as smaller privately funded development stage companies whose narrower product focuses may allow them to be more effective in deploying resources towards a specific industry demand. In addition, we face competition from large research organizations funded by sovereign nations such as China, Russia, Canada, Australia, and the United Kingdom, as well as the European Union, and we believe that additional countries will invest in quantum computing in the future. We will continue to face competition from the existing high-performance computing industry using classical (non-quantum) computers.

 

We believe that competition in this market segment will intensify. Many of our competitors may have longer operating histories, significantly greater financial, technical, product development, and marketing resources, and greater name recognition than we do. Our competitors could use these resources to market or develop products or services that are more effective or less costly than any or all of our products or services.

 

Intellectual Property

 

Our intellectual property consists of patents, trademarks, and trade secrets. Our trade secrets consist of product formulas, research and development, and unpatentable know-how, all of which we seek to protect, in part, by confidentiality agreements. To protect our intellectual property, we rely on a combination of laws and regulations, as well as contractual restrictions. Federal trademark law protects our registered trademarks. We also rely on the protection of laws regarding unregistered copyrights for certain content we create and trade secret laws to protect our proprietary technology. To further protect our intellectual property, we enter into confidentiality agreements with our executive officers, employees, consultants and directors.

 

1 Seskir, Z.C., Korkmaz, R. & Aydinoglu, A.U., The landscape of the quantum start-up ecosystem, EPJ Quantum Technol. 9, 27 (2022), at https://doi.org/10.1140/epjqt/s40507-022-00146-x

 

5

 

 

Trademarks

 

The Company has three registered trademarks, “QPhoton,” “QGraph” and “Qatalyst.” The Company has no pending trademark applications.

 

Patents

 

The Company has two granted United States patents.

 

Country  Serial
No.
  Filing
Date
  Patent
No.
  Issue
Date
  Title  Status  Anticipated
Expiration
Date
USA  17/560,816 12/23/2021  11,436,519  09/06/2022  Machine Learning Mapping for Quantum Processing Units   Granted  12/23/2041
USA  17/810,198 06/30/2022  12,008,436  06/11/2024  Machine Learning Mapping for Quantum Processing Units   Granted  06/30/2042

  

Exclusive License Agreement

 

QCi has an exclusive license to seven patents issued to the Stevens Institute of Technology, pursuant to the license agreement dated December 17, 2020 by and among QPhoton and The Trustees of The Stevens Institute of Technology (the “Licensor”). QPhoton agreed to reimburse the Licensor for patent prosecution expenses in the amount of $125,041 and deliver to the Licensor an annual report and quarterly report pursuant to the terms of the license agreement. As consideration for the license and other rights granted under the license agreement, QPhoton agreed to pay the Licensor (i) $35,000 upon full execution of the license agreement, (ii) $28,000 each annual anniversary of the effective date of the license agreement, (iii) 9% of the membership units of QPhoton and (iv) a royalty of 3.5% of the net sales price of each licensed product sold or license by QPhoton and any affiliate and sublicensee. On June 15, 2022, the Licensor agreed to assign the license agreement to QCi upon consummation of the QPhoton Merger.

 

Government Regulation and Incentives

 

Export Regulation

 

The U.S. government issued regulations in 2024 placing some restrictions on exporting quantum computing products under the Export Administration Act. Those exports will now require a license. We are reviewing the new regulations but do not believe they will have a substantial adverse impact on the Company. The U.S. government has also placed some export restrictions on certain types of cryogenic quantum computing equipment as well as some optical materials. At this time, however, we do not expect there to be significant export limitations on the Company’s products.

 

Incentives

 

The Creating Helpful Incentives to Produce Semiconductors Act of 2022 (the “CHIPS Act”) was designed to address the global computer chip shortage and attract chip manufacturing, and innovation to the United States. The CHIPS Act is a $280 billion spending package aimed at encouraging the growth of the US-based semiconductor industry. To assist in securing the domestic chip supply, the CHIPS Act provides $52.7 billion for American semiconductor research, development, manufacturing, and workforce development. The Company is pursuing opportunities under the CHIPS Act but there is no guarantee that it will actually receive any funding thereunder.

 

Corporate Information

 

Our executive offices are located at 5 Marine View Plaza, Suite 214, Hoboken, NJ 07030, and our telephone number is (703) 436-2121. Our corporate website is www.quantumcomputinginc.com. Information appearing on our website is not part of this Annual Report.

 

Employees

 

As of December 31, 2024, the Company had 41 full-time employees and nine part-time contract staff, 34 of whom are focused on product development. Our employees are not part of a collective bargaining agreement and we believe that our relationships with our employees and contract workers are good. The Company offers a health and welfare benefit plan to current full-time employees that provides medical, dental, vision, life, and disability benefits. The Company also offers a 401(k) retirement savings plan and participation in the stock option plan to all full-time employees. There are no unpaid liabilities under the Company’s benefit plans, and the Company has no obligation to pay for post-retirement health and medical costs of retired employees.

 

6

 

 

ITEM 1A. RISK FACTORS.

 

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties, such as statements of our objectives, expectations and intentions. The cautionary statements made in this Annual Report on Form 10-K should be read as applicable to all forward-looking statements wherever they appear in this report. Our actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences include those discussed below, as well as those discussed elsewhere in this Annual Report on Form 10-K.

 

Risks Related to Our Financial Condition and Status as an Early-Stage Company

 

We are in our early stages and have a limited operating history, which makes it difficult to forecast the future results of our operations.

 

QCi was formed in 2018 and merged with QPhoton in June 2022. As a result of our limited operating history, our ability to accurately forecast our future results of operations is limited and subject to a number of uncertainties, including our ability to plan for and model future growth. Our ability to generate revenues will largely be dependent on our ability to develop and produce a suite of products based on quantum photonic technologies, with steadily increasing capabilities. Our technical roadmap may not be realized as quickly as hoped, or even at all. As a result, our historical results should not be considered indicative of our future performance. Further, in future periods, our growth could slow or decline for a number of reasons, including but not limited to slowing demand for our quantum products and services, increased competition, changes to technology, our inability to scale up our technology, a decrease in the growth of the market, or our failure, for any reason, to continue to take advantage of growth opportunities. Furthermore, the accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. We have not emerged from the development stage and may be unable to raise further equity. These factors, among others, that raise substantial doubt about our ability to continue as a going concern may be partially or fully mitigated by the net proceeds received by the Company in conjunction with the sale of 8,163,266 shares of Common Stock (the “PIPE Shares”) issued to the investors pursuant to certain Securities Purchase Agreements dated January 7, 2025. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty or from the sale of the PIPE Shares.

 

We have also encountered, and will continue to encounter, risks and uncertainties frequently experienced by growing companies in rapidly changing industries. If our assumptions regarding these risks and uncertainties and our future growth are incorrect or change, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations, and our business could suffer. Our success as a business ultimately relies upon fundamental research and development breakthroughs in the coming years. There is no certainty these research and development milestones will be achieved as quickly as hoped, or even at all.

 

We have a history of operating losses and expect to incur significant expenses and continuing losses for the foreseeable future.

 

We incurred net losses each year since 2018 and we believe that we will continue to incur operating and net losses each quarter until at least the time we begin generating significant revenue from our products and services, which may never occur. Even with significant production, we may never become profitable from the sale of our products and services.

 

We expect to incur significantly higher losses in future periods as we continue to incur significant expenses in connection with the design, development and manufacturing of our quantum computers and other products and services, and as we expand our research and development activities, invest in manufacturing capabilities, build up inventories of components for our quantum computers and other products, increase our sales and marketing activities, develop our infrastructure, and increase our general and administrative functions to support our growing operations. We may find that these efforts are more expensive than we currently anticipate or that these efforts may not result in revenues, which would further increase our losses. If we are unable to achieve and/or sustain profitability, or if we are unable to achieve the growth that we expect from these investments, it could have a material adverse effect on our business, financial condition or results of operations. Our business model is unproven and may never allow us to cover our costs.

 

7

 

 

We have a history of accumulated deficits, recurring losses and negative cash flows from operating activities. We may be unable to achieve or sustain profitability or remain a going concern.

 

We are an early-stage company and we have not generated any material revenues to offset our operating expenses. We incurred negative cash flows from operating activities and recurring net losses in fiscal years 2024 and 2023. As of December 31, 2024 and 2023, our accumulated deficit was $200.5 million and $131.9 million, respectively. If we are unable to generate significant revenues in future periods, we will not be able to achieve profitability, and if we should achieve, to maintain profitability. Beyond this, we may incur significant losses in the future for a number of reasons including other risks described in this document, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown events. Accordingly, we may not ever achieve profitability.

 

We may not be able to scale our business quickly enough to meet customer and market demand, which could adversely affect our financial condition and results of operations or cause us to fail to execute on our business strategies.

 

In order to grow our business, we will need to continually evolve and scale our business and operations to meet customer and market demand. Quantum computing technology has never been sold at large-scale commercial levels. Evolving and scaling our business and operations places increased demands on our management as well as our financial and operational resources to:

 

attract new customers and grow our customer base;

 

maintain and increase the rates at which existing customers use our platform, sell additional products and services to our existing customers, and reduce customer churn;

 

invest in our platform and product offerings;

 

effectively manage organizational change;

 

accelerate and/or refocus research and development activities;

 

expand manufacturing and supply chain capacity;

 

increase sales and marketing efforts;

 

broaden customer support and services capabilities;

 

maintain or increase operational efficiencies;

 

implement appropriate operational and financial systems; and

 

establish and maintain effective financial controls and procedures.

 

Commercial traction of quantum computing technology may never occur. We have no experience in producing large quantities of our products and are currently constructing advanced generations of our products. There are significant technological challenges associated with developing, producing, marketing and selling products and services in the high-performance computing industry, including our products and services, and we may not be able to resolve all of the difficulties that may arise in a timely or cost-effective manner, or at all. We may not be able to cost effectively manage production at a scale or quality consistent with customer demand in a timely or economical manner.

 

Our ability to scale is dependent also upon components that we must source from multiple countries, including China. Shortages or supply interruptions in any of these components will adversely impact our ability to generate revenues. Recent tensions between the United States and China have resulted in the U.S.’s imposition of a series of tariffs and other restrictions on imports from China [and sourcing from certain Chinese persons or entities, as well as other business restrictions. Further, deterioration in the political relationship between the U.S. and China result in loss of access to suppliers of key components with little or no warning, which would adversely affect our ability to develop and manufacture our products. We are actively searching for alternative suppliers outside of China, but there is no assurance that we can locate comparable components at reasonable prices within the desired timeframes.

 

If we commence large-scale development of our quantum computers and other products, they may contain defects in design and manufacture that may cause them to not perform as expected or that may require repair and design changes. Our quantum computers are inherently complex and incorporate technology and components that may note have been used for computing products and that may contain defects and errors, particularly when first introduced. We have a limited frame of reference from which to evaluate the long-term performance of our computers. There can be no assurance that we will be able to detect and fix any defects in our quantum computers in a timely manner that does not disrupt our services to our customers. If our technology fails to perform as expected, customers may seek out a competitor or turn away from quantum computing entirely, each of which could adversely affect our sales and brand and could adversely affect our business, prospects and results of operations. If defects in our technology lead to erroneous outputs, third parties relying on those outputs may draw from them erroneous conclusions, creating a risk that we will be liable to those third parties.

 

8

 

 

If we cannot evolve and scale our business and operations effectively, we may not be able to execute our business strategies in a cost-effective manner and our business, financial condition, profitability and results of operations could be adversely affected.

 

Even if the market in which we compete achieves its anticipated growth levels, our business could fail to grow at similar rates, if at all.

 

Our success will depend upon our ability to expand, scale our operations, and increase our sales and support capability. Even if the market in which we compete meets the size estimates and growth forecasted, our business could fail to grow at similar rates, if at all.

 

Our growth is dependent upon our ability to successfully expand our products and services, retain customers, bring in new customers and retain critical talent. Unforeseen issues associated with scaling up and constructing quantum computing technology at commercially viable levels could negatively impact our business, financial condition and results of operations.

 

Our growth is dependent upon our ability to successfully market and sell our quantum computers and quantum computing products and services. We do not have experience with the large-scale production and sale of quantum computing technology. Our growth and long-term success will depend upon the development of our sales and production capabilities.

 

Moreover, because of our advanced technology, our customers will require particular support and service functions, some of which are not currently available and may never be available. If we experience delays in adding such support capacity or servicing our customers efficiently, or experience unforeseen issues with the reliability of our technology, we could overburden our servicing and support capabilities. Similarly, increasing the number of our products and services would require us to rapidly increase the availability of these services. Failure to adequately support and service our customers may inhibit our growth and ability to expand.

 

There is no assurance that we will be able to ramp our business to meet our sales, manufacturing, installation, servicing and quantum computing targets, that expected growth levels will prove accurate or that the pace of growth will continue at the current rate. Failure of QCi to grow at rates similar to that of the broader quantum computing industry may adversely affect our operating results and ability to effectively compete within the industry.

 

We may not manage growth effectively.

 

Our failure to manage growth effectively could harm our business, results of operations and financial condition. We anticipate that a period of significant expansion will be required to address potential growth. This expansion will place a significant strain on our management, operational and financial resources. Expansion will require significant cash investments and management resources and there is no guarantee that they will generate additional sales of our products or services, or that we will be able to avoid cost overruns or be able to hire additional personnel to support us. In addition, we will also need to ensure our compliance with regulatory requirements in various jurisdictions applicable to the sale, installation and servicing of our products. To manage the growth of our operations and personnel, we must establish and maintain appropriate and scalable operational and financial systems, procedures and controls and a qualified finance, administrative and operations staff. We may be unable to acquire the necessary capabilities and personnel required to manage growth or to identify, manage and exploit potential strategic relationships and market opportunities.

 

9

 

 

We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations and may need additional capital sooner than planned to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be sure that additional financing will be available. If we are unable to raise additional funding when needed, we may be required to delay, limit or substantially reduce our development efforts.

 

Our business and future plans for expansion are capital-intensive, and we will require additional capital for equipment and facilities for hardware manufacturing and optical chip fabrication. The specific timing of cash inflows and outflows may fluctuate substantially from period to period. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. Our operating plan may change because of factors currently unknown, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources. Such financings may result in dilution to stockholders, issuance of securities with priority as to liquidation and dividend and other rights more favorable than those of our common stock, imposition of debt covenants and repayment obligations or other restrictions that may adversely affect our business. Any funds we raise may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from disruptions in access to bank deposits or lending commitments due to bank failures, the ongoing war between Russia and Ukraine and the related sanctions imposed against Russia, and the war between Israel and Hamas, the state of the military conflict between Israel and Hezbollah and the related risk of a larger regional conflict. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe that we have sufficient funds for current or future operating plans.

 

There can be no assurance that financing will be available to us on favorable terms, or at all. The inability to obtain financing when needed may make it more difficult for us to operate our business or implement our growth plans and we may be required to delay, limit or substantially reduce our quantum computing development efforts. Our ability to raise additional capital through the sale of securities could be significantly impacted by the resale of our securities by holders of our securities, which could result in a significant decline in the trading price of our securities and potentially hinder our ability to raise capital on terms that are acceptable to us or at all.

 

Failure to identify errors in the quantitative models we utilize to manage our business could adversely impact product performance and client relationships.

 

We employ various quantitative models to manage our business. Any errors in the underlying models or model assumptions could have unanticipated and adverse consequences on our business and reputation.

 

Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with the QPhoton Merger or other ownership changes.

 

We have incurred losses during our history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all.

 

Under current law, U.S. federal net operating loss carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards in taxable years beginning after December 31, 2020, is limited to 80% of taxable income, or less. It is uncertain if and to what extent various states will conform to the current law.

 

In addition, our net operating loss carryforwards are subject to review and possible adjustment by the IRS, and state tax authorities. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), our federal net operating loss carryforwards and other tax attributes will become subject to an annual limitation in the event of certain cumulative changes in the ownership of the Company. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules apply under state tax laws. Our ability to utilize our federal net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with the QPhoton Merger or other transactions. Similar rules may apply under state tax laws.

 

10

 

 

If we earn taxable income, such limitations could result in increased future income tax liability and our future cash flows could be adversely affected. We have recorded a valuation allowance related to our net operating loss carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.

 

Risks Related to Our Business and Industry

 

We have not produced any of our products at volume and we face significant barriers in our attempts to develop and manufacture our products, including the need to invent and develop new technology. If we cannot successfully overcome those barriers, our business will be negatively impacted and could fail.

 

Producing quantum computers, sensors and networks is a difficult undertaking. There are significant manufacturing and engineering challenges that we must overcome. We face significant challenges in completing development of our quantum computers and other products, and in producing quantum computers in sufficient volumes. Even if we complete development and achieve volume production of our products, if the cost, accuracy, performance characteristics or other specifications fall short of our expectations, our business, financial condition and results of operations would be adversely affected.

 

The performance capabilities of our products will depend on the development and production of TFLN Optical Chips to achieve scale, performance and cost. There is significant development and intellectual property risk in the specification, design and development of TFLN Optical Chips and our plans could be impacted by lack of funding, competition or even unknown core technology factors intrinsic to the work. This would limit the ability of QCi to scale its growth to expected levels over the longer term and the Company could lose momentum.

 

We may be unable to reduce the production cost sufficiently, which may prevent us from pricing our quantum systems competitively.

 

Our revenue projections are dependent on the cost per manufactured system decreasing over the next several years as our quantum computers advance. These cost projections are based on economies of scale due to demand for our products and services, technological innovation and negotiations with third-party parts suppliers. If these cost savings do not materialize, the production cost may be higher than projected, making our quantum computing products and services less competitive than those offered by our competitors, which could have a material adverse effect on our business, financial condition or results of operations.

 

If our products and services fail to deliver customer value to a broader range of customers than classical approaches, our business, financial condition and future prospects may be harmed.

 

“Quantum advantage” refers to the moment when a quantum computer can compute faster than existing classical computers, while quantum supremacy is achieved once quantum computers are powerful enough to complete calculations that traditional supercomputers cannot perform at all. Broad quantum advantage is when quantum advantage is seen in many applications and developers prefer quantum computers to a traditional computer. No current quantum computers have reached a broad quantum advantage and they may never reach such advantage. While achieving a broad quantum advantage will be critical to the success of any quantum computing company, including us, it would not necessarily lead to commercial viability of the technology that accomplished such advantage, nor would it mean that such system could outperform classical computers in tasks other than the one used to determine a quantum advantage. As quantum computing technology continues to mature, broad quantum advantage, and quantum supremacy, may take years or decades to be realized, if it ever is. If we cannot develop quantum computers that have quantum advantage, customers may not continue to purchase our products and services. If other companies’ quantum computers reach a broad quantum advantage prior to the time we reach such capabilities, it could lead to a loss of customers and the inability to secure new customers. If any of these events occur, it could have a material adverse effect on our business, prospects, financial condition or results of operations.

 

11

 

 

The quantum computing industry is competitive and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers.

 

Since the QPhoton Merger, our business strategy has broadened to include the manufacture of several lines of hardware in addition to the underlying software. As a result, we now operate in markets that are rapidly evolving and highly competitive. We expect competition to intensify as the marketplace continues to mature and new technologies and competitors enter. Our current competitors include:

 

large, well-established technology companies that generally compete across our products, including IBM, Quantinuum, Google, Microsoft and Amazon;

 

  large research organizations funded by sovereign nations such as China, Russia, Canada, Australia and the United Kingdom, and those in the European Union; additional countries may decide to fund quantum computing programs in the future;

 

  less-established public and private companies with competing technology, including IonQ, Rigetti Computing, PsiQuantum, Xanadu and D-Wave Quantum, and companies located outside the United States; and

 

  new or emerging entrants seeking to develop competing technologies.

 

We compete based on various factors, including technology, price, performance, multi-cloud availability, brand recognition and reputation, customer support and differentiated capabilities, including ease of administration and use, scalability and reliability, data governance and security. Many of our competitors have substantially greater brand recognition, customer relationships, and financial, technical and other resources than we do, including an experienced sales force and sophisticated supply chain management. They may be able to respond more effectively than us to new or changing opportunities, technologies, standards, customer requirements and buying practices. In addition, many countries are focused on developing quantum computing solutions either in the private or public sector and may subsidize quantum computers, which may make it difficult for us to compete. Many of these competitors do not face the same challenges we do in growing our business. In addition, other competitors might be able to compete with us by bundling their other products in a way that does not allow us to offer a competitive solution.

 

Further, the industry might recognize the intrinsic advantages of optical integrated circuits in information processing applications and our competitors could shift to a more direct competitive approach using similar technologies, even with strong intellectual property protection.

 

Additionally, we must be able to achieve our objectives in a timely manner such that we don’t lose ground to competitors, including competing technologies. Because there are a large number of market participants, including certain sovereign nations, focused on developing quantum computing technology, we must dedicate significant resources to achieving any technical objectives on the timelines established by our management team. Any failure to achieve objectives in a timely manner could adversely affect our business, operating results and financial condition.

 

For all of these reasons, competition may negatively impact our ability to maintain and grow consumption of our platform or put downward pressure on our prices and gross margins, any of which could materially harm our reputation, business, results of operations, and financial condition.

 

We rely on access to high-performance third-party classical computing through public clouds and high-performance computing centers to deliver quantum products and services to customers. We may not be able to maintain connectivity with these resources, which could make it harder for us to reach customers or deliver products and services in a cost-effective manner.

 

Our products and services may from time to time incorporate high-performance classical computing through public clouds to provide services to end users and our partners. These public cloud services are predominantly on Amazon Web Services at the present time.

 

12

 

 

Any material change in our contractual and other business relationships with Amazon Web Services or other cloud providers could result in reduced use of our products and services, increased expenses, including service credit obligations, and harm our brand and reputation, any of which could have a material adverse effect on our business, financial condition and results of operations.

 

Further, if our contractual and other business relationships with our partners are terminated or suspended, either by our partner or by us, or suffer a material change to which we are unable to adapt, such as the elimination of services or features on which we depend, we would be unable to provide our quantum computing products and services business at the same scale and would experience significant delays and incur additional expense in transitioning customers to a different public cloud provider.

 

We depend on certain suppliers to source products. Failure to maintain our relationship with any of these suppliers, or a failure to replace any of these suppliers, could have a material adverse effect on our business, financial position, results of operations and cash flows.

 

We buy our products and supplies from companies that manufacture and source products from the United States and abroad. Our ability to develop and maintain relationships with qualified suppliers who can satisfy our standards for quality and delivery in a timely and efficient manner is a significant challenge. Any failure to maintain our relationship with any of our key suppliers, or a failure to replace any such supplier that is lost, could have a material adverse effect on our business, financial position, results of operations and cash flows.

 

We may be required to replace a supplier if their products do not meet our quality or safety standards, or if the United States government imposes restrictions on trade with certain countries, such as China. In addition, our suppliers could discontinue selling products at any time for reasons that may or may not be in our control or the suppliers’ control, including shortages of raw materials, environmental and social supply chain issues, public health emergencies, labor disputes or weather conditions. Disruptions in transportation lines or geopolitical conditions including the ongoing war between Russia and Ukraine, the war between Israel and Hamas, the state of the military conflict between Israel and Hezbollah or an invasion of Taiwan by China, may also cause global supply chain issues that affect us or our suppliers. While we generally have multiple sources of supply, we do rely on a single supplier for materials in some cases. The loss of, or substantial decrease in the availability of, products from our suppliers, or the loss of a key supplier, temporarily or permanently, could result in a material shortage of products, which could lead to price escalations that we may be unable to offset by our prices to our customers. When supply chain issues are later resolved and prices return to normal levels, we may be required to reduce the prices at which we sell our products to our customers in order to remain competitive. In addition, even where these risks do not materialize, we may incur costs as we prepare contingency plans to address such risks. Our operating results and inventory levels could suffer if we are unable to promptly replace a supplier who is unwilling or unable to satisfy our requirements with a supplier providing similar products. In addition, our suppliers’ ability to deliver products may also be affected by raw material and commodity cost volatility or financing constraints caused by credit market conditions, which could materially and negatively impact our net sales and operating costs, at least until alternate sources of supply are arranged. Any delay or unavailability of key products required for our development activities in a timely or cost-effective manner could delay or prevent us from further developing our products and services on our expected timelines or at all and could materially harm our business.

 

TFLN Optical Chips manufacturers and distributors are concentrated primarily in China and other parts of East Asia, which is an area that is or may be subject to geopolitical uncertainty, trade disputes and restrictions, environmental disasters, and other risks. Any disruption to the operations of these manufacturers or distributors could cause significant delays in the production or shipment of our products and impact our financial condition.

 

Our success also depends in part on the manufacturing of TFLN Optical Chips. Unforeseen disruption of the manufacture of TFLN Optical Chips could be caused by a number of events, including a maintenance outage, systems outage or other disruption, power or equipment failure, fires, floods, earthquakes or other natural disasters, social unrest or terrorist activity, work stoppages, public health concerns (including pandemics), regulatory measures, or other operational problems. Any disruption in the manufacture of TFLN Optical Chips resulting from such events could cause significant delays in the development and production of our products.

 

13

 

 

In addition, we may depend on third-party TFLN Optical Chips manufacturing partners or distributors who may be affected by changes in governmental policies, taxation, rising inflation or interest rates, social instability, geopolitical conflicts and tensions, and diplomatic and social developments which are outside of our control.

 

Furthermore, our industry generally relies on a limited number of TFLN Optical Chips manufacturers whose operations tend to be concentrated in China and other parts of East Asia, which makes us especially susceptible to adverse developments in these regions’ economic and political conditions, particularly to the extent that such developments create an unfavorable business environment that significantly affects our operations. Although the governments of certain countries, including the United States, have taken actions to make their countries more attractive for chip manufacturing operations, there can be no assurances that the current geographic concentration of chip manufacturing will be meaningfully changed in the near term or at all.

 

If any of these events, or other macroeconomic trends, should cause a prolonged disruption of operations that impact our third-party TFLN Optical Chips manufacturing partners, they may experience operational downtimes or have to operate at reduced capacities, which could have a material adverse effect on our business, financial condition, and results of operations.

 

In order to compete, we must attract, retain and motivate key associates, and the failure to do so could have an adverse effect on our business, financial condition and results of operations.

 

We depend on our executive officers and management team to run our business. As we develop new business models and new ways of working, we will need to develop suitable skill sets within our organization. In addition, our future success depends on our continuing ability to attract, develop, motivate and retain highly qualified and skilled employees that have highly technical set of skills. The current market for such positions is highly competitive. Qualified individuals are in high demand and we may incur significant costs to attract and retain them. Moreover, the loss of any of our senior management or other key employees or our inability to recruit and develop capable managers could adversely affect our ability to execute our business plan and we may be unable to find adequate replacements.

 

Even if we are successful in developing our products and executing our strategy, competitors in the industry may achieve technological breakthroughs that render our quantum computing systems obsolete or inferior to other products.

 

Our continued growth and success depend on our ability to innovate and develop quantum computing technology in a timely manner and effectively market these products. Without timely innovation and development, our quantum computing products and services could be rendered obsolete or less competitive by changing customer preferences or because of the introduction of a competitor’s newer technologies. We believe that many competing technologies will require a technological breakthrough in one or more problems related to science, fundamental physics or manufacturing. While it is uncertain whether such technological breakthroughs will occur in the next several years, that does not preclude the possibility that such technological breakthroughs could eventually occur. Any technological breakthroughs that render our technology obsolete or inferior to other products could have a material adverse effect on our business, financial condition or results of operations.

 

The quantum computing industry is in its early stages and volatile, and if it does not develop, if it develops slower than we anticipate, if it encounters negative publicity or if our quantum computing products and services do not achieve commercial adoption, the growth of our business will be harmed.

 

The nascent market for quantum computers is still rapidly evolving, characterized by rapidly changing technologies, competitive pricing and competitive factors, evolving government regulation and industry standards, and changing customer demands and behaviors. Our success will depend to a substantial extent on the willingness of our potential customers to use, and increase their utilization of, our products and services, as well as on our ability to demonstrate the value of quantum computing to their respective organization, government agencies, and other purchasers of quantum computing offerings. Negative publicity concerning our products and services or the quantum computing industry as a whole could limit market acceptance of our offerings. If our clients and partners do not perceive the benefits of our products and services, or if they do not drive customer engagement, then our market may not develop at all, or it may develop more slowly than we expect. Similarly, individual and industry concerns or negative publicity regarding technophobic views in the context of quantum computing could limit market acceptance of our quantum computing products and services. If any of these events occur, our business, prospects, financial condition and operating results could be harmed.

 

14

 

 

In addition, our growth and future demand for our products is highly dependent upon the adoption by developers and customers of quantum computers, as well as on our ability to demonstrate the value of quantum computing to our customers. Delays in future generations of our quantum computers or technical failures at other quantum computing companies could limit acceptance of our products and services. Negative publicity concerning our products and services or the quantum computing industry as a whole could limit acceptance of our products and services. While we believe that quantum computing will solve many large-scale problems, it is possible that such problems may never be solvable by quantum computing technology. If our customers and partners do not see the benefits of our products and services, or if our products and services do not drive commercial sales, then demand for our products and services may not develop at all, or it may develop slower than we expect. If any of these events occur, it could have a material adverse effect on our business, financial condition and results of operations.

 

We have experienced in the past and could also suffer future disruptions, outages, defects and other performance and quality problems with our quantum computing products and services, our production technology partners or with the public cloud, data centers and internet infrastructure on which we rely.

 

Our business depends on our quantum computing systems being available through the cloud with a high level of reliability. We have experienced, and may in the future further experience, disruptions, outages, defects and other performance and quality problems with our systems. We have also experienced, and may in the future experience, disruptions, outages, defects and other performance and quality problems with the public cloud and internet infrastructure on which our systems rely. These problems can be caused by a variety of factors, including failed introductions of new functionality, vulnerabilities and defects in proprietary and open- source software, hardware components, human error or misconduct, capacity constraints, design limitations, denial of service attacks or other security-related incidents, foreign objects or debris, weather, construction, supply chain events, or accidents and other force majeure. We do not have a contractual right with our public cloud providers that compensates us for any losses due to availability interruptions in the public cloud.

 

Any disruptions, outages, defects and other performance and quality problems with our quantum computing system or with the public cloud, internet, and other infrastructure on which they rely could result in reduced use of our systems, increased expenses, including service credit obligations, and harm to our brand and reputation, any of which could have a material adverse effect on our business, financial condition and results of operations.

 

Our future growth and success depend on our ability to sell effectively to government entities and large enterprises.

 

Our potential customers are likely to include government agencies and large commercial enterprises. Therefore, our future success will depend on our ability to effectively sell our products to such customers. Sales to these end-customers involve risks that may not be present (or that are present to a lesser extent) with sales to non-governmental agencies or smaller customers. These risks include, but are not limited to, (i) increased purchasing power and leverage held by such customers in negotiating contractual arrangements with us and (ii) longer sales cycles and the associated risk that substantial time and resources may be spent on a potential end-customer that elects not to purchase our solutions. In addition, government contracts generally include the ability of government agencies to terminate early which, if exercised, would result in a lower contract value and lower than anticipated revenues. Such government contracts also may limit our ability to do business with foreign governments or prevent us from selling our products in certain countries.

 

Government agencies and large organizations often undertake a significant evaluation process that results in a lengthy sales cycle. Our contracts with government agencies are typically structured in phases, with each phase subject to satisfaction of certain conditions. As a result, the actual scope of work performed pursuant to any such contracts, in addition to related contract revenue, could be less than total contract value. In addition, product purchases by such organizations are frequently subject to budget constraints, multiple approvals and unanticipated administrative, processing and other delays. Finally, these organizations typically have longer implementation cycles, require greater product functionality and scalability, require a broader range of services, demand that vendors take on a larger share of risks, require acceptance provisions that can lead to a delay in revenue recognition and expect greater payment flexibility. All of these factors can add further risk to business conducted with these potential customers and could lead to lower revenue results than originally anticipated. 

 

15

 

 

Additionally, changes in government spending could negatively impact us. Our anticipated future revenues from the U.S. government are expected to result from contracts awarded under various U.S. government programs. Cost cutting, including through consolidation and elimination of duplicative organizations, has become a major initiative for within the U.S. government. Significant reduction in U.S. government spending could have adverse consequences on our prospects, financial position, results of operations and business.

 

Our quantum computing systems may not be compatible with some or all industry-standard software and hardware in the future, which could harm our business.

 

Since the QPhoton Merger, we have been focusing more of our efforts on creating quantum computing hardware, in addition to refining the software development platform to access our hardware, and application programing interfaces to access our systems. The industry is rapidly evolving, and customers have many choices for programming languages, some of which may not be compatible with our own application programming interfaces. Our quantum computing development platform is designed to be compatible with most major software languages. If a proprietary (not open source) software toolset became the standard for quantum application development in the future by a competitor, however, usage of our hardware might be limited, which would have a negative impact on the Company. Similarly, if a piece of hardware that we could not integrate with became a necessary component for quantum computing (for instance, quantum networking), the result might have a negative impact on the Company.

 

Cybersecurity risks and the failure to maintain the integrity of data belonging to the Company could expose us to data loss, litigation and liability, and our reputation could be significantly harmed.

 

We may from time to time collect and retain large volumes of data relating to our business and from our customers for business purposes, including for transactional and promotional purposes, and our various information technology systems enter, process, summarize and report such data. The integrity and protection of this data is critical to our business. Maintaining compliance with the evolving regulations and requirements applicable to data security and information privacy protection could be difficult and may increase our expenses. In addition, a penetrated or compromised data system or the intentional, inadvertent or negligent release or disclosure of data could result in theft, loss or fraudulent or unlawful use of data relating to our company or our employees, independent distributors or preferred customers, which could harm our reputation, disrupt our operations, or result in remedial and other costs, fines or lawsuits.

 

Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. In addition, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.

 

Computer malware, viruses, hacking, phishing attacks and spamming could harm our business and results of operations.

 

Computer malware, viruses, physical or electronic break-ins and similar disruptions could lead to interruption and delays in our services and operations and loss, misuse or theft of data. Computer malware, viruses, computer hacking and phishing attacks against business networks have become more prevalent and may occur on our systems in the future.

 

Any attempts by hackers to disrupt our internal systems, if successful, could harm our business, be expensive to remedy and damage our reputation or brand. We could incur significant expenses and losses related to direct attacks on our website or internal systems. Efforts to prevent hackers from entering our computer systems are expensive to implement and may limit the functionality of our services. Though it is difficult to determine what, if any, harm may directly result from any specific interruption or attack, any failure to maintain performance, reliability, security and availability of our products and services and technical infrastructure may harm our reputation, brand and our ability to attract customers. Any significant disruption to our website or internal computer systems could result in a loss of customers and could adversely affect our business and results of operations.

 

16

 

 

We have previously experienced, and may in the future experience, service disruptions, outages and other performance problems due to a variety of factors, including infrastructure changes, third-party service providers, human or software errors and capacity constraints. If our software application is unavailable when customers attempt to access it or it does not load as quickly as they expect, customers may seek other services.

 

Our quantum computer products rely on software that is highly technical and complex and may now or in the future contain undetected errors, bugs, or vulnerabilities. Some errors in our software code may only be discovered after the code has been deployed. Any errors, bugs, or vulnerabilities discovered in our code after deployment, inability to identify the cause or causes of performance problems within an acceptable period of time or difficultly maintaining and improving the performance of our platform, particularly during peak usage times, could result in damage to our reputation or brand, loss of revenues, or liability for damages, any of which could adversely affect our business and financial results.

 

We expect to continue to make significant investments to maintain and improve the availability of our cloud- based products and services and to enable rapid releases of new features and products. To the extent that we do not effectively address capacity constraints, upgrade our systems as needed and continually develop our technology and network architecture to accommodate actual and anticipated changes in technology, our business and operating results may be harmed.

 

Unfavorable conditions in our industry or the global economy could limit our ability to grow our business and negatively affect our results of operations.

 

Our results of operations may vary based on the impact of changes in our industry or the global economy on us or our customers and potential customers. Negative conditions in the general economy both in the United States and abroad, including conditions resulting from changes in gross domestic product growth, financial and credit market fluctuations, inflation, international trade relations, tariffs, public health emergencies (such as the recent COVID-19 pandemic), political turmoil, natural catastrophes, warfare, and terrorist attacks on the United States or elsewhere, could cause a decrease in business investments, including the progress on development of quantum technologies, and negatively affect the growth of our business. In addition, in challenging economic times, our current or potential future customers may experience cash flow problems and as a result may modify, delay or cancel plans to purchase our products and services. Additionally, if our customers are not successful in generating sufficient revenue or are unable to secure financing, they may not be able to pay, or may delay payment of, amounts they owe. Moreover, our key suppliers may reduce their output or become insolvent, thereby adversely impacting our ability to continue our research and development activities or manufacture our products.

 

Furthermore, uncertain economic conditions may make it more difficult for us to raise funds through borrowings or sales of debt or equity securities. We cannot predict the timing, location, strength or duration of any economic slowdown, instability or recovery, generally or within any particular industry.

 

Government actions and regulations, such as tariffs and trade protection measures, especially in China and the United States, may adversely impact our business, including our ability to obtain products from our suppliers

 

Government actions and regulations, such as tariffs and trade protection measures, may limit our ability to obtain products from our suppliers or sell our products and services to customers. Political challenges between the United States and countries in which our suppliers are located and changes to trade policies, including tariff rates and customs duties, trade relations between the United States and those countries and other macroeconomic issues could adversely impact our business. During the last few years, including under the new Presidential administration, the United States has imposed tariffs on certain products imported into the United States from China and some other countries, and China and some other countries have imposed tariffs on U.S. imports in response. The U.S. government continues to add additional entities, in China and elsewhere, to restricted party lists impacting the ability of U.S. companies to provide products and technology and, in certain cases, services, to these entities and, in some cases, to receive products, technology or services from these entities. The U.S. government also continues to increase end-use restrictions on the provision of products, technology and services to China and other countries including end-uses related to advanced computing. The new U.S. presidential administration has signaled its intention to use U.S. trade policy, including tariffs and other trade restrictions, as an important foreign policy tool presenting uncertainty regarding the impact of future trade policies on our business. As such, there is also a possibility of future tariffs, trade protection measures or other restrictions imposed on our products or on our customers by the United States, China or other countries that could have a material adverse effect on our business. Our technology could be deemed a matter of national security and, as such, our customer base could be tightly restricted. We also may accept government grants that place restrictions on the business’ ability to operate. Any such actions could impact our business operations and have a material adverse effect on our business prospectus, financial condition and results of operations.

 

17

 

 

In addition, the Chinese government exercises significant control over China’s economy through the allocation of resources, control of the incurrence and payment of foreign currency-denominated obligations, setting of monetary policy and provision of preferential treatment to particular industries or companies. Changes in any of these policies, laws and regulations could adversely affect the overall economy in China or our Chinese suppliers, which could harm our business through higher supply costs, reduced availability or both.

 

Also, due to concerns with the security of products and services from certain telecommunications equipment and services companies based in China, U.S. Congress has enacted bans on the use of certain Chinese-origin components or systems either in items sold to the U.S. government or in the internal networks of government contractors and subcontractors (even if those networks are not used for government-related projects). Further, the Chinese government has responded to these U.S. actions by developing an unreliable entity list, which may limit the ability of companies on the list to engage in business with Chinese counterparties.

 

In June 2022, the import restrictions contained in the Uyghur Forced Labor Prevention Act (“UFLPA”) became effective. The UFLPA creates a rebuttable presumption that any goods mined, produced or manufactured, wholly or in part, in the Xinjiang Uyghur Autonomous Region (“XUAR”) of China, or produced by a listed entity, were made with forced labor and would therefore not be entitled to entry at any U.S. port. Importers may be required to present clear and convincing evidence that such goods are not made with forced labor. While we do not source items from the XUAR or from listed parties, and we have increased our supply chain diligence, there is risk that our ability to import components and products may be adversely affected by the UFLPA.

 

Given the relatively fluid regulatory environment in China and the United States and uncertainty regarding how the U.S. government or Chinese and other foreign governments will act with respect to tariffs and international trade agreements and policies, a trade war, further governmental action related to tariffs or international trade policies, or additional tax or other regulatory changes in the future could directly and adversely impact our financial results and results of operations. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products may be subject to such actions or what actions may be taken by the other countries in retaliation. If we are unable to obtain or use components for inclusion in our products, if component prices increase significantly or if we are unable to export or sell our products to any of our customers, our business, liquidity, financial condition and/or results of operations would be materially and adversely affected.

 

We may become subject to legal proceedings that could have a material adverse impact on our financial position and results of operations.

 

From time to time and in the ordinary course of our business, we and certain of our subsidiaries may become involved in various legal proceedings. All such legal proceedings are inherently unpredictable and, regardless of the merits of the claims, litigation may be expensive, time-consuming and disruptive to our operations and distracting to management. If resolved against us, such legal proceedings could result in excessive verdicts, injunctive relief or other equitable relief that may affect how we operate our business. Similarly, if we settle such legal proceedings, it may affect how we operate our business. Future court decisions, alternative dispute resolution awards, business expansion or legislative activity may increase our exposure to litigation and regulatory investigations. In some cases, substantial noneconomic remedies or punitive damages may be sought. Although we maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular verdict, judgment or settlement that may be entered against us, that such coverage will prove to be adequate or that such coverage will continue to remain available on acceptable terms, if at all. If we incur liability that exceeds our insurance coverage or that is not within the scope of the coverage in legal proceedings brought against us, it could have an adverse effect on our business, financial condition and results of operations.

 

18

 

 

We intend to continue exploring strategic business acquisitions and other business combinations and transactions, which are subject to inherent risks.

 

In order to expand our products and services and grow our market and client base, we may continue to seek and complete strategic business acquisitions and other combinations, investments, or partnerships that we believe are complementary to our business. The identification of suitable acquisition, strategic investment or strategic partnership candidates can be costly and time consuming and can distract our management team from our current operations. The completion of such transactions also have inherent risks that may have a material adverse effect on our business, financial condition, operating results or prospects, including, but not limited to: (i) failure to successfully integrate the business and financial operations, services, intellectual property, solutions or personnel of an acquired business and to maintain uniform standard controls, policies and procedures; (ii) diversion of management’s attention from other business concerns; (iii) entry into markets in which we have little or no direct prior experience; (iv)) failure to achieve projected synergies and performance targets; (v) loss of clients or key personnel; (vi) incurrence of debt or assumption of known and unknown liabilities; (vii)) write-off of software development costs, goodwill, client lists and amortization of expenses related to intangible assets; (viii) dilutive issuances of equity securities; and (ix) accounting deficiencies that could arise in connection with, or as a result of, such transactions, including issues related to internal control over financial reporting and the time and cost associated with remedying such deficiencies. Even if we successfully complete a strategic transaction, we may not be able to effectively integrate the acquired business, technology, systems, control environment, solutions, personnel or operations into our business or not be able to achieve projected results or support the amount of consideration paid for such acquired businesses or invested in such transactions. In addition, we may incur unexpected costs, claims or liabilities during the strategic transaction or that we assume from the acquired company, or we may discover adverse conditions post- acquisition for which we have limited or no recourse, and we may not achieve the anticipated benefits of any strategic transaction.

 

If we fail to establish and maintain an effective system of internal control, we may not be able to report our financial results accurately or prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely impact the trading price of our common stock.

 

Effective internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed. As a result, our small size and any current internal control deficiencies may adversely affect our financial condition, results of operations and access to capital.

 

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.

 

From time to time the global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflation rates higher than historical norms, higher interest rates, bank failures and uncertainty about economic stability. Any volatility or disruptions in market and economic conditions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets were to deteriorate, including as a result of political unrest or war, it may make any necessary financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. While inflation rates have during the last 18 months or so have been more in line with historical levels, the higher than anticipated inflation rates experienced in the wake of the COVID-19 pandemic did, and any similar higher than normal and/or unexpectedly high inflation rates in the future, may adversely affect us by increasing our costs, including labor and employee benefit costs, and costs for equipment and system components associated with system development. In addition, higher inflation could also increase our customers’ operating costs, which could result in reduced budgets for our customers and potentially less demand for our products and services. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition. Further, subsequent decreases in inflation and interest rates may not result in a reduction of costs.

 

19

 

 

We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.

 

Our products, technology and services are subject to U.S. export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control. U.S. export control and economic sanctions laws include restrictions or prohibitions on the sale or supply of certain products, technologies, and services to U.S. Government embargoed or sanctioned countries, governments, persons and entities. In addition, certain products and technology may be subject to export licensing or approval requirements. Exports of our products and technology must be made in compliance with export control and sanctions laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges, fines that may be imposed on us and responsible employees or managers and, in extreme cases, the incarceration of responsible employees or managers.

 

In addition, various countries regulate the import of certain encryption technology, including through import permit and license requirements and have enacted laws that could limit our ability to distribute our products and technologies or could limit our end customers’ ability to implement our services in those countries. Changes in our products or technologies or changes in applicable export or import laws and regulations also may create delays in the introduction and sale of our products and technologies in international markets or, in some cases, prevent the export or import of our products and technologies to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws and regulations, or change in the countries, governments, persons or technologies targeted by such laws and regulations could also result in decreased use of our products and services or in our decreased ability to export or sell our products and services to existing or potential customers. Any decreased use of our products and services or limitation on our ability to export or sell our products and services would likely adversely affect our business, financial condition and results of operations.

 

We expect to incur significant costs in complying with these regulations. Regulations related to quantum computing are currently evolving and we face risks associated with changes to these regulations.

 

We may become subject to product liability claims, which could harm our financial condition and liquidity if we are not able to successfully defend or insure against such claims.

 

We may become subject to product liability claims, even those without merit, which could harm our business prospects, operating results, and financial condition. We may face inherent risk of exposure to claims in the event that our products do not perform as expected or malfunction. A successful product liability claim against us could require us to pay a substantial monetary award. Moreover, a product liability claim could generate substantial negative publicity about our quantum computers and business and inhibit or prevent commercialization of other future quantum computers, which would have material adverse effects on our brand, business, prospects and operating results. Any insurance coverage might not be sufficient to cover all potential product liability claims. Any lawsuit seeking significant monetary damages either in excess of our coverage, or outside of our coverage, may have a material adverse effect on our reputation, business and financial condition. We may not be able to secure additional product liability insurance coverage on commercially acceptable terms or at reasonable costs when needed, particularly if we do face liability for our products and are forced to make a claim under our policy.

 

Risks Related to Intellectual Property

 

Any failure to obtain, maintain and protect our intellectual property rights could impair our ability to protect and commercialize our proprietary products and technology and cause us to lose our competitive advantage.

 

Our success depends, in significant part, on our ability to obtain, maintain, enforce and defend our intellectual property rights, including patents and trade secrets. We rely upon a combination of the intellectual property protections afforded by patent, copyright, trademark and trade secret laws in the United States and other jurisdictions, as well as license agreements and other contractual protections, to establish, maintain and enforce rights in our proprietary technologies. In addition, we seek to protect our intellectual property rights through nondisclosure and invention assignment agreements with our employees and consultants and through non-disclosure agreements with business partners and other third parties.

 

20

 

 

However, we may not be able to prevent unauthorized use of our intellectual property. Our trade secrets may also be compromised, which could cause us to lose our competitive advantage. Third parties may attempt to copy or otherwise obtain, use or infringe our intellectual property.

 

Monitoring and detecting unauthorized use of our intellectual property is difficult and costly, and the steps we have taken or take in the future to prevent infringement or misappropriation may not be sufficient. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive and could divert management’s attention, which could harm our business, results of operations, and financial condition. In addition, existing intellectual property laws and contractual remedies may afford less protection than needed to safeguard our intellectual property portfolio, and third parties may develop competitive offerings in a manner that leaves us with limited means to enforce our intellectual property rights against them.

 

Patent, copyright, trademark and trade secret laws vary significantly throughout the world. A number of foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. Therefore, our intellectual property rights may not be as strong or as easily enforced outside of the United States and efforts to protect against the unauthorized use of our intellectual property rights, technology and other proprietary rights may be more expensive and difficult outside of the United States.

 

Failure to adequately protect our intellectual property rights could result in our competitors using our intellectual property to offer products, potentially resulting in the loss of some of our competitive advantage and a decrease in our revenue, which would adversely affect our business, financial condition and operating results.

 

Our inability to secure patent protection or enforce our patent rights could have a material adverse effect on our ability to prevent others from commercializing similar products or technology.

 

The application and registration of patents involves complex legal and factual questions. As a result, we cannot be certain that the patent applications that we file will result in patents being issued or that our patents (including licensed patents) and any future patents that do issue will afford protection against competitors with similar technology. Numerous patents and pending patent applications owned by others exist in the fields in which we have developed and are developing our products and services, and this may make it difficult for us to obtain certain patent coverage on our own. Any of our existing or pending patents may also be challenged by others on the basis that they are otherwise invalid or unenforceable. Furthermore, patent applications filed in foreign countries are subject to laws, rules and procedures that differ from those of the United States, and thus we cannot be certain that foreign patent applications related to issued U.S. patents will be issued.

 

Even if our patent applications succeed, it is still uncertain whether these patents (or any of the issued patents exclusively licensed to us) will be contested, circumvented, invalidated, found to be unenforceable or limited in scope in the future. The rights granted under any issued patents may not provide us with meaningful protection or competitive advantages. The intellectual property rights of others could bar us from licensing and exploiting any patents that issue from our pending applications, and the claims under any patents that issue from our patent applications may not be broad enough to prevent others from developing technologies that are similar or that achieve results similar to ours. In addition, patents issued to us may be infringed upon or designed around by others and others may obtain patents that we need to license or design around, either of which would increase costs and may adversely affect our business, prospects, financial condition and operating results.

 

We may face patent infringement and other intellectual property claims that could be costly to defend, result in injunctions and significant damage awards, or limit our ability to use certain key technologies in the future, all of which could harm our business.

 

Our success depends, in part, on our ability to develop and commercialize our products and services without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. However, we may not be aware that our products, services or technologies are infringing, misappropriating or otherwise violating third-party intellectual property rights and such third parties may bring claims alleging such infringement, misappropriation or violation.

 

21

 

 

For example, there may be issued patents of which we are unaware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future products, services or technologies. Also, because patent applications can take years to issue and are often afforded confidentiality for some period of time, there may currently be pending applications, unknown to us, that later result in issued patents that could cover our current or future products, services or technologies. The strength of our defenses will depend on the rights asserted, the interpretation of these rights, and our ability to invalidate the asserted rights. However, we could be unsuccessful in advancing non-infringement and/or invalidity arguments in our defense.

 

Although we carry general liability insurance, our insurance may not cover potential claims of this type or may not be adequate to indemnify us for all liability that may be imposed. We cannot predict the outcome of lawsuits and cannot ensure that the results of any such actions will not have an adverse effect on our business, financial condition or results of operations. Even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business and operating results. Further, there could be public announcements of the intellectual property litigation, and if securities analysts, investors or others perceive the potential impact to be negative or risks to be substantial, it could have an adverse effect on the price of our common stock. The occurrence of infringement claims may grow as the market for our products, services and technologies grows. Accordingly, our exposure to damages resulting from infringement claims could increase and this could further exhaust our financial and management resources.

 

Growing our customer base depends upon the effective operation of our applications with operating systems, networks and standards that we do not control.

 

We will be dependent on the interoperability of our applications with operating systems that we do not control, and any changes in such systems that degrade our potential products’ functionality or give preferential treatment to competitive products could adversely affect the usage of our applications on quantum processing units. Additionally, in order to deliver high quality products, it is important that our products work well with a range of quantum computers, conventional computers, systems, networks and standards that we do not control. We may not be successful in developing relationships with key participants in the quantum computing industry or in developing products that operate effectively with these technologies, systems, networks or standards.

 

We may not be able to protect our source code from copying if there is an unauthorized disclosure of source code.

 

Source code, the detailed program commands for our operating systems and other software programs, is critical to our business. While, from time to time, we may license portions of our application and operating system source code to one or more licensees, we take significant measures to protect the secrecy of large portions of our source code. If a significant portion of our source code leaks, however, we might lose future trade secret protection for that source code. It may become easier for third parties to compete with our products by copying functionality, which could adversely affect our revenue and operating margins.

 

Risks Related to Our Common Stock

 

Our stock price has been and may continue to be volatile or may decline regardless of our operating performance, and you may lose part or all of your investment.

 

The market price of our common stock has in the past and may going forward fluctuate widely in response to various factors, some of which are beyond our control, including:

 

  actions by competitors;

 

  actual or anticipated growth rates relative to our competitors;

 

  the public’s response to press releases or other public announcements by us or third parties, including our filings with the Securities and Exchange Commission (the “SEC”);

 

  economic, legal and regulatory factors unrelated to our performance;

 

22

 

 

  any future guidance that we may provide to the public, any changes in such guidance or any difference between our guidance and actual results;

 

  changes in financial estimates or recommendations by any securities analysts who follow our common stock;

 

  speculation by the press or investment community regarding our business;

 

  litigation;

 

  changes in key personnel; and

 

  future sales of our common stock by our officers, directors and significant stockholders.

 

In addition, the stock markets, including the Nasdaq Stock Market LLC (“Nasdaq”) on which our common stock is listed, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These broad market fluctuations may materially affect our stock price, regardless of our operating results. Furthermore, the market for our common stock historically has been limited and we cannot assure you that an active trading market will ever be developed or maintained. The price at which investors purchase shares of our common stock may not be indicative of the price that will prevail in the trading market. Market fluctuations and volatility, as well as general economic, market and political conditions, could reduce our market price. As a result, these factors may make it more difficult or impossible for you to sell your shares of our common stock for a positive return on your investment. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources and the attention of management could be diverted from our business.

 

Future sales of shares of our common stock, or the perception in the public markets that these sales may occur, may depress our stock price.

 

The market price of our common stock could decline significantly as a result of sales of a large number of shares of our common stock. In addition, if our significant stockholders sell a large number of shares, or if we issue a large number of shares, the market price of our stock could decline. Any issuance of additional common stock by us in the future, or warrants or options to purchase our common stock, if exercised, would result in dilution to our existing stockholders. Such issuances could be made at a price that reflects a discount or a premium to the then-current trading price of our common stock. Moreover, the perception in the public market that stockholders might sell shares of our stock or that we could make a significant issuance of additional common stock in the future could depress the market for our shares. These sales, or the perception that these sales might occur, could depress the market price of our common stock or make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. 

 

Delays in filing financial reports, internal control weaknesses, and restatements could hinder our ability to regain Form S-3 eligibility and adversely affect our business and stock price.

 

Subsequent to the issuance of our Annual Report on Form 10-K for the year ended December 31, 2023, and our subsequent retention of BPM LLP to replace BF Borgers CPA PC as our independent registered public accounting firm, management became aware of various adjustments to be recorded to our consolidated financial statements. On September 11, 2024, we filed Amendment 1 to our Annual Report on Form 10-K for the year ended December 31, 2023, restating our financial statements for the years ended December 31, 2023 and 2022 to correct errors primarily related to purchase accounting for the QPhoton Merger, stock-based compensation, and financing costs. We also amended our financial statements for the nine months ended September 30, 2023, in line with the restatement of our annual financial statements. These corrections impacted net loss, goodwill, intangible assets, liabilities, and stockholders’ equity.

 

These restatements were necessitated in part by deficiencies in our internal control over financial reporting, which management concluded was not effective as of September 30, 2024. Material weaknesses in our controls, including those related to the timely detection and correction of financial reporting errors, coupled with the replacement of our independent auditor, resulted in delayed filings of our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, and June 30, 2024.

 

23

 

 

As a result of the failure to timely file our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024, we are currently ineligible to register the offer and sale of our securities using a newly filed registration statement on Form S-3. As of December 31, 2024, we have fully utilized the $100 million “shelf” registration statement on Form S-3 that the SEC declared effective on November 8, 2022.

 

To regain eligibility to use Form S-3, we must be timely and current in our public reporting for a period of 12 months preceding our intended S-3 filing. While we expect to regain eligibility to use Form S-3 as of September 1, 2025, there can be no guarantees that we will remain timely and current in our public reporting through such date. Should we wish to register the offer and sale of our securities to the public prior to the time we are eligible to use Form S-3, both our transaction costs and the amount of time required to complete the transaction could increase, making it more difficult to execute any such transaction successfully and potentially harming our financial condition.

 

While we continue to evaluate steps to remediate the material weaknesses in our internal control over financial reporting, as effective internal controls are necessary for us to provide reliable financial reports and prevent fraud, we can give no assurance that the measures we have taken and plan to take in the future will remediate the material weaknesses or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting, circumvention of these controls, or otherwise. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects. In addition, even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify errors or to facilitate the fair presentation of our consolidated financial statements. Failure to address and remediate any internal control weaknesses could further delay our ability to regain Form S-3 eligibility and adversely affect our business, operations, and stock price.

 

“Penny stock” rules may make buying or selling our common stock difficult, which may make our stock less liquid and make it harder for investors to buy and sell our securities.

 

Trading in our common stock has from time to time been and may continue to be subject to the SEC’s “penny stock” rules. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer that recommends our common stock to persons other than prior customers and accredited investors must, prior to the sale, make a special written suitability determination for the purchaser and receive the purchaser’s written agreement to execute the transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market. In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from effecting transactions in our common stock, which could severely limit the liquidity of, and consequently adversely affect the market price for, our common stock.

 

Shares of our currently issued and outstanding stock may become freely tradable pursuant to Rule 144 and may dilute the market for your shares and have a depressive effect on the price of the shares of our common stock.

 

A substantial minority of our outstanding shares of common stock are “restricted securities” within the meaning of Rule 144 under the Securities Act. In addition, we have issued or obligated to issue options to purchase common stock pursuant to certain employment, director and consultant agreements which shares of common stock, when purchased pursuant to the exercise of such options, would also be considered “restricted securities.” As restricted securities, these shares may be resold only pursuant to an effective registration statement or in accordance with the requirements of Rule 144 or other applicable exemptions from registration under the Securities Act and applicable state securities laws. Rule 144 provides in essence that an Affiliate (as such term is defined in Rule 144(a)(1)) of an issuer who has held restricted securities for a period of at least six months may, under certain conditions, sell every three months, in brokerage transactions, a number of shares that does not exceed the greater of 1% of the issuer’s outstanding shares of common stock or the average weekly trading volume during the four calendar weeks prior to the sale. Rule 144 also permits, under certain circumstances, the sale of securities, without any limitation, by a person who is not an Affiliate of the issuer and who has satisfied a one-year holding period. The resale of significant amounts of our common stock under Rule 144 or under any other exemption from the registration requirements of the Securities Act, if available, or pursuant to subsequent registrations of shares of our common stock, could cause the market price of our shares of common stock to decline significantly.

 

24

 

 

We currently do not intend to pay dividends on our common stock. As a result, your only opportunity to achieve a return on your investment is if the price of our common stock appreciates.

 

We currently do not expect to declare or pay dividends on our common stock. In addition, in the future we may enter into agreements that prohibit or restrict our ability to declare or pay dividends on our common stock. As a result, your only opportunity to achieve a return on your investment will be if the market price of our common stock appreciates and you sell your shares at a profit.

 

You may experience dilution of your ownership interest due to the future issuance of additional shares of our common stock.

 

We are in a capital-intensive business and we do not have sufficient funds to finance the growth of our business or the costs of our development projects or to support our projected capital expenditures indefinitely. As a result, we will very likely require additional funds from future equity or debt financings, which may include the issuance of shares of preferred stock, convertible debt, or warrants to purchase shares of common stock, to purchase capital equipment, complete the development of new products and pay the general and administrative costs of our business. We may in the future issue our previously authorized and unissued securities, resulting in the dilution of the ownership interests of holders of our common stock. We are currently authorized to issue 250,000,000 shares of common stock. The potential issuance of additional shares of common stock or of preferred stock or convertible debt may create downward pressure on the market price of our common stock. We may also issue additional shares of common stock or other securities that are convertible into or exercisable for common stock in the future for capital raising purposes or for other business purposes. Our future issuance of a substantial number of shares of common stock or the sale of a substantial number of shares in the public market, or the perception that such issuances or sales could occur, could adversely affect the prevailing market price of our common stock. A decline in the market price of our common stock could make it more difficult to raise funds through future offerings of our common stock or securities convertible into common stock.

 

In addition, these new securities could contain provisions, such as priorities on distributions and voting rights, that could affect the value of our existing shares of common stock.

 

Our executive officers and directors possess significant voting power with respect to our common stock, which will limit your influence on corporate matters.

 

As of March 18, 2025, our directors and executive officers collectively beneficially own approximately 20.1% of the shares of our common stock including the beneficial ownership of Dr. Yuping Huang of 17.2% of the shares of our common stock.

 

As a result, our insiders have the ability to significantly influence our management and affairs through the election and removal of the members of our board of directors (the “Board”) and all other matters requiring stockholder approval, including any future merger, consolidation or sale of all or substantially all of our assets. This concentrated voting power could discourage others from initiating any potential merger, takeover or other change-of-control transaction that may otherwise be beneficial to our stockholders. Furthermore, this concentrated control will limit the practical effect of your influence over our business and affairs, through any stockholder vote or otherwise. Any of these effects could depress the market price of our common stock.

 

Our articles of incorporation grant the Board the power to issue additional shares of common and preferred shares and to designate other classes of preferred shares, all without stockholder approval.

 

Our authorized capital consists of 260,000,000 shares of capital stock of which 10,000,000 shares are authorized as preferred stock. The Board, without any action by our stockholders, may designate and issue shares of preferred stock in such series as it deems appropriate and establish the rights, preferences and privileges of such shares, including dividends, liquidation and voting rights, provided it is consistent with Delaware law. To date the Board has authorized two classes of Preferred, Series A and Series B, for a total of 4,630,000 authorized shares, leaving an additional 5,370,000 preferred shares to be authorized at the discretion of the Board.

 

25

 

 

The rights of holders of our preferred stock that may be issued could be superior to the rights of holders of our shares of common stock. The designation and issuance of shares of capital stock having preferential rights could adversely affect other rights appurtenant to shares of our common stock. Furthermore, any issuances of additional stock (common or preferred) will dilute the percentage of ownership interest of then-current holders of our capital stock and may dilute our book value per share.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

Not applicable.

 

ITEM 1C. CYBERSECURITY

 

A robust and consistent approach to cybersecurity is critical to achieving our strategic business objectives and protecting our intellectual property. As an advanced technology company developing quantum photonic products, we face a wide range of cybersecurity threats such as ransomware and denial-of-service attacks that affect most industry sectors, to attacks from highly sophisticated adversaries, including nation state actors, that target dual-use advanced technologies such as quantum computing. Our customers, suppliers and other business partners face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially adversely affect our operations, performance and results of operations. We are continually evaluating best practices and methods to protect the Company from a wide range of potential threats. Due to the risks that these cybersecurity threats pose to our business, we are investing in cyber defense systems and training programs.

 

The Board, through the Risk Committee, oversees the Company’s processes for identifying and mitigating risks, including cybersecurity risks. Company management periodically briefs the Board on our cybersecurity and information security policies and plans, and the Board is apprised of cybersecurity incidents deemed to have a moderate or higher business impact. In the event of an incident, the Company has developed an incident response plan, which sets forth the steps to be followed from incident detection and assessment to mitigation, recovery and notification and reporting, including notifying functional areas (e.g. legal), as well as senior leadership and the Board, as appropriate.

 

We continue to evaluate our cybersecurity requirements to address the evolving cybersecurity risks that the Company faces in an increasingly technically capable environment. The Company has implemented policies for its personnel, including awareness programs, travel security programs and other related cybersecurity best practices. The information technology team manages the Company’s cybersecurity policies, including employee training, with the ultimate goal of preventing cybersecurity incidents, if possible, while also maintaining IT system performance and data integrity to minimize the business impact should an incident occur. The Company is coordinating closely with the Board’s Risk Committee to ensure that the Company will implement the appropriate cybersecurity technologies to protect the Company and its intellectual property.

 

Third parties play an important role in our cybersecurity program. We engage third-party services to conduct evaluations of our security controls, including penetration testing and consulting on best practices. The third-party services include testing both the design and operational effectiveness of security controls.

 

Although we take cybersecurity risks seriously, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on the Company. While the Company maintains cybersecurity insurance, the costs related to cybersecurity threats or disruptions may not be fully insured. See Item 1A. “Risk Factors” for a discussion of cybersecurity risks.

 

26

 

 

ITEM 2. PROPERTIES.

 

We maintain our principal office at 5 Marine View Plaza, Suite 214, Hoboken, NJ 07030. The Company leases 7,503 square feet of laboratory and office space in a multistory, multi-tenant building in Hoboken, NJ under a five-year lease ending September 30, 2027. Additionally, the Company leases 9,261 square feet of manufacturing (semiconductor and photonic chip fabrication), laboratory, clean room, and office space in a multi-tenant building in Tempe, AZ for 51-months ending November 30, 2028. The Company also has a short-term agreement for approximately 300 square feet in a multi-tenant facility in Arlington, VA that provides 24/7 furnished co-working space, conference room space, and other services on an as-needed basis.

 

ITEM 3. LEGAL PROCEEDINGS.

 

Except as listed below, there is no action, suit, or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or our subsidiaries, threatened against or affecting the Company, our common stock, our subsidiaries, or the Company’s or its subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on the Company. 

 

BV Advisory v. QCi Appraisal Action

 

BV Advisory Partners, LLC (“BV Advisory”) was purportedly a shareholder of QPhoton, Inc., the predecessor in interest to QPhoton (both referred to as “QPhoton” in this Legal Proceedings discussion). On October 13, 2022, BV Advisory filed a petition in the Court of Chancery of the State of Delaware (the “Delaware Chancery Court”) seeking appraisal rights (the “Appraisal Petition”) on the shares of common stock of QPhoton it allegedly owns (which shares represented 10% of the shares of common stock of QPhoton outstanding immediately prior to the Company’s acquisition of QPhoton) pursuant to Section 262 of the Delaware General Corporation Law. The parties agreed to suspend discovery pending resolution of outstanding motions in two related cases. The Company does not have sufficient information to assess the potential impact of the Appraisal Petition at this time.

 

BV Advisory v. QCi Breach of Contract Lawsuit

 

On March 1, 2021, QPhoton entered into a Note Purchase Agreement with BV Advisory (the “BV Note Purchase Agreement”). Pursuant to the BV Note Purchase Agreement, on March 1, 2021, March 23, 2021, and July 9, 2021, QPhoton and BV Advisory entered into convertible promissory notes for $200,592, $150,000, and $150,000, respectively, for a total of $500,592 (the “BV Notes”). The BV Notes all bore interest at a rate of 6% per annum and matured two years from the issuance date. On June 16, 2022, the effective date of our acquisition of QPhoton, QPhoton tendered a cashier’s check to BV Advisory in the amount of $535,684.24, representing the full principal balance of the BV Notes and accrued interest through June 16, 2022. On July 14, 2022, BV Advisory returned the cashier’s check and disputed the calculation of the amount paid to settle the BV Notes.

 

On August 16, 2022, BV Advisory filed a complaint in the Delaware Chancery Court naming the Company and certain of its directors and officers (among others) as defendants (the “Breach Lawsuit”). BV Advisory Partners, LLC v. Quantum Computing Inc., et al., C.A. No. 2022-0719-VCG (Del. Ch.). BV Advisory sought, among other relief, monetary damages from QPhoton for an alleged breach of the BV Note Purchase Agreement. After the Delaware Chancery Court dismissed BV Advisory’s other claims against the Company and QPhoton, on October 17, 2024, the Delaware Chancery Court entered a Stipulation and Order dismissing BV Advisory’s claim for breach of the BV Note Purchase Agreement, subject to BV Advisory’s right to elect to transfer the BV Note claim to the Superior Court of the state of Delaware (the “Delaware Superior Court”). BV Advisory elected to transfer the claim for breach of the BV Note Purchase Agreement to the Delaware Superior Court. On November 12, 2024, BV Advisory filed a new complaint in the Delaware Superior Court, asserting a claim for breach of the BV Note Purchase Agreement and for breach of the implied covenant of good faith and fair dealing. The Company answered the complaint on December 16, 2024. The Company believes that BV Advisory’s BV Note claims have no merit and intends to defend itself vigorously, but does not have sufficient information to assess the potential impact of the Breach Lawsuit at this time.

 

27

 

 

QCi v. BV Advisory Injunction Lawsuit

 

On January 31, 2025, the Company filed a complaint in Delaware Chancery Court against BV Advisory and its principal Keith Barksdale (the “BV Defendants”) asserting claims for defamation, breach of contract, conversion, aiding and abetting conversion, and misappropriation of trade secrets based on the BV Defendants’ unauthorized possession and dissemination of certain of the Company’s confidential and privileged documents. The Company seeks, among other relief, injunctive relief and damages. On February 11, 2025, the Court granted the Company’s motion for a temporary restraining order and instructed the parties to negotiate an expedited case schedule. On February 13, 2025, the Court entered a stipulated case schedule that set a trial for April 8 and 9, 2025 on the Company’s claims for conversion, aiding and abetting conversion, and misappropriation of trade secrets. The parties are currently engaged in discovery.

 

Securities Class Action Lawsuit

 

On February 25, 2025, a class action lawsuit was filed against the Company and certain of its current and past officers in the United States District Court for the District of New Jersey, by a plaintiff seeking to represent a class of all persons who purchased the Company’s securities between March 30, 2020 and January 15, 2025, alleging violations of Section 10(b) and 20(a) of the Exchange Act. The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose material information about the Company’s customers, contracts and business operations. To date the New Jersey District Court has not certified a class or designated a lead plaintiff. The Company disputes the allegations in the complaint and intends to vigorously defend against the asserted claims.

 

Arbitration over Stock Options

 

In February 2025, the Company entered into arbitrations with two former consultants regarding forfeiture of stock options. The Company had issued stock options to the former consultants in 2020 and 2021 and terminated their agreements in March 2024, at which time the Company informed the former consultants that any vested options had to be exercised within three months of the termination date, per the Company’s equity compensation plans. The former consultants did not exercise their vested options and the options were duly forfeited. In December 2024, the former consultants claimed that they still retained the right to exercise the options, which the Company rejected. The Company believes that these claims are without merit and intends to defend itself vigorously.

 

Concluded Proceedings

 

The Company previously disclosed two legal matters which were concluded during 2024. The defamation action filed by the Company in New Jersey Superior Court in December 2022 against BV Advisory and other parties was dismissed on procedural grounds in May 2024. The receivership petition filed by BV Advisory against the Company in July 2023 in the Delaware Chancery Court was dismissed without prejudice in May 2024.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

28

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Market Information

 

Our common stock is listed on the Nasdaq Capital Market under the symbol “QUBT” and commenced trading on July 15, 2021.

 

Authorized Capital

 

The Company is authorized by its Certificate of Incorporation to issue an aggregate of 250,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, of which 1,550,000 shares are designated as Series A Convertible Preferred Stock and 3,079,864 shares are designated as Series B Preferred Stock. As of March 18, 2025, we had 137,244,545 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

 

Holders of Common Equity

 

As of March 18, 2025, there were approximately 214 stockholders of record of our common stock. Because shares of our common stock are held by depositaries, brokers and other nominees, the number of beneficial holders of our shares is substantially larger than the number of stockholders of record.

 

Dividend Information

 

We have not paid any cash dividends to our holders of common stock. The declaration of any future cash dividends is at the discretion of the Board and depends upon our earnings, if any, our capital requirements and financial position, our general economic condition, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

During the year ended December 31, 2024, we have issued securities that were not registered under the Securities Act, all of which were previously disclosed in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

 

ITEM 6. [Reserved]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis of the results of operations and financial condition for the years ended December 31, 2024 and 2023 should be read in conjunction with our consolidated financial statements and the notes to those consolidated financial statements that are included elsewhere in this Annual Report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. See “Forward-Looking Statements.”

 

You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K,

 

Overview

 

QCi is a development stage company with limited operations and revenue. The Company is developing quantum and ancillary non-quantum products for high-performance computing applications based on proprietary photonics technology. QCi’s products are designed to operate at room temperature and low power at an affordable cost in the areas of high-performance computing, sensing and imaging, and quantum cybersecurity. The Company has generated some revenue based on sales of products and related services to date and is expanding its sales and marketing efforts. The Company’s development team includes optical engineers, mathematicians, physicists, and software developers. 

 

29

 

 

Results of Operations

 

Our results of operations for the years ended December 31, 2024 and 2023 is as follows (in thousands, except percentages):

 

   Year Ended December 31, 
   2024   2023   % Change 
Revenue:            
Total revenue  $373   $358    4%
Gross profit   112    162    (31)%
Gross profit margin   30%   45%     
Operating expenses:               
Research and development   11,318    8,891    27%
Sales and marketing   1,818    1,806    1%
General and administrative   12,913    15,708    (18)%
Total operating expenses   26,049    26,405    (1)%
Loss from operations   (25,937)   (26,243)   (1)%
Non-operating income and (expense):               
Interest and other income   423    295    43%
Interest expense, net   (2,496)   (1,602)   56%
Change in fair value of warrant liabilities   (40,532)   528    NM 
Total non-operating income (expense)   (42,605)   (779)   NM 
Net loss  $(68,542)  $(27,022)   154%

 

Revenues

 

The Company’s revenues during the years ended December 31, 2024 and 2023 consisted of (in thousands):

 

   Year Ended December 31, 
   2024   2023   % Change 
Services  $346   $353    (2)%
Products   27    5    440%
Total  $373   $358    4%

 

Revenues for the year ended December 31, 2024 were $373 thousand compared to $358 thousand for the year ended December 31, 2023, an increase of $15 thousand, or 4%. Revenue was derived from sales of hardware products and professional services in 2024 and 2023, in each case provided to multiple commercial and government customers under multi-month contracts. The year-over-year change was driven by changes in the number of, size of and level of effort performed on active customer proof of concept and research and development services and customer hardware contracts. In 2024, the Company continued to execute its business strategy to provide quantum-ready solutions for solving real-world problems. While we have made significant progress toward this overarching objective, the generation of revenue from customers has been slow to develop, in part due to the fact that quantum computing is a cutting-edge technology for most potential customers, who are therefore proceeding cautiously with small, exploratory contracts to better understand its applicability to their requirements. Accordingly, the Company has focused on providing professional services and research and development offerings to introduce customers to quantum-based solutions to their operating needs as well as on customer education and building customer awareness as a means to generating sales. We have developed and released multiple products, including commercial and research and development offerings and foundry services for TFLN Optical Chips manufacturing that we are now in the process of marketing. As a result, we expect product revenues to continue to increase going forward.

 

Cost of Revenues

 

Cost of revenues, which consists of direct labor expenses, primarily salary costs for engineering and solutions staff delivering services, and other direct component costs for custom hardware on research and development contracts, was $261 thousand for the year ended December 31, 2024, compared to $196 thousand for the prior year, an increase of $65 thousand, or 33%. Cost of revenues for each of the years ended December 31, 2024 and 2023 consists primarily of salary expense. The increase for 2024 was predominantly driven by the increases in direct labor expenses and other direct costs required to perform on the contracts during 2024 compared to the prior year.

 

30

 

 

Gross Margin

 

Gross margin for the year ended December 31, 2024 was $112 thousand compared to $162 thousand for the prior year, a decrease of $50 thousand, or 31%. On a percentage basis, gross margin was 30%, a decrease of 15% year-over-year. The change was the result of a new custom hardware contract that had lower margins due to its cost of revenues being comprised of other direct component costs in addition to direct labor expenses. Our lack of a scaled and distributed base of revenue generation by product and sales channel can result in significant differences in gross margin between reporting periods.

 

Operating Expenses

 

Operating expenses of approximately $26.0 million in 2024 decreased as compared to approximately $26.4 million in 2023 primarily as a result of a decrease in general and administrative expenses, partially offset by an increase in research and development expenses, as set forth in the below tables (in thousands, except percentages).

 

   Year Ended December 31,   % 
   2024   2023   Change 
General and administrative  $12,913   $15,708    (18)%

 

General and administrative expenses consist primarily of compensation expenses for employees performing administrative functions, and professional fees incurred for legal, auditing and other consulting services.

 

General and administrative expenses in 2024 decreased $2.8 million or 27% compared with 2023 primarily due to lower employee- and advisor-related expenses, including stock-based compensation, payroll, bonus and travel expenses, as well as lower legal fees and consulting services driven by changes made within and by the Company’s management team, offset by increased audit fees driven by the Company retaining a new independent registered public accounting firm in May 2024and such firm’s re-audit of the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022.

 

   Year Ended December 31,   % 
   2024   2023   Change 
Research and development  $11,318   $8,891    27%

 

Research and development expenses consist primarily of compensation for employees that primarily engage in research and development efforts and fees for the development of hardware products and supporting software. We focus the bulk of our research and development activities on the continued development of existing products and the development of new offerings for emerging market opportunities.

 

Research and development expenses in 2024 increased $2.4 million or 27% compared with 2023 primarily due to higher employee-related expenses, primarily as a result of higher stock-based compensation and bonus expenses to incentivize and retain key technologists, as well as higher depreciation for long-lived laboratory equipment, offset partially by lower professional and hosting services.

 

   Year Ended December 31,   % 
   2024   2023   Change 
Sales and marketing  $1,818   $1,806    1%

 

Selling and marketing expenses consist primarily of employee compensation as well as customer lead generation activities, tradeshow participation, advertising and other marketing and selling costs.

 

31

 

 

Net selling and marketing expenses in 2024 were largely unchanged as compared with 2023, with increases primarily due to higher stock-based compensation, offset by lower outsourced professional services costs, related marketing program costs, and lower trade show and travel-related costs in 2024.

 

Non-operating Income (Expense)

 

The following table summarizes our non-operating income (expense) for the years ended December 31, 2024 and 2023 (in thousands, except percentages).

 

   Year Ended December 31   % 
   2024   2023   Change 
Interest and other income  $423   $295    43%
Interest expense, net   (2,496)   (1,602)   56%
Change in value of derivative and warrant liabilities   (40,532)   528    NM 
Other income (expense)  $(42,605)  $(779)   NM 

 

Non-operating expense increased to $42.6 million for 2024 compared to $779 thousand for 2023, primarily as the result of a $40.5 million decrease in the change in fair value of the derivative liability for the QPhoton Warrants, as defined below, during 2024 compared to a $528 thousand increase in 2023.

 

The loss on change in value of warrant liability is entirely comprised of mark-to-market adjustments for the QPhoton Warrants, as defined below in the accompanying notes to our consolidated financial statements appearing elsewhere in this report, which had no carrying value as of December 31, 2023. Future mark-to-market adjustments may result in continued losses if the price of the Company’s common stock increases above the closing bid price of $16.55 per share at December 31, 2024; such adjustments may alternatively result in gains if the closing bid share price of the Company’s common stock decreases. See Note 10, Capital Stock, in the accompanying notes to our consolidated financial statements appearing elsewhere in this report for additional information on the QPhoton Warrants.

 

In addition, interest expense, net, which consists of interest on financial liabilities and amortization of debt issuance costs, increased $128 thousand or 43% in 2024 compared to 2023, which increase was primarily attributable to interest paid on the secured convertible promissory note in the original principal amount of $8.25 million that we issued to Streeterville Capital, LLC in August 2024 (the “Streeterville Convertible Note”), which we paid in full as of December 31, 2024. See Note 7, Financial Liabilities, in the accompanying notes to our consolidated financial statements appearing elsewhere in this report for additional information.

 

Liquidity and Capital Resources

 

We have incurred net losses and experienced negative cash flows from operations since inception. Through December 31, 2024, the Company has raised $167.8 million through its issuance of common stock and $20.1 million through its issuance of convertible promissory notes and other debt for a total of $187.9 million. The Company has no lines of credit or short-term debt obligations outstanding. We expect to incur additional losses and higher operating expenses for the foreseeable future as we continue to invest in research and development and go-to-market programs. As of December 31, 2024, the Company had cash and cash equivalents of $78.9 million.

 

Our primary uses of cash are to fund and invest in our operations as we continue to grow our business. We will require a significant amount of cash for continued investment in our Foundry Services offering, including but not limited to our AZ Chips Facility and any future-identified space for expansion, as well as ongoing research and development for our non-linear quantum optical products and photonics chips. Until such time as we can generate significant revenue from sales or subscriptions of our hardware offerings, we expect to finance our operating and investing needs through our cash and cash equivalents and, equity and/or debt financings or other capital sources, including but not limited to U.S. government grant and loan programs. We may, however, be unable to raise sufficient funds or enter into such other arrangements, when needed, on favorable terms, or at all. In particular, uncertain and unfavorable conditions in the United States and global macroeconomic environment, including inflationary pressures, rising interest rates, bank failures, and financial and credit market fluctuations, could reduce our ability to access capital on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, or substantially reduce our product development and go-to-market efforts. There can be no assurances that the Company will be able to secure additional equity and/or debt investments or achieve an adequate sales level. We believe, however, that the Company’s existing cash and cash equivalents, together with any cash generated from operations and the proceeds from any additional equity or debt issuances will be sufficient to meet the Company’s liquidity needs for at least the next 12 months.

 

32

 

 

The following table summarizes total current assets, liabilities and working capital at December 31, 2024, compared to December 31, 2023 (in thousands):

 

   December 31,
2024
   December 31,
2023
   Increase/
(Decrease)
 
Current assets  $79,151   $2,656   $76,495 
Current liabilities  $4,559   $4,812   $(253)
Working capital (deficit)  $74,592   $(2,156)  $76,748 

 

At December 31, 2024, we had working capital of $74.6 million as compared to working capital deficit of $2.2 million at December 31, 2023, an increase of $76.8 million. The increase in working capital is primarily attributable to an increase in cash from the net proceeds of our sales of 16 million shares of common stock for an aggregate of $40 million in November 2024 and 10 million shares of common stock for an aggregate of $50 million in December 2024, and our issuance of 23.7 million shares of common stock for an aggregate of $23.8 million through the Company’s ATM, as defined below, managed by Ascendiant Capital Markets, LLC during 2024, offset by the use of cash to pay for operating expenses and capital investments in property and equipment. For more information on the November and December issuances, please see Note 10, Capital Stock, in the accompanying notes to our consolidated financial statements appearing elsewhere in this report.

 

Cash Flows

 

The following table summarizes our cash flow for the years ended December 31, 2024 and 2023 (in thousands):

 

   Year Ended December 31, 
   2024   2023 
Net cash used in operating activities  $(16,213)  $(18,315)
Net cash used in investing activities   (6,036)   (2,612)
Net cash provided by financing activities   99,135    17,678 
Net increase (decrease) in cash and cash equivalents  $76,886   $(3,249)

 

Net cash used in operating activities for the years ended December 31, 2024 and 2023 was $16.2 million and $18.3 million, respectively, in each case primarily as a result of our net loss in each period offset by noncash adjustments for stock-based compensation, mark-to-market valuation adjustments on financial liabilities, and depreciation and amortization.

 

Net cash used in investing activities for the years ended December 31, 2024 and 2023 was $6.0 million and $2.6 million, respectively, and was attributable to our purchase of TFLN Optical Chips manufacturing equipment for our AZ Chips Facility, as well as computer hardware and laboratory equipment. The increase in 2024 is primarily due to the purchase of additional equipment in connection with establishing the AZ Chip Facility.

 

33

 

 

Net cash provided by financing activities for the years ended December 31, 2024 and 2023 was $99.1 million and $17.7 million, respectively. Cash flows provided by financing activities during year ended December 31, 2024 were attributable to proceeds from our stock issuances in November and December 2024, and the proceeds from our sale of shares of common stock pursuant to the ATM facility and our issuance of the Streeterville Convertible Note, partially offset by repayments on the Streeterville Unsecured Note, as defined below, and the Streeterville Convertible Note as well as redemptions of shares of Series A Preferred Stock.

 

On a long-term basis, our liquidity is dependent on continuation and expansion of operations and receipt of revenues. Demand for the Company’s products and services will be dependent on, among other things, market acceptance of our products and services, the technology market in general, and general economic conditions, which are cyclical in nature. As much revenues will be derived from the sales of our products and services, our business operations may be adversely affected by the products and services offered by our competitors and any prolonged recession periods.

 

Critical Accounting Estimates

 

Certain of our accounting policies require the application of significant judgment by our management, and such judgments are reflected in the amounts reported in our consolidated financial statements. In applying these policies, our management uses judgment to determine the appropriate assumptions to be used in the determination of estimates. Those estimates are based on our historical experience, terms of existing contracts, our observance of market trends, information provided by our strategic partners and information available from other outside sources, as appropriate. Actual results may differ significantly from the estimates contained in our consolidated financial statements.

 

Fair Value of Stock-based Compensation

 

We recognize stock-based compensation expense for all share-based payment awards in accordance with ASC 718, Compensation – Stock Compensation. Stock-based compensation expense for expected-to-vest awards is valued under the single-option approach and amortized on a straight-line basis, accounting for actual forfeitures as they occur. We utilize the Black-Scholes pricing model in order to determine the fair value of stock-based option awards. The Black-Scholes pricing model requires various highly subjective assumptions including volatility, expected option life, and risk-free interest rate. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future.

 

Fair Value of Warrant Liabilities and Derivatives

 

Determining the fair market value of the QPhoton Warrants, which were included in the merger consideration paid to the stockholders of QPhoton (the “QPhoton Merger Consideration”), is a critical accounting estimate. The QPhoton Warrants are comprised of warrants to purchase up to 7,028,337 shares of the Company’s common stock at an exercise price of $0.0001 per share (the “QPhoton Warrants”) and are exercisable when and if stock options and warrants issued by the Company and outstanding as of June 15, 2022 are exercised. The Merger Consideration for shareholders Yuping Huang and The Trustees of the Stevens Institute of Technology was issued in 2022. A third alleged shareholder, BV Advisory, rejected the Merger Consideration and commenced litigation in Delaware Chancery Court (see Note 8, Contingencies – Legal Proceedings, in this Form 10-K for additional information and Item 3, Legal Proceedings, in this Form 10-K for a full discussion), and to date that litigation has not been resolved. Accordingly, as of December 31, 2024 and 2023, we had only issued 6,325,503 of the QPhoton Warrants. In determining the fair market value of the QPhoton Warrants, the Company determines which underlying options and warrants are in-the-money or out-of-the-money at period end by comparing to the bid price of the Company’s common stock, then accounts for changes period-over-period by realizing a mark-to-market gain or loss for the period.

 

An additional critical accounting estimates involves determining the fair value of the conversion features ingerent in the Streeterville Convertible Note (the “Streeterville Derivative Liability”), which involves inherent uncertainties and the application of management judgement. The Streeterville Derivative Liability will be mark-to-market adjusted on a quarterly basis and accreted as interest expense while the Streeterville Convertible Note is outstanding.

 

34

 

 

Fair Market Value and Useful Life of Intangible Assets

 

Determining the fair market value and useful life of the intangible assets acquired by the Company through the QPhoton Merger is another critical accounting estimate. In the absence of market pricing for the intangible assets, the Company relied on independent third-party appraisal experts and comparison with similar transactions to arrive at estimates of value as well as useful life. The Company will perform periodic assessments of the intangible assets for impairment, but if any of the initial estimates are incorrect, that could result in a calculation of amortization expense that is too high or too low.

 

Valuation Allowances for Deferred Taxes

 

Our income tax expense, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect management’s assessment of estimated current and future income taxes to be paid. We are subject to income taxes in the United States. Significant judgments and estimates are required in determining the consolidated income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits.

 

Deferred tax assets and liabilities arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements, which are expected to result in taxable or deductible amounts in the future. In evaluating our ability to recover our deferred tax assets within the jurisdiction from which they arise, for all material jurisdictions, we consider all available positive and negative evidence, including scheduled reversals of deferred tax balances, projected future taxable income, tax-planning strategies and results of recent operations. In projecting future taxable income, we begin with historical results and incorporate assumptions about the amount of future state, federal and foreign pretax operating income adjusted for items that do not have tax consequences. The assumptions about future taxable income require significant judgment and are consistent with the plans and estimates we use to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating results.

 

As of December 31, 2024, we had federal and state net operating loss (“NOL”) carryforwards of approximately $89.4 million, or $19.6 million on a tax-effected basis. We believe that it is more likely than not that the benefit from these NOL carryforwards will not be realized. Accordingly, we have provided a full valuation allowance on any potential deferred tax assets relating to these NOL carryforwards. If our assumptions change and we determine we will be able to realize these NOLs, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets as of December 31, 2024, will be accounted for as a reduction of income tax expense.

 

The calculation of our tax liabilities involves evaluating uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. ASC 740, Income Taxes, states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including the resolution of any related appeals or litigation processes, on the basis of the technical merits.

 

We record unrecognized tax benefits as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a tax payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is made available.

 

We believe that none of the unrecognized tax benefits may be recognized by the end of 2024.

 

Legal and Other Contingencies

 

The outcomes of legal proceedings and claims brought against us are subject to significant uncertainty. An estimated loss from a loss contingency such as a legal proceeding or claim is accrued by a charge to income if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. In determining whether a loss should be accrued we evaluate, among other factors, the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of loss. Changes in these factors could materially impact our consolidated financial statements.

 

35

 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

Our consolidated financial statements are contained in pages F-1 through F-29 which appear at the end of this Annual Report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Exchange Act. In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

As of the end of the period covered by this Annual Report on Form 10-K, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer concluded that as of December 31, 2024, our disclosure controls and procedures were not effective to provide reasonable assurance that (i) the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and President and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. 

 

Report of Management on Internal Control over Financial Reporting

 

Company management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. The Company’s internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by the Board, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Material Weakness in Internal Control over Financial Reporting 

 

Company management has assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013).

 

36

 

 

Based on this assessment, management has determined that the Company’s internal control over financial reporting was not effective.

 

A material weakness, as defined by the Public Company Accounting Oversight Board, is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

The ineffectiveness of the Company’s internal control over financial reporting was due to the following material weaknesses which are common to many small companies with limited staff:

 

  (i) inadequate segregation of duties consistent with control objectives;
     
  (ii) inadequate controls related to revenue recognition;
     
  (iii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both accounting principles generally accepted in the United States of America and SEC Guidelines; and
     
  (iv) inadequate information technology general controls specifically related to security, segregation of duties, user access, restricted access and change management.

 

Management’s Plan to Remediate the Material Weakness 

 

The Company has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. In addition to identifying and remediating design deficiencies in its processes, the Company has formally documented its procedures for many of the significant accounting and financial reporting processes, including implementation of procedures for revenue recognition and segregation of duties. The other remediation actions planned include:

 

  (i) further documentation and implementation of control procedures and the implementation of control monitoring; and
     
  (ii) identify and remedy gaps in our information technology general controls specifically related to the areas of security, user access, restricted access and change management.

 

We are committed to maintaining a strong internal control environment and believe that these remediation efforts will represent significant improvements in our control environment. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

 

Management’s report on internal control over financial reporting was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the SEC that permit a Smaller Reporting Company to provide only Management’s report in this annual report, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected.

 

Changes in Internal Control over Financial Reporting

 

As discussed above, we are implementing certain measures to remediate the material weaknesses identified in the design and operation of our internal control over financial reporting. Other than those measures, there have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION.

 

Rule 10b5-1 Trading Plans

 

During the three months ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified the amount, pricing or timing provisions of a “Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

Not applicable.

 

37

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

Directors and Executive Officers

 

The following table contains information with respect to our directors and executive officers. To the best of our knowledge, none of our directors or executive officers have an arrangement or understanding with any other person pursuant to which he or she was selected as a director or officer. There are no family relationships between any of our directors or executive officers. Directors serve one-year terms. Our executive officers are appointed by and serve at the pleasure of the Board.

 

Name   Current
Age
  Position
Dr. William McGann (1)   67   Chief Executive Officer (CEO) and President (Principal Executive Officer)
Christopher Boehmler   46   Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
Dr. Yuping Huang   45   Chairman of the Board and Chief Quantum Officer
Robert Fagenson   76   Vice Chairman of the Board
Michael Turmelle   65   Director
Dr. Carl Weimer   63   Director
Dr. Javad Shabani   43   Director

 

Dr. McGann has served as the Company’s CEO and President since February 1, 2024. Prior to that, he had served as the Company’s Chief Technology Officer and Chief Operations Officer since January 2022 and as a Director of the Company from September 2021 to December 2021. Prior to joining Quantum Computing, Dr. McGann was the Chief Technology Officer for the Security, Detection and Automation business at Leidos Holdings, Inc., a provider of technical services, primarily to the U.S. government, from May 2019 to January 2022. Dr. McGann has a strong, directed passion for transforming credible science into practical technology solutions in solving some of the world’s greatest challenges. Prior to joining Leidos, Dr. McGann held numerous business and technology leadership positions and roles including (a) Founder of the first explosives trace detection company, Ion Track Instruments, (b) Chief Technology Officer for GE Security, (c) VP of Engineering for United Technologies Fire and Security business, (d) CEO and board member of Implant Sciences Corp., and (e) Chief Technology Officer at L3Harris Aviation Security and Detection business. Dr. McGann holds a Ph.D. in Chemical Physics from the University of Connecticut and undergraduate degrees in Chemistry and Biology.

 

Mr. Boehmler has served as the Company’s Chief Financial Officer since July 1, 2023. Mr. Boehmler joined Quantum Computing Inc. as Controller in March 2022. He worked as an independent consultant from June 2018 until March 2022, serving both private and non-profit organizations. Previous to June 2018, his corporate finance experience includes 12 years in senior management positions for private and public technology-driven and financial institutions, primarily at Bridgewater Associates, LP and Intelsat. During this time, he also led the finance functions for two start-ups where he was instrumental in raising private equity and performing due diligence on acquisition targets. His financial expertise spans capital markets, planning & analysis, accounting operations, management and regulatory reporting, financial systems integrations, and financial risks and controls. He started his career working in the investment banking division of Credit Suisse First Boston, followed by strategic management consulting for Booz Allen Hamilton. Mr. Boehmler has an undergraduate degree in Economics with a minor in Germanic Studies from the University of Chicago.

 

38

 

 

Dr. Huang has served as the Company’s Chairman of the Board since December 10, 2024 and as Chief Quantum Officer and a Director since June 14, 2022. Dr. Huang has over 20 years of experience in commercial and academic settings, with pioneering research in a wide spectrum of quantum physics, optics, and technology. Prior to joining the Company, Dr. Yuping founded QPhoton, Inc., where he served as Chairman of the Board and Chief Executive Officer from 2020 until its acquisition by the Company in 2022. QPhoton was a development stage company commercializing quantum photonic technology and devices to provide innovative and practical quantum solutions for critical challenges facing big data, cyber, remote sensing, and healthcare industries. Dr. Huang worked as a postdoctoral fellow, a research faculty member, and principal investigator at Northwestern University from 2009-2014. Dr. Huang has been a Professor of Physics at the Stevens Institute of Technology, a private research technological university in Hoboken, New Jersey, since 2014 (from 2014 to 2019 as assistant professor, from 2019-2023 as associate professor and as a full professor since 2023). Dr. Huang is the founding director of the Center for Quantum Science and Engineering and Gallagher Associate Professor of Physics at the Stevens Institute of Technology. He received a Bachelor of Science in modern physics from the University of Science and Technology of China in 2004 and a PhD in quantum AMO physics in 2009 from Michigan State University. Dr. Huang’s expertise in quantum physics and optics and leadership experience in quantum research qualifies him to serve as a member of the Board.

 

Mr. Fagenson has served as a Director of the Company since March 2021 and as Vice Chairman since December 10, 2024. Mr. Fagenson has served as a member of the board of directors of National Holdings Corporation (“NHC”), a broker-dealer, since March 2012. He has served as Vice Chairman of the board of directors of NHC since September 2016. Mr. Fagenson previously served as Co-Chief Executive Officer of NHC from January 3, 2017 to January 31, 2017, as Chief Executive Officer and Chairman of the board of directors of NHC from December 2014 to September 2016, and as Executive Vice Chairman of the board of directors of NHC from July 2012 to December 2014. NHC was acquired by B. Riley Financial in February 2024. Mr. Fagenson has been a branch owner at National Securities Corp, an operating company of NHC, since 2012, and president of Fagenson & Co., Inc., a family investment company, since 1982. Mr. Fagenson spent the majority of his career at the New York Stock Exchange (“NYSE”), where he was managing partner of one of the exchange’s largest specialist firms. While at the NYSE, Mr. Fagenson served as a governor on the trading floor and was elected to the NYSE board of directors in 1993, where he served for six years, eventually becoming vice chairman of the NYSE board of directors from 1998 to 1999 and 2003 to 2004. Mr. Fagenson has served as director of the New York City Police Museum since 2005 and as director of the Federal Law Enforcement Officers Association Foundation since 2009. He has also served on the board of directors of Sigma Alpha Mu Foundation since 2011 and on the board of directors of New York Edge since 2015. In addition, Mr. Fagenson served as the non-executive chairman of Document Security Systems, Inc. from 2012 to 2018 (NYSEMKT: DSS). He is currently a member of the alumni boards of the Whitman School of Business at Syracuse University. Mr. Fagenson received his B.S. in Transportation Sciences & Finance from Syracuse University in 1970. Mr. Fagenson’s experience in the financial services industry and in senior leadership positions qualifies him to serve as a member of the board and as chairman of the compensation committee.

 

Mr. Turmelle has served as a Director of the Company since January 2022. Mr. Turmelle has served on the board of directors of Ideal Power Inc. since December 2017 and as chairman of the Ideal Power board since 2021. From January 2018 through January 2024, Mr. Turmelle served as the Managing Director of Hayward Tyler, a United Kingdom private equity-backed manufacturer and service provider of pumps and motors, which he joined in February 2015. Mr. Turmelle also served on the boards of Hayward Tyler and Energy Steel (a Hayward Tyler subsidiary) from 2017 until January 2024. Hayward Tyler designs, manufactures, and services performance-critical electric motors and pumps to meet the most demanding of applications for the global energy industry, as both an original equipment manufacturer supplier and trusted partner. Previously, Mr. Turmelle ran his own consulting company, working with start-ups and turn-arounds in the areas of renewable energy, medical, and other advanced technologies. Mr. Turmelle has served on numerous Boards of Directors including the Board of Directors of Implant Sciences Corp., an explosive and narcotic trace detection company, where he served as Chairman of the Board from 2015 to 2017. Mr. Turmelle was Chief Financial Officer and Chief Operating Officer and a member of the Board of Directors of SatCon Technology Corporation, a maker of energy management systems, from 1992 to 2005. Mr. Turmelle was also on the Board of Directors of Beacon Power, a SatCon spin-off company dealing in flywheel energy storage, from 1996 to 2000. Mr. Turmelle has a BA in Economics from Amherst College and is a graduate of General Electric’s Financial Management Program. Mr. Turmelle’s experience as a public company director and executive as well as extensive experience in finance, business operations and technology, qualifies him to serve as a member of the Board and as chairman of the audit committee.

 

39

 

 

Dr. Weimer has served as a director of the Company since January 14, 2023. Dr. Weimer has over 25 years of experience in the aerospace industry. He has previously been involved in two companies in the aerospace industry, holding positions including Director of Research, Principal Investigator, Chief Systems Engineer, and Chief Technologist. From 1994 through 2000, Dr. Weimer was a Director Research for Ophir Corporation, an aerospace optics company. From 2000 to 2025 he was Technical Leader for Ball Aerospace & Technologies Corp. (now BAE Systems SMS) developing advanced high-reliability instrumentation, and in 2008 he was awarded a NASA Distinguished Public Service Medal for space-based lidar technologies. Since 2014 he’s been the Chief Technologist for the Civil Business Unit Leading a team performing R&D for future space missions. In addition, Dr. Weimer has been a Principal Investigator for the NASA Earth Science Technology Office since 2008, and he holds seven U.S. patents in optical systems. Dr. Weimer received a Bachelor of Science degree from Harvey Mudd College (1984) and a Master of Science (1987) and a PhD (1992) from Colorado State University, all in experimental Physics. He did his graduate and postdoctoral research in the Ion Storage Group at NIST Boulder and a second postdoc in the Optical Standards Group. Dr. Weimer’s expertise in advanced optics and leadership experience in the aerospace industry qualifies him to serve as a member of the Board.

 

Dr. Shabani has served as a director of the Company since April 19, 2024. Dr. Shabani has over 13 years of experience in advanced physics and quantum information physics. Dr. Shabani has been a professor in the New York University Physics Department and director of the NYU Center for Quantum Information Physics since 2024. From 2022 to 2024, he was an Associate Professor at the NYU Physics Department. From 2017 to 2022, he was an Assistant Professor at the NYU Physics Department. From 2015 to 2017, Dr. Shabani was an Assistant Professor at the City College of New York Physics Department. From 2014 to 2015, he was a Project Scientist in the California Nanosystems Institute at the University of California Santa Barbara. He was a Postdoctoral Fellow at the Harvard University Physics Department from 2011 to 2012 and the California Nanosystems Institute at the University of California Santa Barbara from 2012 to 2014. He was awarded the IBM Q Scholar Award in 2021, and the US Air Force Young Investigator Program Award and the US Army Young Investigator Award in 2016. Dr. Shabani holds four patents in quantum physics applications and has published over 85 papers. Dr. Shabani received Bachelor of Science degrees in physics and electrical engineering from Sharif University of Technology (2004) a Master of Science in Electrical Engineering from the University of California, Santa Cruz (2005), a Master of Arts in Electrical Engineering from Princeton University (2007) and a PhD in Electrical Engineering from Princeton University (2011). Dr. Shabani’s scholarship and experience in physics and electrical engineering qualifies him to serve on the Board to help lead the Company towards continued growth and success.

 

Delinquent Section 16(a) Reports

 

Section 16(a) of the Exchange Act requires the Company’s directors, executive officers and persons who beneficially own 10% or more of a class of securities registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Directors, executive officers and greater than 10% stockholders are required by the rules and regulations of the SEC to furnish the Company with copies of all reports filed by them in compliance with Section 16(a).

 

Based solely upon a review of Forms 3 and 4 and amendments thereto furnished to the Company during the fiscal year ended December 31, 2023, including those reports that we have filed on behalf of our directors and Section 16 officers, no director, Section 16 officer, beneficial owner of more than 10% of the outstanding common stock, or any other person subject to Section 16 of the Exchange Act, failed to file with the SEC on a timely basis during the fiscal year ended December 31, 2023, except (i) as previously disclosed by the Company, (ii) Robert Liscouski filed a Form 4 on July 7, 2023, which was delinquent, in connection with his sale of common stock, the earliest of which occurred on November 25, 2022.

 

40

 

 

Code of Ethics

 

The Company currently maintains a code of ethics that applies to all directors, officers, and employees. A copy of our code of ethics can be found on our website at www.quantumcomputinginc.com. We expect that any amendments to such code, or any waivers of its requirements, will be disclosed on our website.

 

Insider Trading Policy

 

The Company has adopted an insider trading policy that governs the purchase, sale and other dispositions of our securities that applies to our officers and directors, as well as our employees that have regular access to material, nonpublic information about the Company in the normal course of their duties. We believe that our insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this Form 10-K.

 

Board Composition and Director Independence

 

The Board is authorized to have up to seven members and currently consists of five members. The nominees elected as directors at the Annual Meeting will serve until our next annual meeting and until their successors are duly elected and qualified. Nasdaq Listing Rule 5605(a)(2) requires a majority of a listed company’s board of directors be composed of independent directors. In addition, Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation, and nominating committees be independent, and that compensation and audit committee members also satisfy additional independence criteria under the Exchange Act. Compensation committee members also should qualify as “non-employee directors” under Rule 16b-3 of the Exchange Act.

 

In making the determination of whether a member of the board is independent, the Board considers, among other things, transactions and relationships between each director and his immediate family and the Company, including those reported under the caption “Certain Relationships and Related-Party Transactions.” The purpose of this review is to determine whether any such relationships or transactions are material and, therefore, inconsistent with a determination that the directors are independent. On the basis of such review and its understanding of such relationships and transactions, the Board affirmatively determined that Robert Fagenson, Michael Turmelle, Carl Weimer and Javad Shabani are qualified as independent and that they have no material relationship with us that might interfere with his exercise of independent judgment.

 

Board Committees; Audit Committee Financial Expert; Stockholder Nominations

 

The Board has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each such committee has its own charter, which is available on our website at www.quantumcomputing.com. Each of such Board committees has the composition and responsibilities described below.

 

The following table identifies the committee members:

  

Name  Audit  Compensation  Nominating and
Corporate
Governance
  Independent 
Robert Fagenson  X  Chairman  X  X 
Michael Turmelle  Chairman  X  X  X 
Javad Shabani     X  X  X 
Carl Weimer  X     Chairman  X 
Yuping Huang             

 

The Board has determined that Michael Turmelle is an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of SEC Regulation S-K.

 

Members will serve on these committees until their resignation or until otherwise determined by the Board.

 

41

 

 

Involvement in Certain Legal Proceedings.

 

Our Chief Executive Officer, Dr. McGann, was the Chief Executive Officer of Implant Sciences Corporation, when it filed a petition for bankruptcy on October 11, 2016 in the Delaware Bankruptcy Court.

 

With the exception of the foregoing, to the best of our knowledge, none of our directors or executive officers has, during the past ten years:

 

  been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
     
  had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
     
  been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;
     
  been found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

 

  been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
     
  been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

42

 

 

ITEM 11. EXECUTIVE COMPENSATION

 

Summary Compensation Table

 

The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the years ended December 31, 2024 and 2023.

 

2024 EXECUTIVE OFFICER COMPENSATION TABLE

 

Name and Principal Position  Year  Salary
($)
  Bonus
($)
  Stock Awards
($)
  Option Awards
($)
  All Other Compensation
($)
  Total
($)
 
William McGann(1)  2024  402,216  42,188  0  151,911  0  596,314 
Chief Executive Officer and President  2023  403,074  0  207,488  0  0  610,562 
Chris Boehmler(2)  2024  300,451  70,313  174,000  313,062  0  857,826 
Chief Financial Officer  2023  260,246  5,000  75,648  163,101  0  503,995 
Robert Liscouski(3)(4)  2024  33,490  0  193,200  0  366,667  593,357 
Chairman  2023  403,130  0  0  75,263  0  478,393 
Yuping Huang   2024   380,369   33,751   0   0   0   414,120  
Chief Quantum Officer   2023   400,300   0   106,496   0   0   506,796  

 

(1)Dr. McGann was appointed CEO and President effective February 1, 2024; prior to that time, he served as the Company’s Chief Operating Officer and Chief Technology Officer.

 

(2) Mr. Boehmler was appointed Chief Financial Officer of the Company on July 1, 2023.

 

(3)Mr. Liscouski was terminated as CEO and President effective January 31, 2024.

 

(4)All other compensation amounts for 2024 consist of severance payments, per Mr. Liscouski’s Separation Agreement and General Release.

 

Employment Agreements and Change-in-Control Provisions

 

Executive Employment Agreements

 

Dr. McGann Employment Agreement

 

We entered into an employment agreement with Dr. William J. McGann, our Chief Executive Officer and President, on January 3, 2022, as amended on February 1, 2024 and December 30, 2024. Dr. McGann’s employment agreement, as amended, is for a term ending on December 31, 2025. Dr. McGann’s employment agreement, as amended, provides for an annual base salary of $420,000, subject to annual review and adjustment as determined by the Board or its compensation committee. Dr. McGann is also eligible to earn an annual cash bonus in an amount of up to 37.5% of his base salary, subject to achieving certain performance milestones established and approved by the Board, with a minimum annual cash bonus of 5%. Pursuant to the agreement, on January 3, 2022, Dr. McGann was granted options to purchase up to 535,000 shares of our common stock, with one-third of the options vesting immediately upon grant and one-third vesting upon each of the first and second anniversary of the date of grant.

 

Pursuant to the terms of his employment agreement, the Company may terminate Dr. McGann’s employment with or without Cause, as defined in the agreement, and Dr. McGann may terminate his employment with or without Good Reason, as defined in the agreement, upon written notice to the Company as set forth in the agreement. Upon termination of Dr. McGann’s employment by the Company without Cause or by Dr. McGann for Good Reason, the Company shall continue to pay Dr. McGann his then current monthly base salary for 12 months from the date of termination. The Company must also continue Dr. McGann’s coverage under and its contributions to his health care, dental, and life insurance benefits for six months, unless he is or becomes covered by an equivalent benefit, and pay him a pro rata portion of any bonus he has earned prior to his termination. In addition, if the Company terminates Dr. McGann’s employment without Cause or he terminates his employment for Good Reason within 12 months after a Change of Control, as define in the agreement, or an acquisition, then the Company must pay to Dr. McGann an additional sum equal to 12 months of his base salary.

 

43

 

 

As a full-time employee of the Company, Dr. McGann is eligible to participate in all of the Company’s bonus and benefit programs.

 

Mr. Boehmler Employment Agreement

 

We entered into an employment agreement with Mr. Christopher Boehmler, our Chief Financial Officer, dated as of June 26, 2023, pursuant to which Mr. Boehmler serves as our Chief Financial Officer. The agreement provides for an indefinite term, that Mr. Boehmler’s employment is at-will, and that either the Company or Mr. Boehmler can terminate his employment for any reason. Mr. Boehmler’s employment agreement provides for an annual base salary of $300,000 per year, subject to annual review and adjustment as determined by the Board or its compensation committee. Under his employment agreement, Mr. Boehmler is also eligible for an annual incentive bonus in the amount of up to 50% of his base salary, subject to Mr. Boehmler achieving certain performance milestones established by the Board or its compensation committee, and, subject to Board approval, an annual grant of options to purchase 125,000 shares of our common stock at an exercise price equal to 110% of the grant date fair market value, one-third of which shall vest on the grant date and the remainder becoming exercisable in equal monthly installments over the following three years. Pursuant to the agreement, Mr. Boehmler was issued options to purchase 300,000 shares of the Company’s common stock in 2023, 100,000 of which vested on the grant date and 100,000 of which shall vest on each of the 12- and 24-month anniversary of the grant date.

 

If the Company terminates Mr. Boehmler’s employment without Cause, as defined in the agreement, or Mr. Boehmler terminates his employment for Good Reason, as defined in the agreement, with 90 days prior notice to the Company and subject to his execution of a release in favor of the Company, the Company shall pay Mr. Boehmler an amount equal to his then current monthly base salary for 12 months from the date of termination. The Company must also, subject to his timely election of continuation coverage under COBRA, continue payment or reimbursement of 100% of Mr. Boehmler’s premiums for such health insurance coverage for six months following his termination or until he becomes covered by an equivalent benefit, and pay him a pro rata portion of any bonus he has earned prior to his termination. In addition, if the Company terminates Mr. Boehmler’s employment without Cause or he terminates his employment for Good Reason within 12 months after a Change of Control, as define in the agreement, then the Company must pay to Mr. Boehmler an additional sum equal to 12 months of his base salary.

 

As a full-time employee of the Company, Mr. Boehmler is eligible to participate in all of the Company’s benefit programs.

 

Mr. Liscouski Employment Agreement

 

The Company and Mr. Robert Liscouski were parties to an amended and restated employment agreement dated as of April 26, 2021, pursuant to which Mr. Liscouski served as our Chief Executive Officer during the fiscal years ended December 31, 2022 and 2023 (the “Liscouski Employment Agreement”). The Liscouski Employment Agreement provided for an initial term of three years and would be automatically renewed for consecutive one-year terms at the end of the initial term unless terminated or either party provided notice of non-renewal to the other. The agreement provided that Mr. Liscouski would receive an annual base salary of $400,000, subject to review and increases (but not decreases) by the Board or its compensation committee and be eligible to earn a performance bonus of up to 50% of his base salary subject to his achieving certain performance milestones established by the Board. The agreement also provided that, beginning on the first anniversary thereof, Mr. Liscouski would receive an annual grant of options to purchase 150,000 shares of our common stock at an exercise price equal to 110% of the grant date fair market value, with one-third vesting on the date of grant and the remainder vesting in equal monthly installments thereafter. Pursuant to the Liscouski Employment Agreement, Mr. Liscouski also received (i) options to purchase 250,000 shares of common stock of the Company upon execution of the agreement and (ii) 250,000 options to purchase shares of common stock of the Company upon the Company’s listing on Nasdaq.

 

In connection with the termination of Mr. Liscouski employment as our Chief Executive Officer on January 31 2024, the Company and Mr. Liscouski entered into a Separation Agreement and General Release. Pursuant to the separation agreement, the Company agreed to pay Mr. Liscouski $400,000, representing 12 months of his base salary, on the Company’s regular payroll dates for 12 months following his termination, to grant him 168,000 shares of Company common stock, and, subject to his timely election of continuation coverage under COBRA, to continue to pay or reimburse 100% of his premiums for such health insurance coverage for 12 months following his termination or until he becomes covered by an equivalent benefit. The separation agreement also provides that Mr. Liscouski’s unvested options and restricted stock grants vested as of his termination date.

 

We also entered into an agreement with Mr. Liscouski, effective as of February 1, 2024, which provides that the Company will pay him a monthly fee of $12,500 for his service as a Director of the Company (including as Chairman of the Board). Such monthly fee will be in lieu of the standard compensation we pay to our directors. Mr. Liscouski served on the Board of Directors from February 2018 to December 2024.

 

44

 

 

Outstanding Equity Awards at Fiscal Year End

 

The following table sets forth information regarding equity awards held by our named executive officers as of December 31, 2024:

 

   Option Awards  Stock Awards 
Name  Number of
securities
underlying
unexercised
options
(#)
exercisable
   Number of
securities
underlying
unexercised
options
(#)
unexercisable
   Option
exercise
price
($)
   Option
expiration
date
  Number of
shares or
units of
stock that
have not
vested
(#)
   Market
value of
shares or
units of
stock that
have not
vested
($)
 
William J. McGann(1)   535,000    0    2.40   January 24, 2027   0    0 
William J. McGann   1,000,000    0    2.37   October 17, 2027          
Chris Boehmler(2)   60,834    30,416    2.56   March 28, 2027   129,850    2,149,018 
Chris Boehmler   5,834    2,916    2.37   October 12, 2027          
Chris Boehmler   200,000    100,000    1.18   December 27, 2028          
Chris Boehmler   53,241    71,759    0.46   October 4, 2029   -    - 
Robert Liscouski(3)   75,000    0    1.00   May 22 2025   0    0 
Robert Liscouski   250,000    0    6.85   April 26, 2026          
Robert Liscouski   250,000    0    2.40   January 24, 2027          
Robert Liscouski   1,500,000    0    2.37   October 17, 2027          
Robert Liscouski   150,000    0    2.61   October 17, 2027          
Robert Liscouski   150,000    0    1.44   December 27, 2028          

 

(1)Dr. McGann’s stock options expiring January 24, 2027 vested as follows: (i) 178,333 options vested on January 24, 2022; (ii) 178,333 options vested on January 24, 2023; and (iii) 178,334 options vested on January 24, 2024. Dr. McGann’s stock options expiring on October 17, 2027 vested as follows: (i) 750,000 options vested on October 17, 2022; and (ii) 250,000 options vested on December 31, 2022.

 

(2)Mr. Boehmler’s stock options expiring March 28, 2027 and October 12, 2027 vest as follows: (i) 33,334 options vested on March 28, 2023; (ii) 33,334 options vested on March 28, 2024; and (iii) 33,332 options vest on March 28, 2025. Mr. Boehmler’s stock options expiring on December 27, 2028 vest as follows: (i) 100,000 options vested on July 1, 2023; (ii) 100,000 options vested on July 1, 2024; and (iii) 100,000 options vest on July 1, 2025. Mr. Boehmler’s stock options expiring October 4, 2029 vest as follows: (i) 48,611 vested as of October 4, 2024; and (ii) the remainder vest in equal monthly increments of 2,315 shares through July 1, 2027, with the final month vesting 2,309 shares. Mr. Boehmler’s 129,850 shares of stock vest on December 31, 2025.

 

(3)25,000 of Mr. Liscouski’s stock options expiring May 22, 2025 vested on each of April 8, 2021; April 8, 2022; and April 8, 2023. Mr. Liscouski’s stock options expiring April 26, 2026 vested on April 26, 2021. Mr. Liscouski’s stock options expiring January 27, 2022 vested as follows: (i) 83,333 options vested on July 15, 2022; (ii) 83,333 options vested on July 15, 2023; and (iii) 83,334 options vested on March 15, 2024, pursuant to this separation agreement. Mr. Liscouski’s stock options expiring October 17, 2027 with an exercise price of $2.37 vested as follows: (i) 1,000,000 options vested on October 17, 2022; and (ii) 500,000 options vested on December 31, 2022. Mr. Liscouski’s stock options expiring October 17, 2027 with an exercise price of $2.61 vested as follows: (i) 63,890 options vested on October 17, 2022; and (ii) 47,226 vested in equal monthly increments of 2,778 shares through February 26, 2024, with the remaining 38,884 options vested March 15, 2024. Mr. Liscouski’s stock options expiring December 27, 2028 vested as follows: (i) 72,224 vested as of December 31, 2023; and (ii) 5,556 vested in equal monthly increments of 2,778 shares through February 26, 2024, with the remaining 72,220 options vested March 15, 2024. Pursuant to Mr. Liscouski’s Separation Agreement all unvested options at the time of Mr. Liscouski’s Separation Agreement vested effective March 15, 2024.

 

45

 

 

Action to Recover Erroneously Awarded Compensation

 

Subsequent to the issuance of our Annual Report on Form 10-K for the year ended December 31, 2023, and our subsequent retention of BPM LLP to replace BF Borgers CPA PC as our independent registered public accounting firm, management became aware of various adjustments to be recorded to our consolidated financial statements. On September 11, 2024, we filed Amendment 1 to our Annual Report on Form 10-K for the year ended December 31, 2023, restating our financial statements for the years ended December 31, 2023 and 2022 to correct errors primarily related to purchase accounting for the QPhoton Merger, stock-based compensation, and financing costs. We also amended our financial statements for the nine months ended September 30, 2023, in line with the restatement of our audited consolidated financial statements. These corrections impacted net loss, goodwill, intangible assets, liabilities, and stockholders’ equity.

 

As the Company does not award incentive-based compensation that would have been subject to recovery based on financial metrics, no recovery was required or sought from any of our executive officers under the Company’s Compensation Recovery Policy.

 

Director Compensation 

 

During the year ended December 31, 2024, the Company’s non-employee directors each received compensation of $9,000 per quarter for their services as directors, plus an additional $4,000 per quarter if they also served as a committee Chair. Amounts are prorated to the amount of service per quarter.

 

Name  Fees Earned or
Paid in Cash
($)
   Stock
Awards
($)
   Stock
Options
($)
   Total
($)
 
Robert Liscouski (1)   129,032    0    0    129,032 
Michael Turmelle   52,000    0    32,492    84,492 
Carl Weimer   36,913    0    32,492    69,405 
Robert Fagenson   52,000    0    32,492    84,492 
Javad Shabani   27,320    12,376    27,433    67,129 

 

(1)Upon Mr. Liscouski’s termination as CEO, the Board approved a separate compensation arrangement for his service as Chairman of $12,500 per month, effective February 1, 2024 through December 10, 2024.

 

In 2025, the Board approved an increase in the non-employee director compensation to a base annual stipend of $60,000, with an annual stipend of $12,000 each to the Vice Chairman and the Chair of the Audit Committee, and annual stipends of $6,000 each to the Chairs of the Risk, Compensation, and Nominating and Governance committees, all cash stipends to be paid in equal quarterly installments.

 

Policies And Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

 

We do not grant equity awards in anticipation of the release of material nonpublic information, and we do not time the release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The following table sets forth certain information as of March 18, 2025 concerning the beneficial ownership of common stock for: (i) each of our directors, (ii) each named executive officer as included in the Summary Compensation Table under “Executive Compensation” above, (iii) all executive officers and directors as a group, and (iv) each person (including any “group” as that term is used in Section 13(d)(3) of the Exchange Act) known by us to be the beneficial owner of 5% or more of our common stock. The address for each of the persons below who are beneficial owners of 5% or more of our common stock is our corporate address at 5 Marine View Plaza, Suite 214, Hoboken, NJ 07030. 

 

Beneficial ownership has been determined in accordance with the rules of the SEC and is calculated based on 137,244,545 shares of our common stock issued and outstanding as of March 18, 2025. Shares of common stock subject to options, warrants, preferred stock or other securities convertible into common stock that are currently exercisable or convertible, or exercisable or convertible within 60 days of March 18, 2024, are deemed outstanding for computing the percentage of the person holding the option, warrant, preferred stock, or convertible security but are not deemed outstanding for computing the percentage of any other person. Under the SEC rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares “voting power,” which includes the power to vote or to direct the voting of such security, or “investment power,” which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has the right to acquire beneficial ownership within 60 days through the exercise of any stock option, warrant or other right. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. Unless otherwise indicated, each of the stockholders named in the table below, or his or her family members, has sole voting and investment power with respect to such shares of our common stock.

 

46

 

 

Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own.

 

Name and Address of Beneficial Owner  Common Stock
Owned
Beneficially
   Percent of
Class
 
Named Executive Officers and Directors        
Dr. William McGann, Chief Executive Officer(1)   1,722,930    1.2%
Chris Boehmler, Chief Financial Officer(2)   727,876    0.5 
Dr. Yuping Huang(3)   24,251,256    17.2 
Robert Fagenson(4)   775,000    0.6 
Michael Turmelle(5)   575,000    0.4 
Dr. Carl Weimer(6)   225,000    0.2 
Dr. Javad Shabani(7)   120,219    0.1 
All directors and officers as a group (8 persons)   28,397,281    20.1 
Other 5% shareholders   0    0 
Total   28,158,959    20.00%

 

(1)Consists of 162,100 shares of common stock owned currently and 1,560,830 shares of common stock underlying vested options to purchase shares of common stock.

 

(2)Consists of 320,010 shares of common stock owned currently and 407,866 shares of common stock underlying vested options to purchase shares of common stock

 

(3)Consists of 23,936,906 shares of common stock owned currently and 314,350 shares of common stock underlying vested options to purchase shares of common stock. This does not include any shares that could be purchased upon exercise of unvested warrants received as consideration in the QPhoton Merger that may vest upon the exercise of outstanding options and other warrants held by officers, employees, directors and investors.

 

(4) Consists of 100,000 shares of common stock owned currently and 675,000 shares of common stock underlying vested options to purchase shares of common stock.

 

(5)Consists of 575,000 shares of common stock underlying vested options to purchase shares of common stock.

 

(6)Consists of 225,000 shares of common stock underlying vested options to purchase shares of common stock.

 

(7)Consists of 12,500 shares of common stock owned currently and 107,719 shares of common stock underlying vested options to purchase shares of common stock.

 

Changes in Control

 

We are not aware of any arrangements that may result in “changes in control” as that term is defined by the provisions of Item 403(c) of Regulation S-K.

 

Equity Compensation Plan Information

 

On July 5, 2022, the Board adopted the Quantum Computing Inc. 2022 Equity and Incentive Plan (the “2022 Plan”), which includes provisions for annual automatic evergreen increases of 1,000,000 shares of common stock. The total number of shares of our common stock reserved for issuance under the 2022 Plan, as of March 18, 2025, is 19.0 million. The principal purpose of the 2022 Plan is to provide an incentive to designated employees, certain consultants and advisors who perform services for us and non-employee directors to contribute to our growth by continuing to align the interests of participants with the interests of our stockholders. The 2022 Plan was approved by a majority of the shareholders in September 2022.

 

47

 

 

The table below sets forth certain information as of our fiscal year ended December 31, 2024 regarding the shares of our common stock available for grant or granted under our equity compensation plan.

 

Plan Category  Number of
securities to
be issued
upon
exercise of
outstanding
options (2)
   Weighted-
average
exercise
price of
outstanding
options
   Number of
securities
available for
future
issuance
under equity
compensation
plans
 
Equity compensation plan approved by security holders – 2022 Quantum Computing Inc. Equity Incentive Plan, as amended   10,454,781   $1.78    2,348,425 
Equity compensation plan approved by security holders – 2019 Quantum Computing Inc. Equity Incentive Plan, as amended   1,760,500   $3.90    0 
Equity compensation not approved by shareholders (1)   767,500   $6.28    0 

 

(1)The total number of stock options issued and outstanding as of March 18, 2025 is 13,555,511.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

There have been no transactions involving the Company since January 1, 2024, or any currently proposed transactions, in which the Company was or is to be a participant and the amount involved exceeds $120,000, and in which any of our directors, executive officers or beneficial holders of more than 5% of our common stock, or any immediate family member of, or person sharing a household with, any of these individuals, had or will have a direct or indirect material interest, other than compensation arrangements that are described under the section captioned “Executive Compensation.”

 

Please see “Board Composition and Director Independence” under “Item 10, Directors, Executive Officers and Corporate Governance” for a discussion of our independent directors.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 

BPM LLP served as our independent registered public accountants for the years ended December 31, 2024 and 2023.

 

Audit Fees

 

The Company originally retained BF Borgers CPA PC (“BF Borgers”) as its independent registered public accounting firm for the Company’s fiscal years ended December 31, 2024 and 2023, then following an order by the SEC on May 3, 2024 suspending BF Borgers from appearing and practicing as an accountant before the SEC, the Company subsequently retained BPM LLP as its independent registered public accounting firm to replace BF Borgers.

 

For such professional services rendered by BPM LLP for the audit of our restated consolidated financial statements, we incurred approximately $332 thousand and $337 thousand, respectively, for the Company’s fiscal years ended December 31, 2024 and 2023.

 

For such professional services rendered by BF Borgers for its original audit of our consolidated financial statements, we were billed approximately $110 thousand and $132 thousand, respectively, for the Company’s fiscal years ended December 31, 2024 and 2023.

 

For the Company’s fiscal years ended December 31, 2024 and 2023, we were billed in fiscal year ended December 31, 2024 approximately $27 thousand for professional services rendered by BF Borgers and $105 thousand by BPM LLP, respectively, related to the Company’s Registration Statements on Form S-3 and Form S-1 and amendments thereto filed with the SEC in those years.

 

Tax Fees

 

We were billed approximately $33 thousand by BPM LLP for the Company’s fiscal year ended December 31, 2024 and $9 thousand by BF Borgers for the Company’s fiscal year ended December 31, 2023 for professional services rendered for tax compliance, tax advice, and tax planning.

 

Pre-Approval Policies

 

All of the above services and fees were reviewed and approved by the Audit Committee. No services were performed before or without approval. 

 

48

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

 

Exhibit       Reference   Filed or Furnished
Number   Exhibit Description   Form   Exhibit   Filing Date   Herewith
2.1   Agreement and Plan of Merger by and among Quantum Computing Inc., Project Alpha Merger Sub I, Inc., Project Alpha Merger Sub II, LLC, QPhoton, Inc., and Yuping Huang, dated as of May 18, 2022   8-K   10.1   05/23/2022    
3.1(i)   Amended and Restated Certificate of Incorporation   10-K/A   3.1(i)   07/10/2023    
3.1(ii)   Certificate of Designations of the Series A Convertible Preferred Stock   8-K   3.1   11/17/2021    
3.1(iii)   Certificate of Amendment of Certificate of Designations of Series A Convertible Preferred Stock of Quantum Computing Inc., filed with the Delaware Secretary of State on December 16, 2021   8-K   3.1   12/17/2021    
3.1(iv)   Certificate of Designation with respect to the Series B Preferred Stock, par value $0.0001 per share, dated June 14, 2022   8-K   3.1   06/21/2022    
3.2   Amended and Restated By-laws   10-K/A   3.2   07/10/2023    
4.1   Common Stock Specimen   10-12(g)   4.1   01/09/2019    
4.2   Description of Securities   10-K   4.4   04/01/2024    
4.3   Form of Placement Agent Warrant   8-K   4.1   12/12/2024    
4.4   Form of Placement Agent Warrant   8-K   4.1   01/08/2025    
4.5   Form of Placement Agent Warrant               X
4.6   Unsecured Promissory Note issued by QPhoton, Inc. to Quantum Computing, Inc., in the amount of $1,250,000, dated February 18, 2022   8-K   10.2   02/23/2022    
10.1*   2019 Quantum Computing Inc. Equity and Incentive Plan   S-1   10.8   11/22/2019    
10.2*   Form Director Agreement   8-K   10.1   02/23/2021    
10.3*   Amended and Restated Employment Agreement, dated as of April 26, 2021, by and between Quantum Computing Inc. and Robert Liscouski   8-K   10.1   04/30/2021    
10.4*   Employment Agreement between Christopher Roberts and Quantum Computing, Inc., dated as of April 26, 2021   8-K   10.2   04/30/2021    
10.5*   Employment Agreement between by and between Quantum Computing Inc. and William McGann, dated as of January 3, 2022   8-K   10.2   01/03/2022    

 

49

 

 

10.6   Note Purchase Agreement, dated as of February 18, 2022, between Quantum Computing Inc. and QPhoton, Inc.   8-K   10.1   02/23/2022    
10.7   Escrow Agreement, dated as of June 16, 2022, by and among Quantum Computing Inc., Yuping Huang and Worldwide Stock Transfer, LLC   8-K   10.2   06/21/2022    
10.8   Stockholders Agreement by and among Quantum Computing, Inc. and each of the Stockholders set forth on Exhibit A thereto, dated as of June 16, 2022   8-K   10.3   06/21/2022    
10.9   Form Registration Rights Agreement   8-K 10.4   06/21/2022    
10.10*   Employment Agreement, dated as of June 15, 2022, by and between Quantum Computing Inc. and Yuping Huang     8-K   10.5   06/21/2022    
10.11   ATM Agreement, dated as of December 5, 2022, between Quantum Computing Inc. and Ascendiant Capital Markets, LLC     8-K   1.1   12/06/2022    
10.12*   Director Agreement between Quantum Computing Inc. and Dr. Carl Weimer, dated January 6, 2023   8-K 10.1   01/09/2023    
10.13   Employment Agreement between Quantum Computing Inc. and Christopher Boehmler, dated as of June 26, 2023     8-K   10.1   06/26/2023    
10.14*   Quantum Computing Inc. 2022 Equity and Incentive Plan   10-K/A   10.42   07/10/2023    
10.15   First Amendment to ATM Agreement, dated as of August 17, 2023, between Quantum Computing Inc. and Ascendiant Capital Markets, LLC     8-K   1.1   08/21/2023    
10.16   Series A Preferred Redemption and Waiver Agreement, dated as of March 19, 2024   8-K   10.1   03/25/2024    
10.17   Separation Agreement, dated as of March 15, 2024, by and between Quantum Computing, Inc. and Robert Liscouski   10-K   10.26   04/01/2024    
10.18*   Director Agreement, dated as of March 8, 2024, by and between Quantum Computing, Inc. and Robert Liscouski   10-K 10.27   04/01/2024    
10.19   Director Agreement between Quantum Computing Inc. and Dr. Javad Shabani, dated April 19, 2024   8-K 10.1   04/25/2024    
10.20   Modification 2 to Consulting Services Agreement, dated as of June 18, 2024, by and between Quantum Computing, Inc. and Christopher Roberts               X
10.21   Secured Promissory Note issued to Streeterville Capital, LLC, dated August 6, 2024   8-K   4.1   08/12/2024    
10.22   Securities Purchase Agreement between Quantum Computing Inc. and Streeterville Capital, LLC, dated August 6, 2024   8-K   10.1   08/12/2024    
10.23   Security Agreement between Quantum Computing Inc. and Streeterville Capital, LLC, dated August 6, 2024   8-K   10.2   08/12/2024    
10.24   IP Security Agreement between Quantum Computing Inc. and Streeterville Capital, LLC, dated August 6, 2024   8-K   10.3   08/12/2024    
10.25   Guaranty by QPhoton, LLC, Qubittech International, Inc., Qubittech, Inc., and QI Solutions, Inc., dated August 6, 2024   8-K   10.4   08/12/2024    
10.26   Form of Securities Purchase Agreement, dated as of November 14, 2024, between Quantum Computing Inc. and each Purchaser (as defined therein)   8-K 10.1   11/15/2024    

 

50

 

 

10.27   Placement Agency Agreement, dated November 14, 2024, between Quantum Computing Inc. and Titan Partners Group LLC, a division of American Capital Partners, LLC   8-K 10.2   11/15/2024    
10.28   Form of Lock-Up Agreement dated November 14, 2024   8-K 10.3   11/15/2024    
10.29   Amendment to Employment Agreement by and between Quantum Computing Inc. and Yuping Huang, dated as of September 1, 2024   10-Q   10.5   11/06/2024    
10.30   Modification 3 to Consulting Services Agreement, dated as of December 20, 2024, by and between Quantum Computing, Inc. and Christopher Roberts               X
10.31   Form of Registered Offering Purchase Agreement, dated as of December 10, 2024, between Quantum Computing Inc. and each Purchaser (as defined therein)   8-K 10.1   12/12/2024    
10.32   Form of Placement Purchase Agreement, dated as of December 10, 2024, between Quantum Computing Inc. and each Purchaser (as defined therein)   8-K 10.2   12/12/2024    
10.33   Placement Agency Agreement, dated December 10, 2024, between Quantum Computing Inc. and Titan Partners Group LLC, a division of American Capital Partners, LLC   8-K 10.3   12/12/2024    
10.34   Form of Lock-Up Agreement dated December 12, 2024   8-K 10.4   12/12/2024    
10.35   Second Amendment to Employment Agreement between Quantum Computing Inc. and William J. McGann, dated as of December 30, 2024   8-K   10.1   12/31/2024    
10.36   Form of Purchase Agreement, dated as of January 7, 2025, between Quantum Computing Inc. and each Purchaser (as defined therein)   8-K 10.1   01/08/2025    
10.37   Placement Agency Agreement, dated January 7, 2025, between Quantum Computing Inc. and Titan Partners Group LLC, a division of American Capital Partners, LLC   8-K 10.2   01/08/2025    
10.38   Form of Lock-Up Agreement dated January 7, 2025   8-K 10.3   01/08/2025    
10.39   First Amendment to Employment Agreement between Quantum Computing Inc. and William J. McGann, dated as of February 1, 2024   S-1   10.7   01/22/2025    
14.1   Quantum Computing Inc. Code of Ethics   8-K   14.1   09/25/2024    
19.1   Quantum Computing Inc. Insider Trading Policy               X
21.1   List of Subsidiaries               X
23.1  

Consent of BPM LLP, Independent Registered Public Accounting Firm

              X
31.1   Principal Executive Officer Certification Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.               X
31.2   Principal Financial Officer Certification Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.               X
32.1   Principal Executive Officer Certification Pursuant to Item 601(b)(32) of Regulation S-K, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.               X
32.2   Principal Financial Officer Certification Pursuant to Item 601(b)(32) of Regulation S-K, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.               X
97.1   Policy relating to recovery of erroneously awarded compensation.   10-K   97.1   04/01/2024    
101.INS   Inline XBRL Instance Document.               X
101.SCH   Inline XBRL Taxonomy Extension Schema Linkbase Document.               X
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.               X
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.               X
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.               X
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.               X
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).               X

 

*Indicates a management contract or compensatory plan or arrangement.

  

51

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: March 20, 2025 Quantum Computing Inc.
     
  By: /s/ Dr. William McGann
    Dr. Willan McGann
    Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacity and on the dates indicated.

 

Name   Capacity   Date
         
/s/ Yuping Huang   Chairman of the Board of Directors and Chief Quantum Officer   March 20, 2025
Yuping Huang        
         
/s/ Dr. William McGann   Chief Executive Officer   March 20, 2025
Dr. Willan McGann   (Principal Executive Officer)    
         
/s/ Christopher Boehmler   Chief Financial Officer, Treasurer   March 20, 2025
Christopher Boehmler   (Principal Financial Officer and
Principal Accounting Officer)
   
         
/s/ Michael Turmelle   Director   March 20, 2025
Michael Turmelle        
         
/s/ Robert Fagenson   Vice Chairman of the Board of Directors   March 20, 2025
Robert Fagenson        
         
/s/ Dr. Carl Weimer   Director   March 20, 2025
Dr. Carl Weimer        
         
/s/ Dr. Javad Shabani   Director   March 20, 2025
Dr. Javad Shabani        

 

52

 

 

QUANTUM COMPUTING INC.

 

Index to the Consolidated Financial Statements

 

Description   Page
Report of Independent Registered Public Accounting Firm (PCAOB ID:207)   F-2
Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023   F-3
Consolidated Statement of Operations for the Year Ended December 31, 2024 and 2023   F-4
Consolidated Statement of Stockholders’ Equity for the Year Ended December 31, 2024 and 2023   F-5
Consolidated Statement of Cash Flows for the Year Ended December 31, 2024 and 2023   F-6
Notes to the Consolidated Financial Statements   F-7

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

Quantum Computing Inc.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Quantum Computing Inc. (a Delaware Corporation) and its subsidiaries (collectively, the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, mezzanine and stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financing reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Valuation of Warrant Liabilities

 

As described in Notes 1 and Note 10, on June 16, 2022, the Company merged with QPhoton, Inc., which was accounted for as a business combination using the acquisition method of accounting. In conjunction with the merger, the Company issued warrants that become exercisable when and if stock options and warrants outstanding as of the time of the merger are exercised. The Company is accounting for these warrants as a derivative liability and is valued at $40.5 million as of December 31, 2024 and resulted in a mark-to-market loss of $40.5 million in the year ended December 31, 2024.

The principal considerations for our determination that performing procedures relating to the valuation of the derivative liability is a critical audit matter due to the significant amount of judgment by management required in estimating the fair value of the warrants, including the use of valuation methodologies that were sensitive to significant assumptions, specifically the probability of the underlying options and warrants being exercised, which is affected by expected future market or economic conditions, which in turn led to significant auditor judgment, subjectivity and effort in performing audit procedures and evaluating audit evidence relating to the analysis..

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, assessing the appropriateness of the valuation methodologies and testing the significant assumptions discussed above, specifically the probability of the underlying options and warrants being exercise, and other factors considered by management in developing the model.

 

/s/ BPM LLP

 

We have served as the Company’s auditor since 2024.

 

San Jose, California

March 20, 2025

 

F-2

 

 

QUANTUM COMPUTING INC.

Consolidated Balance Sheets

(In thousands, except par value)

 

   December 31,   December 31, 
   2024   2023 
Assets        
Current assets:        
Cash and cash equivalents  $78,945   $2,059 
Accounts receivable, net   27    65 
Inventory   18    73 
Loans receivable, net   
-
    279 
Prepaid expenses and other current assets   161    180 
Total current assets   79,151    2,656 
Property and equipment, net   8,212    2,870 
Operating lease right-of-use assets   1,522    1,051 
Intangible assets, net   8,972    12,076 
Goodwill   55,573    55,573 
Other non-current assets   129    129 
Total assets  $153,559   $74,355 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $1,372   $1,462 
Accrued expenses   2,134    639 
Financial liabilities, net of issuance costs   
-
    1,925 
Deferred revenue   79    
-
 
Other current liabilities   974    786 
Total current liabilities   4,559    4,812 
Derivative liability   40,532    
-
 
Operating lease liabilities   1,181    840 
Total liabilities   46,272    5,652 
Contingencies (see Note 8)   
 
    
 
 
Stockholders’ equity:          
Preferred stock, $0.0001 par value, 1,550 shares Series A Preferred authorized; no shares and 1,490 thousand shares issued and outstanding as of December 31, 2024 and 2023, respectively; 3,080 thousand shares of Series B Preferred Stock authorized; no shares issued and outstanding as of December 31, 2024 and 2023   
-
    
-
 
Common stock, $0.0001 par value, 250,000 thousand shares authorized; 129,012 thousand and 77,451 thousand shares issued and outstanding as of December 31, 2024 and 2023, respectively   13    8 
Additional paid-in capital   307,756    200,635 
Accumulated deficit   (200,482)   (131,940)
Total stockholders’ equity   107,287    68,703 
Total liabilities and stockholders’ equity  $153,559   $74,355 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

QUANTUM COMPUTING INC.

Consolidated Statements of Operations

(In thousands, except per share data)

 

   Year Ended 
   December 31, 
   2024   2023 
Total revenue  $373   $358 
Cost of revenue   261    196 
Gross profit   112    162 
Operating expenses          
Research and development   11,318    8,891 
Sales and marketing   1,818    1,806 
General and administrative   12,913    15,708 
Total operating expenses   26,049    26,405 
Loss from operations   (25,937)   (26,243)
Non-operating income (expense)          
Interest and other income   423    295 
Interest expense, net   (2,496)   (1,602)
Change in fair value of warrant liabilities   (40,532)   528 
Loss before income tax provision   (68,542)   (27,022)
Income tax provision   
-
    
-
 
Net loss   (68,542)   (27,022)
           
Less: Series A convertible preferred stock dividends   
-
    861 
Net loss attributable to common stockholders  $(68,542)  $(27,883)
           
Loss per share – basic and diluted  $(0.73)  $(0.42)
Weighted average shares used in computing net loss per common share – basic and dilutive   93,881    66,611 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

QUANTUM COMPUTING INC.

Consolidated Statements of Mezzanine and Stockholders’ Equity

(In thousands, except par value)

 

   Mezzanine   Series A
Preferred
Stock
   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Equity   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balances, January 1, 2023  $
    -
    1,500   $
           -
    55,963   $6   $169,175   $(104,057)  $65,124 
Issuance of shares for cash   
-
         
-
    17,572    2    24,728    
-
    24,730 
Conversion of preferred stock   
-
    (10)   
-
    11    
-
    1    
-
    1 
Preferred stock dividends   
-
    -    
-
    -    
-
    
-
    (861)   (861)
Stock-based compensation   
-
    -    
-
    2,330    
-
    4,238    
-
    4,238 
Stock-based compensation for services   
-
    -    
-
    1,575    
-
    2,493    
-
    2,493 
Net loss   
-
    -    
-
    -    
-
    
-
    (27,022)   (27,022)
Balances, December 31, 2023   
-
    1,490    
-
    77,451    8    200,635    (131,940)   68,703 
Issuance of shares for cash   
-
    -    
-
    49,679    5    106,761    
-
    106,766 
Conversion of Series A preferred stock to common stock   (4,097)   (745)   
-
    745    
-
    4,097    
-
    4,097 
Reclassification of Series A preferred stock to mezzanine equity   8,195    -    
-
    -    
-
    (8,195)   
-
    (8,195)
Repurchase of redeemable shares   (4,098)   (745)   
-
    
-
    
-
    
-
    
-
    
-
 
Stock-based compensation   
-
    -    
-
    995    
-
    4,322    
-
    4,322 
Stock-based compensation for services   
-
    -    
-
    142    
-
    136    
-
    136 
Net loss   
-
    -    
-
    -    
-
    
-
    (68,542)   (68,542)
Balances, December 31, 2024  $
-
    
-
   $
-
    129,012   $13   $307,756   $(200,482)  $107,287 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

QUANTUM COMPUTING INC.

Consolidated Statements of Cash Flows

(In thousands)

 

   Year Ended 
   December 31, 
   2024   2023 
Cash flows from operating activities:        
Net loss  $(68,542)  $(27,022)
Adjustments to reconcile net loss to net cash used in operations          
Depreciation and intangibles amortization   3,798    3,307 
Amortization of issuance costs   2,059    925 
Change in fair value of warrant liability   40,532    (528)
Change in value of derivative   (666)   
-
 
Provision for credit losses   279    279 
Other recognized losses (gains)   4    5 
Stock-based compensation expense   5,782    4,271 
Stock-based compensation expense for services   23    284 
Changes in operating assets and liabilities          
Accounts receivable   38    (52)
Inventories   55    (70)
Prepaid expenses and other current assets   16    (110)
Other non-current assets   
-
    (69)
Accounts payable   (90)   596 
Deferred revenue   79    
-
 
Accrued expenses and other current liabilities   550    110 
Other long-term liabilities   (130)   (241)
Net cash used in operating activities   (16,213)   (18,315)
           
Cash flows from investing activities:          
Purchase of property and equipment   (6,036)   (2,112)
Issuance of loan receivable   
-
    (500)
Net cash used in investing activities   (6,036)   (2,612)
           
Cash flows from financing activities:          
Proceeds raised from financial liabilities, net of issuance costs   6,995    
-
 
Payments of financial liabilities   (10,313)   (6,187)
Series A Preferred stock dividend payments   (215)   (865)
Repurchase of Series A preferred stock   (4,098)   
-
 
Proceeds from issuance of common stock   106,766    24,730 
Net cash provided by financing activities   99,135    17,678 
           
Net increase (decrease) in cash   76,886    (3,249)
Cash and cash equivalents, beginning of period   2,059    5,308 
Cash and cash equivalents, end of period  $78,945   $2,059 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $268   $813 
Non-cash investing and financing activities:          
Reclassification of Series A preferred stock to mezzanine equity  $8,195   $
-
 
Valuation of derivative associated with convertible financial liability  $666   $
-
 
Conversion of Series A preferred to common stock  $4,097   $- 
Operating lease right-of-use assets obtained in exchange for operating lease liabilities  $765   $- 

 

The accompanying notes are an integral part of these financial statements.

 

F-6

 

 

QUANTUM COMPUTING INC.

Notes to Consolidated Financial Statements

December 31, 2024

 

Note 1 – Nature of the Organization and Business

 

Corporate History

 

Quantum Computing Inc. (“QCi” or the “Company”) was formed in the State of Nevada on July 25, 2001, under its original name, Ticketcart, Inc., which was changed to Innovative Beverage Group Holdings, Inc. in 2009. The Company redomiciled to Delaware on February 22, 2018 and changed its name to Quantum Computing Inc. Effective July 20, 2018, the trading symbol for the Company’s common stock, par value $0.0001, on the OTC Market changed from “IBGH” to “QUBT”. On July 15, 2021 the Company uplisted to The Nasdaq Stock Market LLC. On June 16, 2022, the Company merged with QPhoton, Inc. (“QPhoton”), a developer of quantum photonic systems and related technologies and applications. The QPhoton Merger enabled us to develop hardware applications integrated with the Company’s software platform, Qatalyst, that existed before the QPhoton Merger.

 

Nature of Business

 

QCi is an American company utilizing integrated photonics and non-linear quantum optics to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging and cybersecurity applications based on patented and proprietary photonics technology. QCi’s products are designed to operate at room temperature and at very low power levels compared to other quantum systems currently available in the market, such as superconducting, ion-trap, or annealing architectures. Our core photonics technology enables the execution of a go-to-market strategy which emphasizes scalability, accessibility and affordability. Our quantum machines, supported by professional services through our “Quantum Solutions” offering, enable subject matter experts (SMEs) and end users to deliver critical business solutions involving highly complex optimization problems.

 

The leading application of our quantum offerings today is our Entropy Quantum Computing. Our longer-term product development plan is to migrate the EQC’s current design, as well as other product designs based on discrete components, to a set of optical integrated circuits (TFLN Optical Chips) built on TFLN wafers.

 

Liquidity

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, the realization of assets, and the satisfaction of liabilities in the normal course of business. We have not achieved a level of sales adequate to support the Company’s cost structure. The Company has historically incurred losses and negative cash flows from operations. During the year ended December 31, 2024, the Company issued 49,679 shares of common stock for net proceeds of $106.8 million. Cash and cash equivalents on hand were $78.9 million as of December 31, 2024. As of December 31, 2024, the Company also had an accumulated deficit of $200.5 million and working capital of $74.6 million. In January 2025, the Company issued 8,163,266 shares of common stock for net proceeds of $93.3 million. As a result, the Company has adequate cash and cash equivalents on hand to meet its obligations over the next 12 months.

 

Note 2 – Significant Accounting Policies:

 

Basis of Presentation and Principles of Consolidation:

 

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (the “FASB”), including ASC 810, Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is December 31.

 

F-7

 

 

Risk and Uncertainties

 

The Company is subject to certain risks and uncertainties and believes changes in any of the following areas could have a material adverse effect on the Company’s future consolidated financial position or consolidated results of operations or cash flows: new product development, including market receptivity; litigation or claims against the Company based on intellectual property, patent, product regulation or other factors; competition from other products; general economic conditions; the ability to attract and retain qualified employees; and, ultimately, to sustain profitable operations.

 

Reclassifications

 

Certain reclassifications have been made to the fiscal year 2023 consolidated financial statements to conform ot the fiscal year 2024 presentation. The reclassifications had no impact on net loss, total assets, total liabilities, or stockholders’ equity.

 

Use of Estimates

 

These consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of goodwill and intangible assets, deferred tax assets, equity-based transactions and liquidity assessment. Actual results may differ from these estimates.

 

Segments

 

Our Chief Operating Decision Maker (“CODM”), the Chief Executive Officer, manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources and assess performance. Further, the CODM reviews and utilizes natural expenses, such as employee wages and benefits at a consolidated level, to manage the Company’s operations and strategic growth initiatives. Other segment items include interest income, interest expense, deferred offering costs, changes in fair value of derivative warrant liabilities and other operational expenses which are reflected in the consolidated statements of operations.

 

Cash and Cash Equivalents

 

Highly liquid investments with a maturity of three months or less when purchased are considered to be cash equivalents. The Company maintains its cash in mutual funds and deposit and money market accounts with high quality financial institutions which, at times, may exceed federally insured limits. As of December 31, 2024 and December 31, 2023, the Company had $78.9 million and $960 thousand, respectively, in cash equivalents invested in mutual funds. The Company has not experienced any losses on these deposits and believes it is not exposed to significant credit risk on cash. 

 

Revenue

 

The Company recognizes revenue in accordance with ASC 606 – Revenue from Contracts with Customers, by analyzing contracts with its customers using a five-step approach:

 

  1. Identify the contract;
     
  2. Identify the performance obligations;
     
  3. Determine the transaction price;

 

  4. Allocate the transaction price to the performance obligations; and
     
  5. Recognize revenue when performance obligations are satisfied.

 

F-8

 

 

The revenue the Company has recognized in the years ended December 31, 2024 and 2023 were primarily derived from contracts to perform professional services. Revenue from time and materials-based contracts is recognized as the direct hours worked during the period times the contractual hourly rate, plus direct materials and other direct costs as appropriate, plus negotiated materials handling burdens, if any. Revenue from units-based contracts is recognized as the number of units delivered or performed during the period times the contractual unit price. Revenue from fixed price contracts is recognized as work is performed with estimated profits recorded on a percentage of completion basis. The Company has no cost-plus type contracts at this time.

 

The Company includes depreciation and amortization expenses in manufacturing overhead, which is a component of cost of revenue. However, at the present time manufacturing overhead, including depreciation and amortization expense related to production equipment, is not material and the primary components of cost of revenue are direct labor and direct materials, with a small amount of shipping expenses.

 

The Company’s revenues consist of (in thousands):

 

   Year Ended December 31, 
   2024   2023   % Change 
Services  $346   $353    (2)%
Products   27    5    440%
Total  $373   $358    4%

 

The Company disaggregates revenue from contracts with customers based on the timing of transfer of goods or services to customers (point-in-time or over time) and geographic region based on the shipping location of the customer. The geographic regions that are tracked for the years ended December 31, 2024 and 2025 are the Americas and Europe.

 

Total net sales based on the disaggregation criteria described above are as follows (in thousands):

 

   Year Ended December 31, 
   2024   2023 
   Point-in-Time   Over Time   Total   Point-in-Time   Over Time   Total 
Americas  $27   $346   $373   $          5   $337   $342 
Europe   
-
    
-
    
-
    
-
    16    16 
Total  $27   $346   $373   $5   $353   $358 

 

Accounts Receivable

 

Accounts receivable consists of amounts due from customers for work performed on contracts. The Company records accounts receivable at their net realizable value. Periodically, the Company evaluates its accounts receivable to establish a provision for credit losses, when deemed necessary, based on the history of past write-offs, collections and current credit conditions. The customer accounts receivable as of December 31, 2024 are considered not fully collectible and thus the Company has recorded a provision for credit losses of $3.5 thousand; the customer accounts receivable as of December 31, 2023 were considered fully collectible.

 

F-9

 

 

Provision for Credit Losses

 

The Company estimates losses on loans and other financial instruments in accordance with Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 introduces the current expected credit losses (“CECL”) methodology for estimating allowances for credit losses. The CECL framework requires the Company to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supporting forecasts. Under CECL, the allowance for credit losses is measured as the difference between the financial asset’s cost basis and the net amount expected to be collected on the financial asset. CECL allows us to use information about past events including historical loan loss experience, current conditions, and reasonable and supportable forecasts to assess the collectability of the financial assets. The receivables for financial assets as of December 31, 2024 and 2023 are not considered fully collectible and thus management has recorded a provision for credit losses. See Note 9, Loan Receivable, for additional information.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis which approximates actual cost on a first in-first out method. Lower of cost or net realizable value is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory and are charged to cost of revenue. Once the cost of the inventory is reduced, a new lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Factors influencing these adjustments include changes in demand, product life cycle and development plans, component cost trends, product pricing, physical deterioration and quality issues. Revisions to these adjustments would be required if these factors differ from our estimates.

 

Operating Leases

 

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets are included in right-of-use assets, net on the consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current operating lease liabilities and non-current operating lease liabilities, respectively, on the consolidated balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. All of our operating leases are comprised of office space leases, and as of December 31, 2024 and 2023, we had no finance leases.

 

Business Combinations and Valuation of Goodwill

 

We account for business combinations under the acquisition method of accounting. This method requires the recording of acquired assets and assumed liabilities at their acquisition date fair values. The excess of the purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded withing general and administrative expenses.

 

The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company performs an annual impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to assess impairment, its common stock price is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit and can lead to potential impairment in future periods. The Company performed its annual impairment test during the second quarter of fiscal 2024 and 2023 and determined that its goodwill was not impaired. As of December 31, 2024 and 2023, we had not identified any factors that indicated there was an impairment of our goodwill and determined that no additional impairment analysis was then required.

 

F-10

 

 

Property and Equipment

 

Property and equipment are stated at cost or contributed value. Depreciation of furniture, software and equipment is calculated using the straight-line method over their estimated useful lives, and leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the lease term. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as a gain or loss on sale of equipment. Maintenance and repairs are charged against expense as incurred.

 

Impairment of Long-Lived Assets

 

The Company has long-lived assets such as tangible property and equipment, identified intangible assets consisting of acquired patents and core technology. When events or changes in circumstances occur that could indicate the carrying value of long-lived assets may not be recoverable, the Company assesses recoverability by determining whether the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. If the undiscounted cash flow is less, an impairment charge is recognized for the excess of the carrying amounts of these assets over the fair values. Fair values are determined by discounted future cash flows, appraisals or other methods.

 

During years ended December 31, 2024 and 2023, the Company did not record any impairment from long-lived assets.

 

Fair Value of Financial Instruments

 

The carrying amount of certain financial instruments held by the Company, such as cash equivalents, accounts receivable, contract assets and liabilities, accounts payable, and accrued and other current liabilities, approximate fair value due to their short maturities. The carrying amount of the liabilities for the convertible preferred stock warrants represent their fair value. The carrying amounts of the Company’s borrowings and lease liabilities approximate fair value due to the market interest rates that these obligations bear and interest rates currently available to the Company.

 

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

 

  Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;

 

  Level 2 Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

 

  Level 3 Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

 

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2024 and 2023, the Company had $78.9 million of the $78.9 million cash and cash equivalents and $960 thousand of the $2.1 million cash and cash equivalents, respectively, in Level 1 assets, comprised of U.S. Government mutual funds, and $40.5 million and no carrying value, respectively, for Level 3 liabilities, which are comprised of derivative and warrant liabilities. See Note 10, Capital Stock, for a full discussion of the warrant liability.

 

F-11

 

 

Research and Development Costs

 

Research and development costs include costs directly attributable to the conduct of research and development programs, including the cost of services provided by outside contractors, acquiring work-in-progress intellectual property, development, and mandatory compliance fees and contractual obligations. All costs associated with research and development are expensed as incurred.

 

Software Development Costs

 

Software development costs incurred subsequent to the establishment of technological feasibility for software intended to be sold, licensed or otherwise marketed to customers will be capitalized, but development costs not meeting the criteria for capitalization are expensed as incurred. With respect to internal use software, the Company will capitalize such development costs incurred during the application development stage, but development costs incurred prior to that stage will be expensed as incurred. No amortization expense will be recorded until the software is ready for its intended use. To date, the Company has not incurred any material capitalizable software development costs.

 

Stock-based Compensation

 

Stock-based compensation expense for expected-to-vest awards is valued under the single-option approach and amortized on a straight-line basis, accounting for actual forfeitures as they occur. We utilize the Black Scholes pricing model in order to determine the fair value of stock-based option awards. The Black Scholes pricing model requires various highly subjective assumptions including volatility, expected option life, and risk-free interest rate. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, management concludes that it is more-likely-than-not that the deferred tax assets will not be realized. Realization of deferred tax assets is also dependent upon future earnings, if any, the timing and amount of which are uncertain.

 

The Company records a liability for the uncertain tax positions taken or expected to be taken on the Company’s tax return when it is more-likely-than-not that the tax position might be challenged despite the Company’s belief that the tax return positions are fully supportable, and additional taxes will be due as a result. To the extent that the assessment of such tax positions changes, for example, based on the outcome of a tax audit, the change in estimate is recorded in the period in which the determination is made. The provision for income taxes includes the impact of provisions for uncertain tax positions.

 

Net Loss Per Share

 

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus the number of additional common shares that would have been outstanding if the common share equivalents had been issued (computed using the “If-Converted” method), unless the effect of such issuances would have been anti-dilutive.

 

F-12

 

 

The following table sets forth the computation of basic and diluted loss per share (in thousands, except for per share data):

 

   Year Ended
December 31,
 
   2024   2023 
Numerator:        
Net loss  $(68,542)  $(27,022)
Less: Series A convertible preferred stock dividends   
-
    861 
Net loss attributable to common stockholders – basic and diluted  $(68,542)  $(27,883)
Denominator:          
Weighted average shares used in computing net loss per common share – basic and diluted   93,881    66,611 
Net loss per common share – basic and diluted  $(0.73)  $(0.42)

 

Net loss per share is based on the weighted average number of common shares and common share equivalents outstanding during the period.

 

In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted common stock and warrants are excluded and diluted loss per share is equal to basic loss per share. Due to a net loss in the years ended December 31, 2024 and 2023, there were therefore no dilutive securities and hence basic and diluted loss per share were the same. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive (in thousands):

 

   Year Ended December 31, 
   2024   2023 
Warrants   2,583    6,053 
Options   12,907    12,280 
Unvested restricted common stock   2,997    1,192 
Total potentially dilutive shares   18,487    19,525 

 

As all potentially dilutive securities are anti-dilutive as of December 31, 2024 and 2023, diluted net loss per share is the same as basic net loss per share for each period.

 

Recently Adopted Accounting Standards

 

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which amends reportable segment requirements, primarily through enhanced disclosures about significant segment expenses, including for public entities that have a single reportable segment. The standard is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024 and have made the necessary reportable segment disclosures (See Note 3, Segment Reporting).

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

 

On December 14, 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under ASU 2023-09, entities are required to uniformly classify and present greater disaggregation of information in the rate reconciliation and income taxes paid. ASU 2023-09 is intended to benefit users of our consolidated financial statements by improving transparency and decision usefulness of income tax disclosures. The new standard is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this new guidance to have a material impact on our consolidated financial statements and have decided not to early adopt ASU 2023-09.

 

F-13

 

 

Note 3 - Segment Reporting

 

The Company operates as one operating segment as its CODM reviews financial information on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. In addition to consolidated net loss, our CODM reviews and utilizes natural expenses, such as employee wages and benefits at a consolidated level, to manage the Company’s operations and strategic growth initiatives. The following table presents segment information of revenue, significant expenses and net loss (in thousands):

 

   Year Ended December 31, 
   2024   2023 
Revenue  $373   $358 
Less:          
Salaries and employee related costs   9,534    9,745 
Stock-based compensation   5,805    4,555 
Rent and facilities   751    575 
Professional services and legal fees   2,959    3,963 
Technology & IT costs   1,062    1,198 
Other sales and marketing costs   734    1,471 
Direct and indirect materials   99    39 
Depreciation and amortization expense   3,798    3,307 
Other operational expenses   1,568    1,748 
Operating loss   (25,937)   (26,243)
Other income (expense)          
Interest expense   (254)   (602)
Interest and other income (expense) (1)   (1,819)   (705)
(Gain) loss on change in fair value of warrant liabilities   (40,532)   528 
Segment and net loss  $(68,542)  $(27,022)

 

(1)Includes interest income of $423 thousand and $295 thousand for the years ended December 31, 2024 and 2023, respectively.

 

Note 4 – Intangible Assets, net

 

As a result of the merger with QPhoton in June 2022, the Company has the following amounts related to intangible assets, net (in thousands):

 

   December 31, 2024   December 31, 2023 
   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount 
Non-compete agreement with founder  $3,251   $(2,800)  $451   $3,251   $(1,715)  $1,536 
Website domain name and trademark   1,009    (521)   488    1,009    (320)   689 
Technology and licensed patents   12,731    (4,698)   8,033    12,731    (2,880)   9,851 
Total  $16,991   $(8,019)  $8,972   $16,991   $(4,915)  $12,076 

 

F-14

 

 

The amortization expense of the Company’s intangible assets for both the years ended December 31, 2024 and 2023 was approximately $3.1 million. The Company expects future amortization expense to be the following (in thousands):

 

   Amortization 
2025  $2,472 
2026   2,021 
2027   1,903 
2028   1,819 
2029   757 
Thereafter   
-
 
Total  $8,972 

 

Note 5 – Income Taxes

 

The Company’s provision for income taxes differs from the amount determined by applying the applicable federal statutory tax rate to the loss before income taxes due to the valuation allowance for the net deferred income tax assets. A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:

 

   Year Ended December, 31 
   2024   2023   2022 
Federal statutory income tax rate   21.0%   21.0%   21.0%
State income taxes, net of federal benefit   (3.1)%   0.0%   0.0%
Warrant mark-to-market adjustments   (12.4)%   2.0%   2.7%
Change in business credits   0.5%   0.0%   0.0%
Other permanent differences   (0.1)%   (0.3)%   (0.1)%
True-ups   0.0%   0.0%   0.0%
Change in deferred tax asset valuation allowance   (6.0)%   (22.3)%   (23.7)%
Effective income tax rate   0.0%   0.4%   0.0%

 

Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of both temporary and permanent differences in the U.S. GAAP vs tax treatment of certain types of expenses, including stock-based compensation, depreciation and amortization, research and development and meals and entertainment. Additionally, the Company’s policy is to account for interest and penalties as income tax expense. As of December 31, 2024, the Company had no interest related to unrecognized tax benefits, and no amounts for penalties related to unrecognized tax benefits were recognized in the provision for income taxes. We do not anticipate any significant change within twelve months of this reporting date.

 

As of December 31, 2024, the Company had federal and state net operating loss carryforwards of approximately $89 million and $7 million, respectively. All of the federal NOL carryforwards were generated during 2018 or later and will carryforward indefinitely but will be subject to 80% taxable income limitation beginning tax years after December 31, 2021, as provided by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act (PL 116-136). State net operating loss will begin to expire in 2043 for state tax purposes. Furthermore, the utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has determined that ownership changes have occurred, primarily driven by the Transactions, and hence the Company’s ability to use its NOLs or tax credit carryforwards may be restricted.

 

As of December 31, 2024, in addition to the $89.4 million in tax-effected NOL carryforwards, at an assumed tax rate of 30%, the significant components of the Company’s net deferred tax assets included stock-based compensation of $14 million, capitalized research and development expenditures of approximately $3 million. As of December 31, 2023, in addition to the $13 million in tax-effected NOL carryforwards, also at an assumed tax rate of 26%, the significant components of the Company’s net deferred tax assets included stock-based compensation of $11 million and capitalized research and development expenditures of approximately $2 million. The Company believes that it is more likely than not that the benefit from the net deferred tax assets will not be realized. Accordingly, it has provided a full valuation allowance on any potential deferred tax assets The valuation allowance increased by approximately $16 million for the period ended December 31, 2024. The provision for income taxes is not material in the years presented due to there being no taxable income.

 

F-15

 

 

The Company has federal R&D credit carryforwards of approximately $878 thousand. The Company has no state R&D credit carryforwards.

 

The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, with varying statutes of limitations. The tax years from inception through 2024 remain open to examination due to the carryover of unused net operating losses that are being carried forward for tax purposes. 

 

Uncertain Tax Positions

 

The Company has unrecognized tax benefits related to research and development credit carryforwards. A full valuation allowance has been provided against the Company’s research and development credits. Therefore, any adjustments to these unrecognized tax benefits would be offset by corresponding adjustments to the valuation allowance, resulting in no impact on the consolidated balance sheet or statement of operations.

 

   December 31,
2024
 
Beginning balance as of December 31, 2023  $
-
 
Changes related to tax positions taken in the prior year   96,767 
Changes related to tax positions taken in the current year   167,774 
Ending balance as of December 31, 2024  $263,541 

 

Note 6 – Property and Equipment, net

 

The Company’s property and equipment, net are primarily located at the Company’s leased facilities in Hoboken, NJ and Tempe, AZ and consist of (in thousands):

 

   December 31, 
Classification  2024   2023 
Computer and laboratory equipment  $8,438   $2,999 
Network equipment   29    29 
Furniture and fixtures   37    32 
Software   77    49 
Leasehold improvements   597    33 
Total cost of property and equipment   9,178    3,142 
Accumulated depreciation   966    272 
Property and equipment, net  $8,212   $2,870 

 

The approximate $6.0 million increase in property and equipment is primarily driven by purchases of laboratory equipment, as well as leasehold improvements, in establishing the AZ Chips Facility.

 

The Company began depreciating select property and equipment at the AZ Chips Facility as they were put in service during the year ended December 31, 2024, and recorded total depreciation expense of $694 thousand and $203 thousand during the years ended December 31, 2024 and 2023, respectively, using useful lives of the Company’s long-lived assets as follows:

 

   Estimated
Useful Life
(Years)
 
Computer and laboratory equipment   5 
Network equipment   4 
Furniture and fixtures   7 
Software   3 
Leasehold improvements   Lessor of lease term or 5 

 

$5.4 million of property and equipment have yet to be placed in service and have not started depreciating.

 

Maintenance and repairs are charged to operations when incurred. When property and equipment are sold or otherwise disposed, the asset account and related accumulated depreciation and amortization accounts are relieved, and any gain or loss is included in other income or expense. There were no significant gains or losses in the year ended December 31, 2024 and 2023, respectively.

 

F-16

 

 

Note 7 – Financial Liabilities

 

 The Company has the following amounts related to financial liabilities (in thousands):

 

   December 31, 
   2024   2023 
Remaining loan balances  $
         -
   $2,063 
Remaining unamortized debt issuance costs   
-
    (138)
Financial liabilities, net  $
-
   $1,925 

 

Additionally, the Company has no and $14 thousand of accrued interest as of December 31, 2024 and 2023, respectively, which is included in Other Current Liabilities.

 

Secured Promissory Note

 

On August 6, 2024, the Company entered into a Securities Purchase Agreement (the “Secured SPA”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which the Company issued and sold to Streeterville a Secured Convertible Promissory Note (the “Streeterville Convertible Note”) in the original principal amount of $8.25 million. The principal amount includes an original issue discount of $750 thousand. Streeterville paid $7.5 million in cash for the Streeterville Convertible Note. The Streeterville Convertible Note accrues interest at a rate of 10% per annum and has a maturity date of February 6, 2026, unless earlier prepaid, redeemed or accelerated in accordance with its terms prior to such date. The Company intends to use the net proceeds from the sale of the Streeterville Convertible Note primarily for general working capital purposes, including for (i) operations as the Company increases its sales and marketing efforts; (ii) capital expenditures in outfitting its chip fabrication facility in Tempe, AZ; and (iii) for any other planned or unplanned expenditures that might arise in support of the Company’s business plan. Ascendiant Capital Markets, LLC served as the placement agent on the transaction and received a fee of $450 thousand, and the Company recognized $55 thousand in other issuance costs, primarily for legal services. The Company repaid the Streeterville Convertible Note on November 18, 2024. As of December 31, 2024, there was no outstanding balance and the Company has no further obligations with respect to the Secured SPA or Streeterville Convertible Note.

 

Unsecured Promissory Note

 

On September 23, 2022, the Company entered into a note purchase agreement (the “Unsecured NPA”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which Streeterville purchased an unsecured promissory note (the “Note” or the “Streeterville Unsecured Note”) in the initial principal amount of $8.25 million. The Streeterville Unsecured Note bore interest at 10% per annum. The maturity date of the Note was defined as 18 months from the date of its issuance (the “Maturity Date”). The Streeterville Unsecured Note carried an original issue discount of $750 thousand, which was included in the principal balance of the Note. If the Company had elected to prepay the Streeterville Unsecured Note prior to the Maturity Date, it would have paid to Streeterville 120% of the portion of the Outstanding Balance the Company would have elected to prepay. As of December 31, 2024, Streeterville has redeemed the full principal amount of the Unsecured NPA. There was an outstanding balance of $1.9 million as of December 31, 2023. As of December 31, 2024, there was no outstanding balance and the Company has no further obligations with respect to the Unsecured NPA or Streeterville Unsecured Note.

 

Note Purchase Agreement – the Company and Wholly-Owned Subsidiary QPhoton

 

On February 18, 2022, the Company entered into a Note Purchase Agreement (the “QCi Note Purchase Agreement”) with QPhoton, pursuant to which the Company agreed to loan money to QPhoton using two unsecured promissory notes (each, a “QCi Note”), each in the principal amount of $1.25 million, subject to the terms and conditions of the QCi Note Purchase Agreement. Also, on February 18, 2022, pursuant to the terms of the QCi Note Purchase Agreement, the Company loaned the principal amount of $1.25 million to QPhoton. On April 1, 2022, pursuant to the terms of the QCi Note Purchase Agreement, the Company loaned the principal amount of $1.25 million to QPhoton, for a total loan under the two QCi Notes of $2.5 million.

 

The QCi Note Purchase Agreement contains customary representations and warranties by QPhoton and the Company, as well as a “most favored nations” provision for the benefit of the Company. The QCi Notes issued under the QCi Note Purchase Agreement, including the QCi Notes issued on February 18, 2022 and April 1, 2022, provide that the indebtedness evidenced by the applicable QCi Note bears simple interest at the rate of 6% per annum (or 15% per annum during the occurrence of an event of default, as defined in the QCi Notes), and becomes due and payable in full on the earlier of (i) March 1, 2023, subject to extension by one year at the option of QPhoton, (ii) a change of control (as defined in the QCi Notes) of QPhoton or (iii) an event of default. As a result of the merger, the QCi Note and accrued interest is eliminated through consolidation. However, the two QCi Notes were not forgiven or converted to equity, remain outstanding under the terms and conditions of the QCi Note Purchase Agreement, and are eliminated for presentation purposes in these consolidated financial statements.

 

F-17

 

 

Note 8 – Contingencies 

 

Indemnification Arrangements

 

We enter into standard indemnification arrangements in our ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties (generally our business partners or customers) in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to our products. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these agreements is minimal.

 

We have entered into indemnification agreements with our directors and officers that may require us to indemnify our directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of a culpable nature. These agreements also require us to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified and to make good faith determination whether or not it is practicable for us to obtain directors and officers insurance. We currently have directors and officers liability insurance.

 

Legal Proceedings

 

From time to time, we may be involved in legal proceedings arising in the ordinary course of business. In general, management believes that ordinary course of business matters will not have a material adverse effect on our consolidated financial position or consolidated results of operations and are adequately covered by our liability insurance. However, it is possible that consolidated cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one of more of these contingencies or because of the diversion of management’s attention and the incurrence of significant expenses.

 

See Part I, Item 3, Legal Proceedings, in this Form 10-K for additional details on the status of the following proceedings.

 

BV Advisory v. QCi Breach Lawsuit

 

At the time of the QPhoton Merger in June 2022, QPhoton had an outstanding balance of principal and interest due to BV Advisory based on a note purchase agreement that QPhoton had entered into with BV Advisory on March 1, 2021 (the “BV Note Purchase Agreement”). Accordingly, the Company has recorded an estimated payable (the “BV Advisory Payable”), recognized as other current liabilities on the consolidated financial statements, based on best available information in the amount of $536 thousand as of December 31, 2024 and 2023.

 

On August 16, 2022, BV Advisory filed a complaint Delaware Chancery Court naming the Company and certain of its directors and officers (among others) as defendants seeking, among other relief, monetary damages for an alleged breach of the BV Note Purchase Agreement. During the year ended December 31, 2024, BV Advisory’s other claims were dismissed by the Delaware Chancery Court and BV Advisory transferred its claim for breach of the BV Note Purchase Agreement to the Delaware Superior Court. The Company believes that BV Advisory’s claims have no merit and intends to defend itself vigorously. BV Advisory’s claims are not covered by the Company’s liability insurance, nor does the Company believe it is necessary to accrue an amount in addition to the BV Advisory Payable at this time.

 

BV Advisory v. QCi Appraisal Action

 

BV Advisory was purportedly a shareholder of QPhoton, Inc., the predecessor in interest to QPhoton, LLC, a wholly owned subsidiary of the Company (both referred to as “QPhoton” in this Legal Proceedings discussion). BV Advisory rejected the Merger Consideration (as defined below) and on October 13, 2022 filed a petition in the Delaware Chancery Court seeking appraisal of the shares of QPhoton it allegedly owned (which shares represented 10% of the shares of QPhoton outstanding immediately prior to the Company’s acquisition of QPhoton). The Appraisal Petition is currently pending in Delaware Chancery Court. The Company included BV Advisory’s purported ownership of QPhoton in the purchase price accounting for the QPhoton Merger.

 

F-18

 

 

The Company’s total purchase price of QPhoton was approximately $71.0 million, or $69.9 million net of cash acquired, consisting of Company common stock, Series B Preferred Stock and QPhoton Warrants (as defined below). While the total shares of the Company’s common stock on an as-converted basis offered in the QPhoton Merger was 36,600,823 (the “Merger Consideration”), the fair market valuation contemplated 31,299,417 of the shares, which assumed full conversion of the 2,377,028 shares of Series B Preferred Stock to common stock at the 10:1 ratio, and that only 1,726,931 of the warrants to purchase up to 7,028,337 shares of the Company’s common stock (the “QPhoton Warrants”) would eventually be exercised (specifically only the QPhoton Warrants for which the associated Company options and/or warrants had an exercise price at or below $2.27 at the time of the QPhoton Merger).

 

Accordingly, as of December 31, 2024 and 2023, the Company has neither issued 2,957,251 shares of the Company’s common stock on an as converted basis (the “Unissued QPhoton Shares”) nor 702,834 warrants to purchase shares of the Company’s common stock (the “Unissued QPhoton Warrants”) that were included in the Merger Consideration. The Unissued QPhoton Shares are included in the statement of stockholder’s equity as additional paid in capital as of as of December 31, 2024 and 2023, and the Unissued QPhoton Warrants have a carrying value of $40.5 million as a liability on the Company’s consolidated balance sheet as of December 31, 2024, and no carrying value as a liability on the Company’s consolidated balance sheet as of December 31, 2023.

 

QCi v. BV Advisory Injunction Lawsuit

 

On January 31, 2025, the Company filed a complaint in Delaware Chancery Court against BV Defendants (BV Advisory and its principal Keith Barksdale) asserting claims for defamation, breach of contract, conversion, aiding and abetting conversion, and misappropriation of trade secrets based on the BV Defendants’ unauthorized possession and dissemination of certain of the Company’s confidential and privileged documents. The Company seeks, among other relief, injunctive relief and damages. On February 11, 2025, the Court granted the Company’s motion for temporary restraining order and instructed the parties to negotiate an expedited case schedule. On February 13, 2025, the Court entered a stipulated case schedule that set a trial for April 8 and 9, 2025 on the Company’s claims for conversion, aiding and abetting conversion, and misappropriation of trade secrets. The parties are currently engaged in discovery. The Company does not believe it is necessary to accrue a litigation reserve at this time.

 

Securities Class Action Lawsuit

 

On February 25, 2025, a class action lawsuit was filed against the Company and certain of its current and past officers in the New Jersey District Court, by a plaintiff seeking to represent a class of all persons who purchased the Company’s securities between March 30, 2020 and January 15, 2025, alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose material information about the Company’s customers, contracts and business operations. To date, the New Jersey District Court has not certified a class or designated a lead plaintiff. The Company disputes the allegations in the complaint, intends to vigorously defend against the claims asserted, and does not believe it is necessary to accrue a litigation reserve at this time.

 

Arbitration over Stock Options

 

In February 2025, the Company entered into arbitrations with Former Consultants (two individuals) regarding forfeiture of stock options. The Company had issued stock options to the consultants in 2020 and 2021 and terminated the Former Consultants’ agreements in March 2024, at which time the Company informed the Former Consultants that any vested options had to be exercised within three months of the termination date, per the Company’s Equity and Incentive Plans. The Former Consultants did not exercise their vested options, and the options were duly forfeited. In December 2024, the Former Consultants claim that they still retain the right to exercise the options, which the Company has rejected. The Company believes these claims are without merit, intends to defend itself vigorously, and does not believe it is necessary to accrue a litigation reserve at this time.

 

F-19

 

 

Note 9 – Loan Receivable

 

On May 16, 2023, the Company entered into a Summary of Proposed Terms (the “Letter of Intent”) with millionways, Inc (“millionways”) to provide bridge loans to millionways and enter into due diligence to acquire up to 100% of the AI firm. On June 6, 2023, the Company entered into a note purchase agreement (the “MW Agreement”) with millionways, pursuant to which the Company agreed to purchase from millionways up to three unsecured promissory notes (each, a “MW Note”), in an aggregate principal amount of up to $2.0 million, subject to the terms and conditions of the MW Agreement. Also on June 6, 2023, pursuant to the terms of the MW Agreement, the Company purchased the MW Notes from millionways and loaned an aggregate principal amount of $500 thousand to millionways.

 

The MW Agreement contains customary representations and warranties by millionways and the Company, as well as a “most favored nations” provision for the benefit of the Company. The MW Notes issued under the MW Agreement, including the MW Notes issued on June 6, 2023, provide that the indebtedness evidenced by the applicable MW Note bears simple interest at the rate of 10% per annum (or 15% per annum during the occurrence of an event of default, as defined in the MW Notes), and becomes due and payable in full on the earlier of (i) May 16, 2024, (ii) a change of control (as defined in the MW Notes) of millionways, (iii) dollar-for-dollar prepayment for additional capital received through any vehicle from a third party or (iv) an event of default.

 

The Company reserved $558 thousand of the outstanding $558 thousand receivable as uncollectible based on credit risk in the consolidated financial statements as of December 31, 2024, however, as of March 18, 2025, is actively seeking collection of $658 thousand, including principal and interest.

 

Note 10 – Capital Stock

 

Authorized Classes of Stock

 

As of December, 2024, the Company’s Board of Directors has authorized two classes of preferred stock. The Board has authorized 1,550,000 shares of preferred stock as Series A preferred stock, par value $0.0001 per share, none of which are issued and outstanding at December 31, 2024, and 1,490,004 of which were issued and outstanding as of December 31, 2023. The Board has also authorized 3,079,864 shares of preferred stock as Series B preferred stock, par value $0.0001 per share, none of which are issued and outstanding at December 31, 2024 and 2023.

 

Series A Convertible Preferred Offering

 

From November 10, 2021 through November 17, 2021, the Company conducted a private placement offering (the “Private Placement”) pursuant to securities purchase agreements with 7 accredited investors (the “Series A Investors”), whereby the Series A Investors purchased from the Company an aggregate of 1,545,459 shares of the Company’s newly created Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”) and warrants to purchase 1,545,459 shares of the Company’s common stock (the “Preferred Warrants”) for an aggregate purchase price of $8.5 million. The Private Placement was completed and closed to further investment on November 17, 2021.

 

The Series A Preferred Stock ranks senior to common stock with respect to the payment of dividends and liquidation rights. Each holder of Series A Preferred Stock is entitled to receive, with respect to each share of Series A Preferred Stock then outstanding and held by such holder, dividends at the rate of 10% per annum (the “Preferred Dividends.”) The Company is obligated to pay the Preferred Dividends quarterly, in arrears, within 15 days of the end of each quarter. The Company has the option to pay the Preferred Dividends in cash or in common stock, at a price per share of common stock equal to the average of the closing sale price of the common stock for the 5 trading days preceding the applicable dividend payment date. The Preferred Dividends are accrued monthly, but not compounded, and are recorded as interest expense, because the Preferred Dividends are mandatory and not declared at the discretion of the Board of Directors.

 

The number of shares of the Company’s common stock issuable upon conversion of any share of Series A Preferred Stock shall be determined by dividing (x) the Conversion Amount of such share of Series A Preferred Stock by (y) the Conversion Price. “Conversion Amount” means, with respect to each share of Series A Preferred Stock, as of the applicable date of determination, the sum of (1) the stated value thereof plus (2) any accrued dividends. “Conversion Price” means, with respect to each share of Series A Preferred Stock, as of any optional conversion date, Mandatory Conversion Date or other date of determination, $5.50, subject to adjustment for stock splits, dividends, recapitalizations and similar corporate events.

 

F-20

 

 

The Preferred Warrants were two-year warrants to purchase shares of the Company’s common stock at an exercise price of $7.00 per share, subject to adjustment, were exercisable at any time on or after the date that was six months following the issuance date, and provided for cashless exercise in the event the underlying shares of the Company’s common stock are not registered. As of December 31, 2023, all of the Preferred Warrants had expired unexercised.

 

In connection with the Purchase Agreement, the Company and the Series A Investors entered into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company agreed to file a registration statement to register the shares of the Company’s common stock underlying the Series A Preferred Stock and warrants within 180 days. Pursuant to the Registration Rights Agreement, the Series A Investors received certain rights, including but not limited to piggyback registration rights, providing that the holder be given notice of any proposed registration of securities by the Company, and requiring that the Company register all or any portion of the registrable securities that the holders request to be registered, in each case, subject to the terms and conditions of the Registration Rights Agreement. On April 27, 2022 the Company filed a Registration Statement on Form S-3 to register the resale of the shares of common stock as required by the Registration Rights Agreement. The Form S-3 went effective on June 2, 2022.

 

On June 13, 2022, one of the Series A Investors, Falcon Capital Partners, converted 45,455 shares of Series A Preferred Stock into 47,728 shares of the Company’s common stock.

 

On February 9, 2023, one of the Series A Investors, Greenfield Children, LLC, converted 10,000 shares of Series A Preferred Stock plus accrued dividends into 11,096 shares of the Company’s common stock.

 

On March 19, 2024, the Company entered into a Redemption and Waiver Agreement (the “Series A Redemption Agreement”) with the current holders (the “Series A Holders”) of its Series A Preferred Stock. Accordingly, $8.125 million of additional paid in capital was reclassified from shareholders’ equity to mezzanine equity (the “Mezzanine Equity”) on the Company’s consolidated balance sheet in accordance with Accounting Series Release No. 268, Presentation in Financial Statements of “Redeemable Preferred Stocks”. The Mezzanine Equity was valued at the date of the Private Placement issuance. Pursuant to the Series A Redemption Agreement, the Company agreed to redeem all outstanding shares of the Series A Preferred Stock for an aggregate cash purchase price of $8,195,000, or $5.50 per share, at its sole discretion, in 18 monthly payments (each a “Monthly Redemption Threshold” payment), which may be accelerated at the Company’s sole discretion and which does not prevent the Series A Holders from converting outstanding shares of Series A Preferred Stock at a conversion price of $5.50 per share. In addition, the Series A Holders agreed to waive (the “Waivers”), on a month-by-month basis following each monthly payment, certain rights granted to them in (i) the Preferred Stock Certificate of Designation (the “Preferred Stock COD”), including for the accrual and payment of accrued and future dividends; and (ii) the Preferred Stock Securities Purchase Agreement (the “Preferred Stock SPA”). In the event the Company opts to not make a Monthly Redemption Threshold payment, the Waivers are forfeited and the terms revert to those detailed in the Preferred Stock COD and Preferred Stock SPA. During the year ended December 31, 2024, the Company redeemed 745,047 shares of Series A Preferred Stock for approximately $4.1 million in cash paid to the Series A Holders.

 

During November 2024 and December 2024, the Series A Holders converted 744,957 shares of Series A Preferred Stock into 744,957 shares of the Company’s common stock. As of December 31, 2024, there were no shares of Series A Preferred Stock issued and outstanding and the Mezzanine Equity valuation was reduced to zero.

 

At-the-Market Facility

 

During the years ended December 31, 2024 and 2023, the Company sold 23,679,391 and 17,571,926 shares of common stock, respectively, through its At-The-Market (ATM) facility, managed by Ascendiant Capital Markets, LLC, at an average price of $1.21. The Company received net aggregate proceeds of $48.5 million, of which $23.8 million and $24.7 million, respectively, was received during the years ended December 31, 2024 and 2023.

 

F-21

 

 

Registered Direct Offering

 

On November 14, 2024, the Company entered into securities purchase agreements (the “November RDO SPAs”) for a registered direct offering (the “November RDO”) to sell an aggregate of 16 million shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $2.50 per share (the “November RDO Shares”), resulting in gross proceeds of $40 million, before deducting placement agent commissions and other offering expenses. On November 18, 2024, the Company completed the sale of the November RDO Shares and announced its intention to use the net proceeds from the November RDO for the repayment of debt, working capital, and general corporate purposes. Specifically, the Company used approximately $9.3 million of the gross proceeds to pay in full the Streeterville Convertible Note.

 

In conjunction with the November RDO SPAs, the Company also entered into a placement agency agreement with Titan Partners Group LLC (“Titan”), a division of American Capital Partners, LLC (the “November Placement Agent”) dated November 14, 2024, pursuant to which the November Placement Agent will act as the exclusive placement agent for the Company in connection with the November RDO. The Company agreed to pay the November Placement Agent a cash fee of 7.25% of the gross proceeds from the November RDO and to issue to the November Placement Agent (or its designees) 800,000 five-year warrants representing 5% of the securities sold in the November RDO, which will be exercisable beginning on May 13, 2025, and have an initial exercise price per share of the Company’s common stock of $2.875. In addition, the Company agreed to reimburse the November Placement Agent for up to $100,000 of its fees and expenses in connection with the November RDO.

 

Registered Direct and Private Placement Offerings

 

On December 10, 2024, the Company entered into securities purchase agreements (the “December RDO SPAs”) for a registered direct offering (the “December RDO”), an aggregate of 1,540,000 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $5.00 per share. Also on December 10, 2024, the Company entered into securities purchase agreements, pursuant to which the Company agreed to issue in a concurrent private placement (the “December Private Placement” and together with the December RDO, the “December SPAs”), an aggregate of 8,460,000 shares (the “December Placement Shares”) of common stock at a purchase price of $5.00 per share. The December SPAs closed on December 12, 2024. The December RDO resulted in gross proceeds of $7.7 million and the December Private Placement resulted in gross proceeds of $42.3 million, in each case before deducting placement agent commissions and other offering expenses. Furthermore, the Company filed a registration statement registering the resale of the December Placement Shares on December 20, 2024, which went effective January 6, 2025.

 

In conjunction with the December SPAs, the Company also entered into a placement agency agreement with Titan (the “December Placement Agent”), dated December 10, 2024, pursuant to which the December Placement Agent will act as the exclusive placement agent for the Company in connection with the December SPAs. The Company agreed to pay the December Placement Agent a cash fee of 7% of the gross proceeds from the December SPAs and to issue to the December Placement Agent (or its designees) 500,000 five-year warrants (representing 5% of the securities sold in the Offerings), which will be exercisable beginning on June 8, 2025, and have an initial exercise price per share of the Company’s common stock of $5.75. In addition, the Company agreed to reimburse the December Placement Agent for up to $100,000 of its fees and expenses in connection with the December SPAs.

 

The combined amount of net proceeds raised from the ATM and RDOs was $106.8 million and $24.7 million for the years ended December 31, 2024 and 2023, respectively.

 

Warrants

 

The table below summarizes the warrants outstanding at December 31, 2024 (in thousands, except exercise prices):

 

Issuance Date  Expiration Date  Exercise Price   Issued   Exercised   Forfeited /
Canceled
   Warrants
Outstanding
 
August 18, 2020  August 18, 2025  $2.00    171    (150)   
-
    21 
June 16, 2022  May 9, 2027  $0.0001    6,325    
-
    (4,121)   2,204 
November 18, 2024  November 18, 2029  $2.875    800    
-
    
-
    800 
December 12, 2024  December 12, 2029  $5.75    500    
-
    
-
    500 

 

F-22

 

 

In connection with a restricted stock units offering in June 2020, the Company issued warrants in August 2020 to purchase 171,000 shares of the Company’s common stock, at an exercise price of $2.00. Those warrants are exercisable for five years from the date of issuance.

 

In connection with the QPhoton Merger on June 16, 2022, the Company issued 6.3 million warrants to purchase shares of the Company’s common stock at an exercise price of $0.0001. Those warrants are exercisable when and if stock options and warrants issued by the Company and outstanding as of June 15, 2022 (the “Underlying Options”) are exercised. As of December 31, 2024, all of the QPhoton Warrants linked to the outstanding Underlying Options are expected to be exercised as the exercise prices of all the Underlying Options are below the closing stock price as of December 31, 2024. The 6.3 million issued warrants represent a portion of the 7.0 million warrants included in the Merger Consideration, having been received by two QPhoton shareholders. A third alleged shareholder rejected the Merger Consideration and commenced litigation, and to date that litigation has not been resolved and the associated 702,834 warrants have not been issued, of which 457,926 would have been canceled to date due to forfeitures of Underlying Options. See Part I, Item 3, Legal Proceedings, for additional information on the status of the litigation.

 

As of December 31, 2024, of the 6.3 million QPhoton Warrants issued, approximately 65% have been forfeited because the corresponding Underlying Options had expired or been forfeited. Further, as discussed in Note 2, Significant Accounting Policies – Fair Value of Financial Instruments, the QPhoton Warrants issued on June 16, 2022, are considered Level 3 liabilities for fair value measurement on the valuation hierarchy. In determining the fair market value of the QPhoton Warrants, the Company determines which underlying options and warrants are in-the-money or out-of-the-money at period end by comparing to the bid price of the Company’s common stock, then accounts for changes period-over-period by realizing a mark-to-market gain or loss for the period. Due to the difference between the exercise price and the market value of the Company's stock as of the balance sheet dates, the market value of the stock and the probability of the underlying options and warrants being exercised are the only significant inputs in the valuation of the warrant liability. Accordingly, the Company recognized a mark-to-market loss of $40.5 million and a mark-to-market gain of $528 thousand during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the QPhoton Warrants have a carrying value of $40.5 million as a liability on the Company’s consolidated balance sheet, an increase of $40.5 million as compared to the Company’s December 31, 2023 consolidated balance sheet, where the QPhoton Warrants had no carrying value as a liability on the Company’s consolidated balance sheet.

 

Note 11 – Stock-based Compensation

 

Incentive Plans

 

The Quantum Computing Inc. 2019 Equity and Incentive Plan, as amended in 2021 (the “2019 Plan”) enabled the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company up to a total of 3.0 million shares of common stock, all of which have been issued.

 

On July 5, 2022, the Board of Directors adopted the Quantum Computing Inc. 2022 Equity and Incentive Plan (the “2022 Plan”), which was approved by a majority of the shareholders in September 2022. The 2022 Plan initially provided for the issuance of up to 16 million shares of the Company’s common stock and includes provisions for annual automatic evergreen increases of 1,000,000 shares of common stock. As of December 31, 2024, the total number of shares of our common stock reserved for issuance under the 2022 Plan is 18 million and a total of 13 million shares and options were issued and outstanding under the 2022 Plan.

 

Options

 

The following table summarizes the Company’s option activity for the year ended December 31, 2024 (in thousands, except exercise price and contractual life data):

 

   Number
Outstanding
   Weighted
Average
Exercise
Price per
Share
   Weighted
Average
Remaining
Contractual
Life (Years)
 
Balance as of January 1, 2023   9,165    3.51    4.2 
Granted   5,340    1.38    5.0 
Forfeited   (662)   4.41    - 
Balance as of December 31, 2023   13,843   $2.64    3.7 
Granted   830    0.92    5.0 
Forfeited   (1,690)   4.14    - 
Balance as of December 31, 2024   12,983   $2.34    2.9 
                
Vested and exercisable as of December 31, 2023   8,803    3.21    3.4 
Vested and exercisable as of December 31, 2024   9,646   $2.66    2.7 

 

F-23

 

 

The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December 31, 2024 and 2023:

 

   Year Ended 
   December 31, 
   2024   2023 
Exercise price  $0.461.12   $0.851.84 
Risk-free interest rate   4.25.2 %    4.75.0 % 
Expected volatility   90105 %    98137 % 
Expected dividend yield   0%   0%
Expected life of options (in years)   5.0    5.0 

 

The following table summarizes the exercise price range as of December 31, 2024 (in thousands):

 

Exercise Price  Outstanding
Options
   Exercisable
Options
 
$ 0.00 – 1.00   230    122 
$ 1.00 – 2.00   5,803    2,928 
$ 2.00 – 3.00   5,879    5,525 
$ 3.00 – 6.00   38    38 
$ 6.00 – 8.00   683    683 
$ 8.00 – 12.00   350    350 
    12,983    9,646 

 

The weighted average grant-date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $0.92 per share and $1.38 per share, respectively. As of December 31, 2024, total unrecognized compensation cost related to common stock options was $3.1 million, which is expected to be recognized over a period of 3.0 years.

 

Restricted Stock

 

As of December 31, 2024, there were 1.3 million shares of the Company’s common stock issued and unvested that had been awarded as stock-based compensation under the 2022 Plan. The following table summarizes the Company’s activity for restricted stock tied to vesting schedules for the year ended December 31, 2024 (in thousands):

 

   Number
Outstanding
   Weighted
Average Fair
Value
 
Unvested as of January 1, 2023   50   $5.70 
Granted   2,429    1.36 
Vested   (1,046)   1.48 
Forfeited   (24)   1.28 
Unvested as of December 31, 2023   1,409   $1.42 
Granted   904    1.58 
Vested   (1,049)   1.82 
Unvested as of December 31, 2024   1,264   $1.20 

 

F-24

 

 

Stock-based compensation

 

The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):

 

   Year Ended 
   December 31, 
   2024   2023 
Research and development  $4,024   $2,080 
Selling and marketing   301    (279)
General and administrative   1,457    2,470 
Total stock-based compensation  $5,782   $4,271 

 

For the years ended December 31, 2024 and 2023, the consolidated statement of stockholders’ equity was lower by $1.5 million and $33 thousand, respectively, as compared to the consolidated statement of cash flows for timing differences between award dates and the realization of stock-based compensation expense.

 

In terms of new issuances, the Company issued 995 thousand shares of the Company’s common stock to employees in the year ended December 31, 2024 (the “2024 SBC Awards), as compared to 2.3 million in the year ended December 31, 2023 (the “2023 SBC Awards”).

 

The 2024 SBC Awards included 218 thousand such shares issued to former executives per their respective employment and separation agreements (the “Separation Agreement Shares”) and 777 thousand such shares issued as performance and incentive awards, which included 727 thousand shares of the Company’s common stock issued to 30 employees as payment in lieu of cash for 2023 performance bonuses (the “2024 Performance Incentive Shares”) and 50 thousand shares of common stock as retention bonuses to five employees identified as key technical staff (the “2024 Retention Incentive Shares”). The 2024 Performance Incentive Shares are restricted with the following vesting schedule: one-half vested on December 31, 2024 and one-half will vest on December 31, 2025. The 2024 Retention Incentive Shares are restricted and vested on December 31, 2024.

 

The Company recognized $197 thousand and $815 thousand, respectively, of stock-based compensation expense during the year ended December 31, 2024 in conjunction with the Separation Agreement Shares and 2024 Retention Incentive Shares, and does not expect future expense related to these issuances as they are fully vested. In conjunction with the 2024 Performance Incentive Shares, the Company recognized $244 thousand of stock-based compensation expense during the year ended December 31, 2024, and expects future expense related to these offerings to total $244 thousand in the year ending December 31, 2025.

 

The 2023 SBC Awards included 854 thousand shares of the Company’s common stock issued to 35 employees as payment in lieu of cash for 2022 performance bonuses (the “2023 Performance Incentive Shares”) and 1.5 million shares of the Company’s common stock as long-term incentive bonuses to five employees identified as key technical staff (the “2023 Retention Incentive Shares”). The 2023 Performance Incentive Shares are restricted and vested in equal halves on each of December 31, 2023 and 2024. As of December 31, 2024, the Company canceled 23,600 of the issued shares that were forfeited by employees no longer with the Company and does not expect future expense related to these offerings as they are fully vested. The 2023 Retention Incentive Shares are restricted and vest annually in equal amounts over a five-year period as follows: 20% vested or will vest on each December 31 of 2023, 2024, 2025, 2026 and 2027, subject to the grantee continuing to perform services for the Company in the capacity in which the grant was received on each applicable vesting date. In conjunction with the 2023 Performance Incentive Shares, the Company recognized $462 thousand of stock-based compensation expense during the year ended December 31, 2024 and does not expect future expense related to these offerings as they are fully vested. In conjunction with the 2023 Retention Incentive Shares, the Company recognized $533 thousand and $320 thousand, respectively, of stock-based compensation expense during the years ended December 31, 2024 and 2023, and expects future expense related to these offerings to total $1.3 million over the remaining vesting periods. 

 

F-25

 

 

Stock-based compensation for services

 

The Company recognized $23 thousand and $284 thousand, respectively, during the years ended December 31, 2024 and 2023 in stock-based compensation for services in lieu of cash payments to certain consultants, including expenses for both shares issued and stock option awards granted. For the years ended December 31, 2024 and 2023, the statement of stockholders’ equity was higher by $114 thousand and $2.2 million, respectively, as compared to the statement of cash flows for timing differences between award dates and the realization of stock-based compensation for services expense.

 

In terms of issuances, the Company issued 142 thousand shares of the Company’s common stock to various consultants for market and media advisory services in the year ending December 31, 2024, as compared to 1.6 million shares of the Company’s common stock in the year ending December 31, 2023 (the “2023 Advisor Shares”). The Company issued 1.5 million of the 2023 Advisor Shares to a consultant who served as an advisor on the QPhoton Merger (the “QPhoton Advisor Shares”), comprised of 750 thousand such shares to Draper, Inc. and 750 thousand such shares to Carriage House Capital, Inc, and issued 75 thousand of the 2023 Advisor Shares to FMW Media Works as compensation for services rendered in support of marketing and communications. For the QPhoton Advisor Shares, the expense was recognized in 2022 at the time of the merger, though the shares were not awarded and issued until 2023.

 

Note 12 – Related Party Transactions

 

There were no related party transactions during the years ended December 31, 2024 and 2023. 

 

Note 13 – Operating Leases

 

As of December 31, 2024, the Company has use of space in three different locations, Hoboken, NJ, Tempe, AZ, and Arlington, VA, under lease or membership agreements, which expire at various dates through November 30, 2028. The Company’s leases do not provide an implicit rate, and the rates implicit in our leases are not readily determinable. Therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating lease assets and liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company’s leases all contain options to extend or renew the lease or membership term.

 

The table below reconciles the undiscounted future minimum lease payments under these operating leases to the total operating lease liabilities recognized on the consolidated balance sheet as of December 31, 2024 (in thousands):

 

Year  Lease Payments
Due
 
2025  $437 
2026   591 
2027   515 
2028   212 
Total minimum payments   1,755 
Less: imputed interest   (136)
Present value of operating lease liabilities   1,619 
Less: current portion included in other current liabilities   (438)
Long-term operating lease liabilities  $1,181 

 

F-26

 

 

Other information related to operating lease liabilities consists of the following:

 

   Year Ended December 31, 
   2024   2023 
         
Cash paid for operating lease liabilities  $385   $411 
Weighted average remaining lease term in years   3.3    3.7 
Weighted average discount rate   10%   10%

 

Note 14 – License Agreement – Stevens Institute of Technology

 

Effective December 17th, 2020, QPhoton signed a License Agreement with the Stevens Institute. The License Agreement enables the Company to commercially use technology such as licensed patents, licensed patent applications and licensed “Know-How”. QPhoton is also able to issue sublicenses for the technology under the agreement. The agreement is effective until the later of: (i) the 30-year anniversary of the effective date, or (ii) the expiration of the licensed patent or licensed patent application that is last to expire. As part of the merger of the Company and QPhoton, the Stevens License Agreement was assigned to the Company.

 

During the term of the agreement and prior to any commercialization or sublicensing of the technology by the Company, the Company shall be required to submit annual reports to the Stevens Institute reporting on all research, development, and efforts toward commercialization and/or sublicensing made during the year. Once any commercialization and/or sublicensing has been initiated, the Company shall deliver quarterly reports to the Stevens Institute reporting on the revenue received by the Company, all sublicenses derived from the sale of licensed products, and the net sales price associated with each transaction. The Company will be responsible for reimbursing Stevens for any costs associated with the prosecution and maintenance of the licensed patents and licensed patent applications moving forward.

 

Consideration for the agreement

 

As consideration for the license and other rights granted under the agreement, QPhoton agreed to pay the following: (i) $35 thousand within 30 days of execution of the agreement, (ii) $28 thousand within 30 days of each annual anniversary of the effective date, (iii) equity in the Company equivalent to 9.0% of the membership units of the Company within 30 days of the execution of the agreement, and (iv) royalties of 3.5% of the Net Sales Price of each licensed product sold or licensed by the Company during the quarter then-ended, for which it also received payment, concurrent with the delivery of the relevant quarterly report.

 

As of December 31, 2024, the Company has begun to commercialize some of the licensed technology, though the Company has not recorded any related revenue and hence has not incurred any royalty expenses payable to the Stevens Institute.

 

Note 15 – Subsequent Events:

 

On January 7, 2025, the Company entered into securities purchase agreements (the “January SPAs”) pursuant to which the Company agreed to issue, in a private placement (the “January Private Placement”), an aggregate of 8,163,266 shares (the “January Placement Shares”) of the Company’s common stock, par value $0.0001 per share, at a purchase price of $12.25 per share. The January SPAs required the Company to file a registration statement registering the resale of the January Placement Shares by January 24, 2025. The Company’s Registration Statement on Form S-1 (File No. 333-284416), to register resale of the the shares sold in this offering was filed on January 22, 2025 and became effective on February 3, 2025. The January Private Placement resulted in gross proceeds of approximately $100 million before deducting placement agent commissions and other offering expenses. The closing of the January Private Placement took place on January 9, 2025, following the satisfaction of customary closing conditions.

 

Pursuant to the January SPAs, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents, or file any registration statement or any amendment or supplement thereto, for a period of 75 days after the closing date of the January Private Placement, subject to certain customary exceptions, without the consent of the January SPAs purchasers and the January Placement Agent, as defined below.

 

F-27

 

 

The Company also entered into a placement agency agreement with Titan (the “January Placement Agent”), dated January 7, 2025, pursuant to which the January Placement Agent will act as the exclusive placement agent for the Company in connection with the January SPAs. The Company agreed to pay the January Placement Agent a cash fee of 6% of the gross proceeds from the January SPAs and to issue to the January Placement Agent (or its designees) 326,531 five-year warrants (representing 4% of the securities sold in the Placement), which will be exercisable beginning on July 6, 2025, and have an initial exercise price per share of the Company’s common Stock of $14.0875. In addition, the Company agreed to reimburse the January Placement Agent for up to $100,000 of its fees and expenses in connection with the January SPAs.

 

As a condition of the January SPAs, the Company’s directors and executive officers entered into Lock-Up Agreements with the Company pursuant to which they agreed for a period of 60 days after the closing date of the January SPAs, subject to certain exceptions, not to directly or indirectly offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position with respect to, any shares of the Company’s common stock or securities convertible, exchangeable or exercisable into the Company’s common stock, that they beneficially own, hold, or thereafter acquire, or make any demand for or exercise any right or cause to be filed a registration, including any amendments thereto, with respect to the registration of any the Company’s common stock or common stock equivalents or publicly disclose the intention to do any of the foregoing.

 

On January 28, 2025, the Delaware Chancery Court reassigned the BV Advisory appraisal action from Vice Chancellor Glasscock (following his retirement on January 15, 2025) to Vice Chancellor Bonnie David, effective as of that date.

 

On January 31, 2025, the Company filed a complaint in Delaware Chancery Court against BV Defendants (BV Advisory and its principal Keith Barksdale) asserting claims for defamation, breach of contract, conversion, aiding and abetting conversion, and misappropriation of trade secrets based on the BV Defendants’ unauthorized possession and dissemination of certain of the Company’s confidential and privileged documents. The Company seeks, among other relief, injunctive relief and damages. On February 11, 2025, the Court granted the Company’s motion for temporary restraining order and instructed the parties to negotiate an expedited case schedule. On February 13, 2025, the Court entered a stipulated case schedule that set a trial for April 8 and 9, 2025 on the Company’s claims for conversion, aiding and abetting conversion, and misappropriation of trade secrets.

 

On February 25, 2025, a class action lawsuit was filed against the Company and certain of its current and past officers in the New Jersey District Court, by a plaintiff seeking to represent a class of all persons who purchased the Company’s securities between March 30, 2020 and January 15, 2025, alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose material information about the Company’s customers, contracts and business operations. To date the New Jersey District Court has not certified a class or designated a lead plaintiff. The Company disputes the allegations in the complaint and intends to vigorously defend against the claims asserted.

 

In February 2025, the Company entered into arbitrations with two former consultants (two individuals) regarding forfeiture of stock options. The Company had issued stock options to the consultants in 2020 and 2021 and terminated the former consultants’ agreements in March 2024, at which time the Company informed the former consultants that any vested options had to be exercised within three months of the termination date, per the 2019 Plan and the 2022 Plan. The former consultants did not exercise their vested options, and the options were duly forfeited. In December 2024, the former consultants claimed that they still retained the right to exercise the options, which the Company rejected. The Company believes these claims are without merit and intends to defend itself vigorously.

 

There are no other events of a subsequent nature that in management’s opinion are reportable.

 

F-28

 

http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember P2Y http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent P5Y 0001758009 false FY 0001758009 2024-01-01 2024-12-31 0001758009 2024-06-30 0001758009 2025-03-18 0001758009 2024-12-31 0001758009 2023-12-31 0001758009 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001758009 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001758009 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001758009 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001758009 2023-01-01 2023-12-31 0001758009 qubt:MezzanineEquityMember 2022-12-31 0001758009 us-gaap:PreferredStockMember 2022-12-31 0001758009 us-gaap:CommonStockMember 2022-12-31 0001758009 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001758009 us-gaap:RetainedEarningsMember 2022-12-31 0001758009 2022-12-31 0001758009 qubt:MezzanineEquityMember 2023-01-01 2023-12-31 0001758009 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001758009 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001758009 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001758009 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001758009 qubt:MezzanineEquityMember 2023-12-31 0001758009 us-gaap:PreferredStockMember 2023-12-31 0001758009 us-gaap:CommonStockMember 2023-12-31 0001758009 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001758009 us-gaap:RetainedEarningsMember 2023-12-31 0001758009 qubt:MezzanineEquityMember 2024-01-01 2024-12-31 0001758009 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001758009 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001758009 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001758009 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001758009 qubt:MezzanineEquityMember 2024-12-31 0001758009 us-gaap:PreferredStockMember 2024-12-31 0001758009 us-gaap:CommonStockMember 2024-12-31 0001758009 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001758009 us-gaap:RetainedEarningsMember 2024-12-31 0001758009 2024-10-01 2024-12-31 0001758009 2018-07-20 0001758009 us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0001758009 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001758009 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001758009 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001758009 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001758009 qubt:ServicesMember 2024-01-01 2024-12-31 0001758009 qubt:ServicesMember 2023-01-01 2023-12-31 0001758009 qubt:ServicesMember 2024-12-31 0001758009 qubt:ProductsMember 2024-01-01 2024-12-31 0001758009 qubt:ProductsMember 2023-01-01 2023-12-31 0001758009 qubt:ProductsMember 2024-12-31 0001758009 country:US us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0001758009 country:US us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0001758009 country:US 2024-01-01 2024-12-31 0001758009 country:US us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0001758009 country:US us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0001758009 country:US 2023-01-01 2023-12-31 0001758009 srt:EuropeMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0001758009 srt:EuropeMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0001758009 srt:EuropeMember 2024-01-01 2024-12-31 0001758009 srt:EuropeMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0001758009 srt:EuropeMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0001758009 srt:EuropeMember 2023-01-01 2023-12-31 0001758009 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0001758009 us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0001758009 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0001758009 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0001758009 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001758009 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001758009 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001758009 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001758009 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001758009 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001758009 qubt:ChiefOperatingDecisionMakerMember 2024-01-01 2024-12-31 0001758009 qubt:ChiefOperatingDecisionMakerMember 2023-01-01 2023-12-31 0001758009 qubt:NonCompeteAgreementWithFounderMember 2024-12-31 0001758009 qubt:NonCompeteAgreementWithFounderMember 2023-12-31 0001758009 us-gaap:TrademarksAndTradeNamesMember 2024-12-31 0001758009 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001758009 qubt:TechnologyAndLicensedPatentsMember 2024-12-31 0001758009 qubt:TechnologyAndLicensedPatentsMember 2023-12-31 0001758009 2021-01-01 2021-12-31 0001758009 2022-01-01 2022-12-31 0001758009 us-gaap:ComputerEquipmentMember 2024-12-31 0001758009 us-gaap:ComputerEquipmentMember 2023-12-31 0001758009 qubt:NetworkEquipmentMember 2024-12-31 0001758009 qubt:NetworkEquipmentMember 2023-12-31 0001758009 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001758009 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001758009 us-gaap:SoftwareDevelopmentMember 2024-12-31 0001758009 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001758009 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001758009 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001758009 qubt:SecuredSPAMember 2024-08-06 0001758009 qubt:SecuredSPAMember 2024-08-06 2024-08-06 0001758009 qubt:StreetervilleMember 2024-08-06 0001758009 2024-08-06 2024-08-06 0001758009 qubt:StreetervilleUnsecuredNoteMember 2022-09-23 0001758009 qubt:StreetervilleUnsecuredNoteMember 2022-09-23 2022-09-23 0001758009 qubt:StreetervilleUnsecuredNoteMember 2023-01-01 2023-12-31 0001758009 qubt:StreetervilleUnsecuredNoteMember 2024-01-01 2024-12-31 0001758009 qubt:QCiNotePurchaseAgreementMember 2022-02-18 0001758009 2022-02-18 0001758009 2022-04-01 0001758009 2022-04-01 2022-04-01 0001758009 qubt:QCiNotePurchaseAgreementMember 2022-04-01 0001758009 qubt:BVAdvisoryMember 2024-12-31 0001758009 qubt:BVAdvisoryMember 2023-12-31 0001758009 qubt:BVAdvisoryPartnersLLCMember 2022-10-13 0001758009 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001758009 qubt:QPhotonWarrantsMember 2024-01-01 2024-12-31 0001758009 us-gaap:WarrantMember 2024-12-31 0001758009 qubt:UnissuedQPhotonSharesMember 2024-01-01 2024-12-31 0001758009 qubt:UnissuedQPhotonSharesMember 2023-01-01 2023-12-31 0001758009 qubt:UnissuedQPhotonWarrantsMember 2024-12-31 0001758009 qubt:millionwaysMember 2023-05-16 0001758009 qubt:UnsecuredPromissoryNotesMember 2023-06-06 2023-06-06 0001758009 qubt:MWAgreementMember 2023-06-06 2023-06-06 0001758009 qubt:MWNoteMember 2023-06-06 0001758009 us-gaap:SubsequentEventMember 2025-03-18 0001758009 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001758009 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001758009 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001758009 us-gaap:SeriesAPreferredStockMember 2021-11-17 2021-11-17 0001758009 us-gaap:SeriesAPreferredStockMember 2021-11-17 0001758009 qubt:PreferredWarrantsMember us-gaap:SeriesAPreferredStockMember 2021-11-17 0001758009 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001758009 us-gaap:CommonStockMember 2024-12-31 0001758009 qubt:FalconCapitalPartnersMember us-gaap:SeriesAPreferredStockMember 2022-06-13 2022-06-13 0001758009 qubt:FalconCapitalPartnersMember us-gaap:CommonStockMember 2022-06-13 2022-06-13 0001758009 qubt:GreenfieldChildrenLLCMember us-gaap:SeriesAPreferredStockMember 2023-02-09 2023-02-09 0001758009 qubt:GreenfieldChildrenLLCMember us-gaap:CommonStockMember 2023-02-09 2023-02-09 0001758009 us-gaap:SeriesAPreferredStockMember 2024-03-19 0001758009 us-gaap:SeriesAPreferredStockMember 2024-03-19 2024-03-19 0001758009 2024-03-19 0001758009 us-gaap:SeriesAPreferredStockMember 2024-11-30 2024-11-30 0001758009 us-gaap:SeriesAPreferredStockMember 2024-12-31 2024-12-31 0001758009 qubt:AscendiantCapitalMarketsMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001758009 qubt:AscendiantCapitalMarketsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001758009 qubt:AscendiantCapitalMarketsMember 2024-12-31 0001758009 qubt:AscendiantCapitalMarketsMember 2024-01-01 2024-12-31 0001758009 qubt:AttheMarketFacilityMember 2024-01-01 2024-12-31 0001758009 qubt:AttheMarketFacilityMember 2023-01-01 2023-12-31 0001758009 2024-11-14 0001758009 us-gaap:CommonStockMember 2024-11-14 0001758009 2024-11-14 2024-11-14 0001758009 2024-11-18 0001758009 2024-11-18 2024-11-18 0001758009 us-gaap:WarrantMember 2024-11-18 2024-11-18 0001758009 2024-12-10 0001758009 us-gaap:CommonStockMember 2024-12-10 0001758009 us-gaap:PrivatePlacementMember 2024-12-10 0001758009 2024-12-10 2024-12-10 0001758009 qubt:RegisteredDirectOfferingMember 2024-12-10 2024-12-10 0001758009 qubt:DecemberPlacementAgentMember 2024-12-10 0001758009 qubt:RegisteredDirectOfferingMember 2023-01-01 2023-12-31 0001758009 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001758009 2022-06-16 2022-06-16 0001758009 qubt:QPhotonMergerMember 2024-12-31 0001758009 us-gaap:WarrantMember 2024-12-31 0001758009 us-gaap:WarrantMember 2023-12-31 0001758009 qubt:August182020Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001758009 qubt:August182020Member us-gaap:WarrantMember 2024-12-31 0001758009 qubt:June162022Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001758009 qubt:June162022Member us-gaap:WarrantMember 2024-12-31 0001758009 qubt:November182024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001758009 qubt:November182024Member us-gaap:WarrantMember 2024-12-31 0001758009 qubt:December122024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001758009 qubt:December122024Member us-gaap:WarrantMember 2024-12-31 0001758009 qubt:TwoThousandAndNineteenEquityAndIncentivePlanMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandAndTwentyTwoEquityAndIncentivePlanMember 2022-07-05 2022-07-05 0001758009 us-gaap:CommonStockMember 2022-07-05 0001758009 qubt:TwoThousandAndTwentyTwoEquityAndIncentivePlanMember 2024-12-31 0001758009 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001758009 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001758009 us-gaap:StockOptionMember 2023-12-31 0001758009 us-gaap:RestrictedStockMember qubt:TwoThousandAndTwentyTwoEquityAndIncentivePlanMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyFourSBCAwardsMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyFourSBCAwardsMember 2023-01-01 2023-12-31 0001758009 qubt:SeparationAgreementSharesMember 2024-01-01 2024-12-31 0001758009 qubt:PerformanceAndIncentiveAwardsMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyFourSBCAwardsMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyThreePerformanceBonusesMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyFourRetentionIncentiveSharesMember 2024-01-01 2024-12-31 0001758009 qubt:SeparationAgreementSharesMember qubt:TwoThousandTwentyFourRetentionIncentiveSharesMember 2024-01-01 2024-12-31 0001758009 qubt:SeparationAgreementSharesMember qubt:TwoThousandTwentyFourRetentionIncentiveSharesMember 2023-01-01 2023-12-31 0001758009 qubt:TwoThousandTwentyFourPerformanceIncentiveSharesMember 2024-01-01 2024-12-31 0001758009 srt:ScenarioForecastMember qubt:TwoThousandTwentyFourPerformanceIncentiveSharesMember 2025-01-01 2025-12-31 0001758009 qubt:TwoThousandTwentyThreeSBCAwardsMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2023-01-01 2023-12-31 0001758009 qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2024-01-01 2024-12-31 0001758009 srt:ScenarioForecastMember qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2025-01-01 2025-12-31 0001758009 srt:ScenarioForecastMember qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2026-01-01 2026-12-31 0001758009 srt:ScenarioForecastMember qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2027-01-01 2027-12-31 0001758009 qubt:TwoThousandTwentyThreePerformanceIncentiveSharesMember 2024-01-01 2024-12-31 0001758009 qubt:TwoThousandTwentyThreeRetentionIncentiveSharesMember 2023-01-01 2023-12-31 0001758009 qubt:TwoThousandTwentyThreeSBCAwardsMember 2023-01-01 2023-12-31 0001758009 qubt:QPhotonMergerMember 2023-01-01 2023-12-31 0001758009 qubt:QPhotonMergerMember 2023-01-01 2023-12-31 0001758009 qubt:CarriageHouseCapitalIncMember 2023-01-01 2023-12-31 0001758009 qubt:FMWMediaWorkMember 2023-01-01 2023-12-31 0001758009 2022-12-31 2022-12-31 0001758009 srt:MinimumMember 2024-12-31 0001758009 srt:MaximumMember 2024-12-31 0001758009 srt:MinimumMember 2023-12-31 0001758009 srt:MaximumMember 2023-12-31 0001758009 srt:MinimumMember 2024-01-01 2024-12-31 0001758009 srt:MaximumMember 2024-01-01 2024-12-31 0001758009 srt:MinimumMember 2023-01-01 2023-12-31 0001758009 srt:MaximumMember 2023-01-01 2023-12-31 0001758009 qubt:ZeroPointZeroZeroToOnePointZeroZeroMember 2024-12-31 0001758009 qubt:OnePointZeroZeroToTwoPointZeroZeroMember 2024-12-31 0001758009 qubt:TwoPointZeroZeroToThreePointZeroZeroMember 2024-12-31 0001758009 qubt:ThreePointZeroZeroToSixPointZeroZeroMember 2024-12-31 0001758009 qubt:SixPointZeroZeroToEightPointZeroZeroMember 2024-12-31 0001758009 qubt:EightPointZeroZeroToTwelvePointZeroZeroMember 2024-12-31 0001758009 us-gaap:RestrictedStockMember 2022-12-31 0001758009 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001758009 us-gaap:RestrictedStockMember 2023-12-31 0001758009 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001758009 us-gaap:RestrictedStockMember 2024-12-31 0001758009 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001758009 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001758009 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-12-31 0001758009 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001758009 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001758009 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001758009 us-gaap:SubsequentEventMember 2025-01-07 2025-01-07 0001758009 us-gaap:SubsequentEventMember 2025-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure qubt:Employees

Exhibit 4.5

 

FORM OF AGENT’S PURCHASE WARRANT

 

QUANTUM COMPUTING INC.

 

Warrant Shares:   Initial Exercise Date: May 13, 2025
   
  Issue Date: November 18, 2024

 

This AGENT’S PURCHASE WARRANT (the “Warrant”) certifies that, for value received,           or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date referred to above as the Initial Exercise Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November 14, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from QUANTUM COMPUTING INC., Delaware corporation (the “Company”), up to             shares of common stock (as subject to adjustment hereunder, the “Warrant Shares”), par value $0.0001 per share (the “Common Stock”) of the Company. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Placement Agent Agreement (the “Placement Agreement”), dated November 14, 2024, between the Company and Titan Partners Group LLC, a division of American Capital Partners, LLC, as placement agent.

 

Section 2. Exercise.

 

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by email (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $2.875, subject to adjustment hereunder (the “Exercise Price”).

 

1

 

 

c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A)  = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

  (B)  = the Exercise Price of this Warrant, as adjusted hereunder; and

 

  (X)  = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock are then listed or quoted on The New York Stock Exchange, the NYSE American or any tier of The Nasdaq Stock Market (each, a “Trading Market”), the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock are then listed or quoted as reported by Bloomberg L.P. (“Bloomberg”) (based on a trading day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock are listed or quoted on the OTCQB or OTCQX (each as operated by OTC Markets Group, Inc., or any successor market), the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock are not then listed or quoted for trading on the OTCQB or OTCQX Markets and if prices for the Common Stock are then reported in the OTC Pink Market published by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a Common Stock as determined by an independent appraiser selected in good faith by the Board of Directors of the Company and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.

 

 If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be tacked onto the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).

 

Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

 

2

 

 

d) Mechanics of Exercise.

 

i.Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company by the Holder of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

  ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

  iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however, that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with the return to the Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of the Holder’s right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).

 

3

 

 

  iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

  v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

  vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

  vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

4

 

 

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

Section 3. Certain Adjustments.

 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or any grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then in effect.

 

5

 

 

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

c) Pro Rata Distribution. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution (other than cash) of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.

 

d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

6

 

 

e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f) Notice to Holder.

 

i.Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

  

ii.Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

7

 

 

Section 4. Transfer of Warrant.

 

a) Transferability. Pursuant to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the commencement of sales of the offering pursuant to which this Warrant is being issued, except as permitted under FINRA Rule 5110(e)(2). Subject to the foregoing restriction, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

8

 

 

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by or on behalf of the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d) Representation by Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 5. Registration Rights.

 

a) To the extent the Company does not maintain an effective registration statement for the Warrant Shares and in the further event that the Company files a registration statement with the Securities and Exchange Commission covering the sale of its shares of Common Stock (other than a registration statement on Form S-4 or S-8, or on another form, or in another context, in which such “piggyback” registration would be inappropriate), then, for a period of three (3) years from the commencement of sales of the Offering, the Company shall give written notice of such proposed filing to the Holder as soon as practicable but in no event less than ten (10) days before the anticipated filing date, which notice shall describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the offering, and offer to the Holder in such notice the opportunity to register the sale of such number of shares of Warrant Shares as such Holder may request in writing within five (5) days following receipt of such notice (a “Piggyback Registration”). The Company shall cause such Warrant Shares to be included in such registration and shall use its commercially reasonable efforts to cause the managing underwriter or underwriters of a proposed underwritten offering to permit the Warrant Shares requested to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of such Warrant Shares in accordance with the intended method(s) of distribution thereof. All Holders proposing to distribute their securities through a Piggyback Registration that involves an underwriter or underwriters shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggyback Registration. Furthermore, each Holder must provide such information as reasonably requested by the Company (which information shall be limited to that which is required for disclosure under the Securities Act and the forms, rules and regulations promulgated thereunder) to be included in the registration statement timely or the Company may elect to exclude such Holder from the registration statement.

 

b) In addition, to the extent the Company does not maintain an effective registration statement for the Warrant Shares, for a period of three (3) years from the commencement of sales of the Offering, the Holder shall be entitled to one (1) demand right for the registration of the Warrant Shares at the Company’s expense (other than any underwriting discounts, selling commissions, share transfer taxes applicable to the sale of the Warrant Shares, and fees and disbursements of counsel for the Holder) (the “Demand Registration”). In the event of a Demand Registration, the Company shall use its commercially reasonable efforts to register the applicable Warrant Shares within sixty (60) days after receiving the Demand Registration. All Holders of Warrant Shares proposing to distribute their securities through a Demand Registration that involves an underwriter or underwriters shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Demand Registration. Furthermore, each Holder must provide such information as reasonably requested by the Company (which information shall be limited to that which is required for disclosure under the Securities Act and the forms, rules and regulations promulgated thereunder) to be included in the registration statement timely or the Company may elect to exclude such Holder from the registration statement.

 

9

 

 

c) Notwithstanding the foregoing, the registration rights described in this Section 5 shall be subject to limitations imposed by the Commission’s rules or comments of the Commission staff in connection with its review of the registration statement for any such resale registration. Moreover, notwithstanding the foregoing registration obligations of the Company, if the Company furnishes to the Holders requesting a Demand Registration a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for a registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such Demand Registration or withdraw a related registration statement for a period of not more than forty-five (45) calendar days; provided, however, that the Company may not invoke this right more than twice in any twelve (12) month period or during the twelve (12) month period prior to the Termination Date.

 

Section 6. Miscellaneous.

 

a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

 

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

d) Authorized Shares.

 

i.The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

10

 

 

ii.Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

iii.Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e) Governing Law; Venue. This Warrant shall be deemed to have been executed and delivered in New York and both this Warrant and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect, and in all other respects by the laws of the State of New York applicable to agreements wholly performed within the borders of such state and without regard to the conflicts of laws principals thereof (other than Sections 5-1401 and 5-1402 of The New York General Obligations Law). Each of the Holder and the Company: (a) agrees that any legal suit, action or proceeding arising out of or relating to this Warrant and/or the transactions contemplated hereby shall be instituted exclusively in the Supreme Court of the State of New York, New York County, or in the United States District Court for the Southern District of New York, (b) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (c) irrevocably consents to the jurisdiction of Supreme Court of the State of New York, New York County, or in the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Holder and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the Supreme Court of the State of New York, New York County, or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified mail to the Company’s address or delivered by Federal Express via overnight delivery shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon the Holder mailed by certified mail to the Holder’s address or delivered by Federal Express via overnight delivery shall be deemed in every respect effective service process upon the Holder, in any such suit, action or proceeding. THE HOLDER (ON BEHALF OF ITSELF, ITS SUBSIDIARIES AND, TO THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS RESPECTIVE EQUITY HOLDERS AND CREDITORS) HEREBY WAIVES ANY RIGHT HOLDER MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS WARRANT AND THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT.

 

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

11

 

 

h) Notices. Any and all notices or other communications or deliveries to be provided hereunder shall be made in accordance with Section 11 of the Underwriting Agreement.

 

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

  

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

 

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

********************

 

(Signature Page Follows)

 

12

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

  QUANTUM COMPUTING INC.
     
  By:  
  Name:                 
  Title:  

 

13

 

 

NOTICE OF EXERCISE

 

To: QUANTUM COMPUTING INC.

 

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment shall take the form of (check applicable box):

 

in lawful money of the United States; or

 

if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity: _____________________________________________________________

 

_________________________________________________________________________________

Signature of Authorized Signatory of Investing Entity:

 

__________________________________________________________________________________

Name of Authorized Signatory:

 

__________________________________________________________________________________

Title of Authorized Signatory:

 

Date: ______________________________________________________________________________

 

14

 

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name:    
    (Please Print)
     
Address:    
    (Please Print)
     
Phone Number:    
     
Email Address:    
Dated: _________, ________    
     
Holder’s Signature: ______________________________    
     
Holder’s Address: _______________________________    

 

15

 

Exhibit 10.20 

 

 

MODIFICATION 2 TO CONSULTING SERVICES AGREEMENT

 

Between

 

QUANTUM COMPUTING INC. and CHRISTOPHER ROBERTS

 

This Second Modification to the Consulting Services Agreement dated July 1, 2023 (the “Second Modification”), is made as of the 18th day of June, 2024 (the “Effective Date”) and amends the Consulting Services Agreement dated July 1, 2023 (the “Consulting Agreement”), between Christopher Roberts (the “Consultant”), and Quantum Computing Inc (the “Company”).

 

The Consulting Agreement is amended in part to extend the Consultancy Term in paragraph 2 for an additional six (6) month term. For avoidance of doubt, the termination date of the Consulting Agreement has been changed to December 31, 2024.

 

The Consulting Agreement is amended in part to expand the reimbursement of expenses in paragraph 3 to provide that the Company will reimburse documented COBRA health, dental and vision insurance premiums, in addition to approved travel and meal expenses, during the Term of the Consulting Agreement.

 

All other provisions of the Consulting Agreement will remain unchanged.

 

Agreed to between the parties: 

 

Consultant: CHRISTOPHER ROBERTS  

Quantum Computing Inc.

 

 

Signature: /s/ Chris Roberts

 

 

Signature: /s/ Chris Boehmler

 

Typed Name: Chris Roberts

 

 

Typed Name: Chris Boehmler

 

Title: Consultant

 

 

Title: Chief Financial Officer

 

Date: June 18, 2024

 

 

Date: June 18, 2024

 

Exhibit 10.30

 

 

MODIFICATION 3 TO CONSULTING SERVICES AGREEMENT

 

Between

 

QUANTUM COMPUTING INC. and CHRISTOPHER ROBERTS

 

This Third Modification (the “Third Modification”) is made as of the 20th day of December, 2024 (the “Effective Date”) and amends the Consulting Services Agreement dated July 1, 2023 (the “Consulting Agreement”), between Christopher Roberts (the “Consultant”) and Quantum Computing Inc. (the “Company”).

 

The Consulting Agreement is amended in part to extend the Consultancy Term in paragraph 2 for an additional twelve (12) month term. For avoidance of doubt, the termination date of the Consulting Agreement has been changed to December 31, 2025.

 

All other provisions of the Consulting Agreement and the changes to paragraph 3 in the Second Modification dated June 18, 2024, will remain unchanged.

 

Agreed to between the parties: 

 

Consultant: CHRISTOPHER ROBERTS  

Quantum Computing Inc.

 

 

Signature: /s/ Chris Robertstna

 

 

Signature: /s/ Chris Boehmler

 

Typed Name: Chris Roberts

 

 

Typed Name: Chris Boehmler

 

Title: Consultant

 

 

Title: Chief Financial Officer

 

Date: December 20, 2024

 

 

Date: December 20, 2024

 

5 Marine View Plaza, Suite 214, Hoboken, NJ 07030

Exhibit 19.1

 

Quantum Computing, Inc.

POLICY ON INSIDER TRADING

 

This Insider Trading Policy (“Policy”) sets forth the policies of Quantum Computing, Inc (the “Company”) on trading and causing the trading of securities while in possession of confidential information.

 

Purpose

 

The Board of Directors of the Company has adopted this Policy to provide guidance to the Company’s directors, officers, and employees about trading in the Company’s securities and the securities of any publicly traded companies with whom the Company has a business relationship.

 

This Policy is designed to: (i) promote compliance with applicable securities laws in order to preserve the Company's reputation for integrity and ethical conduct, (ii) provide guidelines for transactions in the securities of the Company, and (iii) provide guidelines for the handling of confidential information about the Company and any companies with which the Company does business.

 

Scope

 

The policy applies to the following “Covered Persons”: (i) all directors of the Company; and (ii) all officers of the Company and its subsidiaries; and (iii) all employees in the finance, accounting, analytics, legal, and corporate development & strategy functions—as well as personal or administrative assistants to any of the aforementioned—that have regular access to material, nonpublic information about Quantum Computing, Inc. in the normal course of their duties.

 

Sections 1 through 3 and Section 5 apply to the following “Associated Person(s)”: members of your immediate family and persons sharing your household; it also covers venture capital funds and other entities (such as partnerships, trusts and corporations) that are affiliated or associated with such person(s). Affiliated means directly or indirectly controlled or controlled by, or under common control with, such person(s). Associated means (1) a corporation or organization (other than the Company or a majority-owned subsidiary of the Company) of which such person(s) is an officer or partner or is directly or indirectly the beneficial owner of 10% or more of any class of equity securities or (2) any trust in which such person(s) has a substantial beneficial interest or as to which such person serves as trustee or in a similar capacity.

 

1

 

 

1.The Basic Policy—No Trading or Causing Trading While in Possession of Material Non-Public Information

 

(a)No person associated with the Company may purchase or sell any security, whether or not issued by the Company, while in possession of material non-public information concerning the security. (The terms “material” and non-public” are defined in Section 2 below.)

 

(b)No person associated with the Company who knows of material non-public information may communicate that information to any other person if he or she has reason to believe that the information may be improperly used in connection with securities trading.

 

(c)Covered Persons and Associated Persons must “preclear” all trading in securities of the Company in accordance with the procedures set forth in Section 4 below.

 

(d)This Policy applies to all transactions in the Company’s equity securities, including common stock and any other type of securities that the Company may issue, such as preferred stock, notes, bonds, convertible debentures and warrants, and exchange-traded options (including puts and calls) and other derivative securities. This Policy applies to sales, purchases, gifts, exchanges, pledges, options, hedges, puts, calls and short sales.

 

(e)This Policy does not apply to a surrender of shares to the Company or the retention and withholding from delivery to the applicable officer, director or employee of shares by the Company (i.e., a so-called “net settlement”) upon vesting of restricted stock in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement or the Company plan pursuant to which the restricted stock was granted.

 

2.The Law Against “Insider Trading”

 

One of the principal purposes of the federal securities laws is to prohibit so-called insider trading. In recent years this has become a major focus of the enforcement program of the Securities and Exchange Commission and of criminal prosecutions brought by United States Attorneys.

 

(a)Application to Non-Insiders and to Securities Other Than Securities of the Company

 

Prohibitions against “insider trading” apply to trades, tips, and recommendations by any person—including all persons associated with the Company —if the information involved is “material” and “non-public.” Thus, for example, the prohibitions would apply if you trade on the basis of material non-public information you obtain regarding the Company, its borrowers, customers, suppliers, or other corporations with which the Company has contractual relationships or may be negotiating transactions. For compliance purposes, you should never trade, tip, or recommend securities (or otherwise cause the purchase or sale of securities) while in possession of information that you have reason to believe is material and non-public unless you first consult with, and obtain the advance approval of, the Company’s Chief Compliance Officer (the “Compliance Officer”).

 

2

 

 

(b)Materiality

 

Insider trading restrictions come into play if the information you possess is “material.” Materiality, however, involves a low threshold.

 

Information is generally regarded as “material” if it has market significance, that is, if its public dissemination is likely to affect the market price of securities, or if it otherwise is information that a reasonable investor would want to know before making an investment decision. Information dealing with the following subjects is reasonably likely to be found material in particular situations:

 

Significant changes in the Company’s prospects;

 

Significant write-downs in assets or increases in reserves;

 

Developments regarding significant litigation or government agency investigations;

 

Liquidity problems;

 

Changes in earnings estimates or unusual gains or losses in major operation;

 

Major changes in management;

 

Changes in dividends;

 

Extraordinary borrowings;

 

Award or loss of a significant contract;

 

Changes in debt ratings;

 

Proposals, plans, or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures, recapitalizations, strategic alliances, licensing arrangements, or purchases or sales of substantial assets;

 

Public offerings; and

 

Pending statistical reports (e.g., consumer price index, money supply and retail figures, or interest rate developments).

 

Material information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as a merger, acquisition, or introduction of a new product, the point at which negotiations or product development are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company’s operations or stock price should it occur. Thus, information concerning an event that would have a large effect on stock price, such as a merger, may be material even if the possibility that the event will occur is small. When in doubt about whether particular non-public information is material, exercise caution. Consult the Compliance Officer before making a decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates.

 

3

 

 

(c)Non-Public Information

 

Insider trading prohibitions come into play when you possess information that is material and “non-public.” The fact that information has been disclosed to a few members of the public does not make it public for insider trading purposes. To be “public” the information must have been disseminated in a manner designed to reach investors generally. Even after public disclosure of information regarding the Company, you must wait two full business days for the information to be absorbed by public investors before you can treat the information as public.

 

Non-public information may include:

 

Information available to a select group of analysts or brokers or institutional investors;

 

Undisclosed facts that are the subject of rumors, even if the rumors are widely circulated; and

 

Information that has been entrusted to the Company on a confidential basis until a public announcement of the information has been made and enough time has elapsed for the market to respond to a public announcement of the information (two full business days).

 

As with questions of materiality, when in doubt about whether information is non-public, call the designated Compliance Officer or assume that the information is “non-public” and, therefore, treat it as confidential.

 

3.Severe Penalties for Violating Insider Trading Laws

 

Penalties for trading on or communicating material non-public information are severe, both for individuals involved in such unlawful conduct and their employers and supervisors. A person who violates the insider trading laws can be sentenced to a substantial jail term and required to pay a penalty of several times the amount of profits gained or losses avoided.

 

Moreover, Congress has passed insider trading legislation that, in a significant departure from prior law, explicitly empowers the Securities and Exchange Commission to seek substantial penalties from any person who, at the time of an insider trading violation, “directly or indirectly controlled the person who committed such violation.” Such persons may be held liable for up to the greater of $1 million or three times the amount of the profit gained or loss avoided. Thus, even for violations that result in a small or no profit, the Securities and Exchange Commission can seek a minimum of $1 million from the Company and various management and supervisory personnel.

 

4

 

 

Given the severity of the potential penalties, compliance with the policies set forth in Section 1 of this Statement is absolutely mandatory, and noncompliance is a ground for dismissal. Exceptions to these policies, if any, may only be granted by the Compliance Officer and must be provided before any activity contrary to the above policies takes place.

 

4.Preclearance of Securities Transactions

 

Because Covered Persons are likely to obtain material non-public information on a regular basis, the Company requires all such persons to preclear all purchases and sales of the Company’s securities in accordance with the following procedures:

 

(a)Subject to the exemption in part “(d)” below, no Covered Person may, directly or indirectly, purchase or sell any security issued by the Company without first obtaining prior approval from the Compliance Officer. These procedures also apply to transactions by such person’s spouse, other persons living in such person’s household and minor children, and to transactions by entities over which such person exercises control.

 

(b)The Compliance Officer shall record the date each request is received and the date and time each request is approved or disapproved. Unless revoked, a grant of permission will normally remain valid until the close of trading two business days following the day on which it was granted.

 

(c)Requests are most likely to be approved for trading that is to occur in the following “window periods”:

 

(i)    Commencing at the close of trading on the second full business day following the date of public disclosure of the financial results for a particular fiscal quarter or year and continuing until the eleventh business day of the third month of the next fiscal quarter. For example, if public disclosure occurs on Monday, May 14th, trading requests would likely be approved from Thursday, May 17th through Thursday, June 14th; or

 

(ii)    Following the wide dissemination of information on the status of the Company and current results.

 

(d)Preclearance is not required for purchases and sales of securities under a preexisting written plan, contract, instruction, or arrangement that is adopted pursuant to Securities and Exchange Commission Rule 10b5-1(c) (17 C.F.R. § 240.10b5-1(c)) and approved in writing by the Compliance Officer or such other person as the Board of Directors may designate from time to time (the “Authorizing Officer”). Generally, Rule 10b5-1(c) trading plans are developed in consultation with individual counsel and not the responsibility of the Compliance Officer. For more information about Rule 10b5-1 trading plans, see Section 5 below.

 

5

 

 

5.Rule 10B5-1 Trading Plans, Section 16 and Rule 144

 

A.Rule 10b5-1 Trading Plans

 

(1)Overview.

 

Rule 10b5-1 will protect directors, officers and employees from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in the Company’s stock (a “Trading Plan”) entered into in good faith and in accordance with the terms of Rule 10b5-1 and all applicable state laws and will be exempt from the trading restrictions set forth in this Policy. The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company’s securities, and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company’s securities. Each such Trading Plan, and any modification thereof, must be submitted to and pre-approved by the Compliance Officer, or such other Authorizing Officer, who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing Officer.

 

Trading Plans do not exempt individuals from complying with Section 16 short swing profit rules or liability.

 

Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of trading windows and black-out periods, even when there is undisclosed material information. A Trading Plan may also help reduce negative publicity that may result when key executives sell the Company’s stock. Rule 10b5-1 only provides an “affirmative defense” in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.

 

A director, officer or employee may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading window period outside of the trading black-out period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company’s Securities Counsel to assist in the preparation and filing of a required Form 4. Such reporting may be oral or in writing (including by e-mail) and should include the identity of the reporting person, the type of transaction, the date of the transaction, the number of shares involved and the purchase or sale price. However, the ultimate responsibility, and liability, for timely filing remains with the Section 16 reporting person.

 

6

 

 

The Company reserves the right from time to time to suspend, discontinue, or otherwise prohibit any transaction in the Company’s securities, even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company’s right to prohibit transactions in the Company’s securities. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section 5 and result in a loss of the exemption set forth herein.

 

Officers, directors, and employees may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company’s stock, including the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, the Company requires a cooling-off period of 30 days between the establishment of a Trading Plan and commencement of any transactions under such plan. An individual may adopt more than one Trading Plan. Please review the following description of how a Trading Plan works.

 

Pursuant to Rule 10b5-1, an individual’s purchase or sale of securities will not be “on the basis of” material, non-public information if:

 

First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).

 

Second, the Trading Plan must either:

 

specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold;

 

include a written formula or computer program for determining the amount, price and date of the transactions; or

 

prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company’s stock under the Trading Plan in question.

 

Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.

 

(2)Revocation of and Amendments to Trading Plans

 

Revocation of Trading Plans should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Trading Plan will be subject to the prior review and approval of the Compliance Officer or Authorizing Officer. Revocation is effected upon written notice to the broker. Once a Trading Plan has been revoked, the participant should wait at least 30 days before trading outside of a Trading Plan and 180 days before establishing a new Trading Plan.

 

7

 

 

A person acting in good faith may amend a prior Trading Plan so long as such amendments are made outside of a quarterly trading black-out period and at a time when the Trading Plan participant does not possess material, non-public information. Plan amendments must not take effect for at least 30 days after the plan amendments are made.

 

Under certain circumstances, a Trading Plan must be revoked. This may include circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. The Compliance Officer or Authorizing Officer is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.

 

(3)Discretionary Plans

 

Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred to a broker, are permitted if pre-approved by the Compliance Officer or Authorizing Officer.

 

The Compliance Officer or Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company’s stock or option exercises, including but not limited to, blind trusts, discretionary accounts with banks or brokers, or limit orders. The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company’s stock once the Trading Plan or other arrangement has been pre-approved.

 

(4)Reporting (if Required)

 

If required, an SEC Form 144 will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote at the bottom of the Form 144 should indicate that the trades “are in accordance with a Trading Plan that complies with Rule 10b5-1 and expires _____.” For Section 16 reporting persons, Form 4s should be filed before the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date of such notification is not later than the third business day following the trade date. A similar footnote should be placed at the bottom of the Form 4 as outlined above.

 

(5)Options

 

Exercises of options for cash may be executed at any time. “Cashless exercise” option exercises through a broker are subject to trading windows. However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and with the number of shares to be exercised left blank.

 

8

 

 

Once a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing and the Compliance Officer or Authorizing Officer will fill in the number of shares and the date of exercise on the previously signed exercise form. The insider should not be involved with this part of the exercise.

 

(6)Trades Outside of a Trading Plan

 

During an open trading window, trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading Plan continues to be followed.

 

(7)Public Announcements

 

The Company may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1. It will consider in each case whether a public announcement of a particular Trading Plan should be made. It may also make public announcements or respond to inquiries from the media as transactions are made under a Trading Plan.

 

(8)Prohibited Transactions

 

The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company’s securities.

 

(9)Limitation on Liability

 

None of the Company, the Compliance Officer, the Authorizing Officer or the Company’s other employees will have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Section 5 or a request for pre-clearance submitted pursuant to Section 5 of this Policy. Notwithstanding any review of a Trading Plan pursuant to this Section 5 or pre-clearance of a transaction pursuant to Section 5 of this Policy, none of the Company, the Compliance Officer, the Authorizing Officer or the Company’s other employees assumes any liability for the legality or consequences of such Trading Plan or transaction to the person engaging in or adopting such Trading Plan or transaction.

 

B.Section 16: Insider Reporting Requirements, Short-Swing Profits and Short Sales

 

(1)Reporting Obligations Under Section 16(a): SEC Forms 3, 4 and 5

 

Section 16(a) of the 1934 Act generally requires all officers, directors and 10% stockholders (“insiders”), within 10 days after the insider becomes an officer, director or 10% stockholder, to file with the SEC an “Initial Statement of Beneficial Ownership of Securities” on SEC Form 3 listing the amount of the Company’s stock, options and warrants which the insider beneficially owns. Following the initial filing on SEC Form 3, changes in beneficial ownership of the Company’s stock, options and warrants must be reported on SEC Form 4, generally within two business days after the date on which such change occurs, or in certain cases on Form 5, within 45 days after fiscal year end. A Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings. In certain situations, purchases or sales of Company stock made within six months prior to the filing of a Form 3 must be reported on Form 4. Similarly, certain purchases or sales of Company stock made within six months after an officer or director ceases to be an insider must be reported on Form 4.

 

9

 

 

(2)Recovery of Profits Under Section 16(b)

 

For the purpose of preventing the unfair use of information which may have been obtained by an insider, any profits realized by any officer, director or 10% stockholder from any “purchase” and “sale” of Company stock during a six-month period, so called “short-swing profits,” may be recovered by the Company. When such a purchase and sale occurs, good faith is no defense. The insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.

 

The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports of ownership filed with the SEC on Form 3, Form 4, or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations. In addition, liabilities under Section 16(b) may require separate disclosure in the Company’s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders. No suit may be brought more than two years after the date the profit was realized. However, if the insider fails to file a report of the transaction under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed. Failure to report transactions and late filing of reports require separate disclosure in the Company’s proxy statement.

 

Officers and directors should consult the attached “Short-Swing Profit Rule Section 16(b) Checklist” attached hereto as “Attachment A” in addition to consulting the Compliance Officer prior to engaging in any transactions involving the Company’s securities, including without limitation, the Company’s stock, options or warrants.

 

(3)Short Sales Prohibited Under Section 16(c)

 

Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company’s equity securities. Short sales include sales of stock which the insider does not own at the time of sale, or sales of stock against which the insider does not deliver the shares within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c). Insiders violating Section 16(c) face criminal liability.

 

10

 

 

The Compliance Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16. 

 

C.Rule 144

 

Rule 144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales of “restricted securities” and “control securities.” “Restricted securities” are securities acquired from an issuer, or an affiliate of an issuer, in a transaction or chain of transactions not involving a public offering. “Control securities” are any securities owned by directors, executive officers or other “affiliates” of the issuer, including stock purchased in the open market and stock received upon exercise of stock options. Sales of Company restricted and control securities must comply with the requirements of Rule 144, which are summarized below:

 

Holding Period. Restricted securities must be held for at least six months before they may be sold in the market.

 

Current Public Information. The Company must have filed all SEC-required reports during the last 12 months or such shorter period that the Company was required to file such reports.

 

Volume Limitations. For affiliates, total sales of Company common stock for any three-month period may not exceed the greater of: (i) 1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement published by the Company, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144.

 

Method of Sale. For affiliates, the shares must be sold either in a “broker’s transaction” or in a transaction directly with a “market maker.” A “broker’s transaction” is one in which the broker does no more than execute the sale order and receive the usual and customary commission. Neither the broker nor the selling person can solicit or arrange for the sale order. In addition, the selling person or Board member must not pay any fee or commission other than to the broker. A “market maker” includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous basis.

 

Notice of Proposed Sale. For affiliates, a notice of the sale (a Form 144) may be required to be filed with the SEC at the time of the sale. Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 and in complying with the other requirements of Rule 144.

 

11

 

 

If you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm’s Rule 144 compliance procedures in connection with all trades. 

 

6.Prohibited Activities

 

(a) ProhibitionsExcept for limited exceptions described below, the following activities are prohibited under this Policy:

 

(i) No Covered Person may purchase, sell, transfer or effectuate any other transaction in Company securities while in possession of material nonpublic information concerning the Company or its securities. This prohibition includes sales of shares received upon exercise of stock options or upon vesting of Restricted Stock Units and Awards, and shares held in the Company’s 401(k) plan.

 

(ii) No Covered Person may “tip” or disclose material nonpublic information concerning the Company or its securities to any outside person (including family members, affiliates, analysts, investors, members of the investment community and news media). Should a Covered Person inadvertently disclose such information to an outsider, the Covered Person must promptly inform the Compliance Officer regarding this disclosure. The Company will take steps necessary to preserve the confidentiality of the information, including requiring the outsider to agree in writing to comply with the terms of this Policy and/or sign a confidentiality agreement.

 

(iii) No Covered Person may purchase Company securities on margin, hold Company securities in a margin account, or otherwise pledge Company securities as collateral for a loan because, in the event of a margin call or default on the loan, the broker or lender could sell the shares at a time when the Covered Person is in possession of material nonpublic information, resulting in liability for insider trading. In addition, pledging of securities by Covered Persons, including margin arrangements, can be perceived to undermine the alignment of their interests and incentives with the long-term interests of other stockholders.

 

(iv) Short-term and speculative trading in Company securities, as well as hedging and other derivative transactions involving Company securities, can create the appearance of impropriety and may become the subject of an SEC investigation, particularly if the trading occurs before a major Company announcement or is followed by unusual activity or price changes in the Company’s stock. These types of transactions can also result in inadvertent violations of insider trading laws and/or liability for short-swing profits under Section 16(b) of the Securities Exchange Act of 1934. Therefore, it is the Company’s policy to prohibit the following activities, even if you are not in possession of material nonpublic information:

 

1.No Covered Person may trade in any interest or position relating to the future price of Company securities, such as put or call options or other derivatives, or short sale of Company securities.

 

12

 

 

2.No Covered Person may hedge Company securities. A “hedge” is a transaction designed to offset or reduce the risk of a decline in the market value of an equity security, and can include, but is not limited to, prepaid variable forward contracts, equity swaps, collars, and exchange funds.

 

3.Covered Persons may not trade in securities of the Company on an active basis, including short term speculation.

 

(v) No Covered Person may trade in securities of another company if the Covered Person is in possession of material nonpublic information about that other company which the Covered Person learned in the course of their work for the Company.

 

(vi) ”Quiet” Periods. The Company’s announcement of its quarterly financial results has the potential to have a material effect on the market for the Company's securities. Therefore, to avoid even the appearance of trading on the basis of material non-public information, Covered Persons who are subject to the pre-clearance procedure set forth above may not, except as expressly permitted under this Policy, carry out any transaction in the Company’s securities during the period beginning on the 15th day of the last month of each quarter (March, June, September, December) and ending on the third business day following the release of the Company’s earnings for that quarter.

 

(vii) Event-Specific Quiet Periods. The Company reserves the right to close any open window period at any time if the Compliance Officer, or his or her designee, determines, in his or her sole discretion, that there may be material non-public information with respect to the Company. If the Company closes an open window, it will not pre- clear any transaction that is not expressly permitted by this Policy during the period that such open window is closed.

 

The Company may on occasion issue interim earnings guidance or other potentially material information by means of a press release, Current Report on Form 8-K, or other means designed to achieve widespread dissemination of the information. Covered Persons should anticipate that trading will be prohibited while the Company is in the process of assembling the information to be released and until the information has been released and absorbed by the market.

 

From time to time, an event may occur that is material to the Company and is known by only a few directors, executives, or other employees. So long as the event remains material and non-public, the persons who are aware of the event, as well as all Designated Persons, may not trade in the Company’s securities.

 

The existence of an event-specific quiet period will not be announced, other than to those who are aware of the event giving rise to the quiet period. If, however, a person whose trades are subject to the pre-clearance requirements set forth above desires to effect a transaction during an event-specific quiet period, the Compliance Officer may refuse to grant permission to carry out the transaction and will have no obligation to disclose to the person the reason for the refusal or the reason for the event-specific quiet period. Any person who becomes aware of the existence of an event-specific quiet period shall not disclose the existence of the quiet period to any other person. The failure of the Compliance Officer to inform a person that they are subject to an event-specific quiet period will not relieve that person of the obligation not to trade while aware of material non- public information.

 

13

 

 

(b) Exceptions to Prohibited Activities. Prohibitions in trading securities under this Policy do not include:

 

(i) The investment of 401(k) plan contributions in a Company stock fund in accordance with the terms of the Company's 401(k) plan. However, any changes in your investment election regarding the Company’s stock are subject to trading restrictions under this Policy.

 

(ii) The exercise of vested employee stock options where no Company stock is sold to fund the option exercise.1

 

(iii) The receipt of Company stock upon vesting of Restricted Stock Units and Awards, as well as the withholding of Company stock by the Company in payment of tax obligations.

 

(iv) Company securities purchased or sold under a Company authorized Rule 10b5-1 Trading Plan (see Section 4(d) above).

 

(v) Transfers of Company stock by a Covered Person into a trust for which the Covered Person is a trustee, or from the trust back into the name of the Covered Person.

 

7.Blackout Periods Applicable to Covered Persons

 

(a) No Trading During Blackout Periods. No Covered Person may trade or effectuate any other transactions in Company securities during regular blackout periods or during any special blackout periods designated by the Compliance Officer (except for the limited exceptions described in Section 5(b) above). Remember that even during an open trading window, you may not trade in Company securities if you are in possession of material nonpublic information concerning the Company or its securities.

 

(b) Regular Blackout Periods Defined. Subject to obtaining trading pre-approval from the Compliance Officer, Covered Persons may not trade in Company securities during the period beginning on the 15th day of the last month of each quarter (March, June, September, December) and ending on the third business day following the release of the Company’s earnings for that quarter. To provide clarity, the Compliance Officer will notify Covered Persons, in advance of each quarter end, of the date on which the blackout period begins and ends. Trades made pursuant to an approved 10b5-1 Trading Plan (see Section 4(d) above) are exempted from this restriction.

 

 

1While vested employee stock options may be exercised at any time under this Policy, the sale of any stock acquired through such exercise is subject to this Policy.

 

14

 

 

(c) Special Blackout Periods. From time to time, the Compliance Officer may determine that trading in Company securities is inappropriate during an otherwise open trading window due to the existence of material nonpublic information. Accordingly, the Compliance Officer may prohibit trading at any time by announcing a special blackout period. The Compliance Officer will provide notice of any modification of the trading blackout policy or any additional prohibition on trading during the period when trading is otherwise permitted under this Policy. The existence of a special blackout period should be considered confidential information and Covered Persons are prohibited from communicating the existence of a special blackout period to anyone who is not a Covered Person.

 

(d) Blackout Periods Required by the Sarbanes-Oxley Act of 2002. In order to comply with certain provisions of the Sarbanes-Oxley Act of 2002, no director or executive officer of the Company may, directly or indirectly, purchase, sell or otherwise acquire or transfer any equity security of the Company during any period of time that participants in the Company’s 401(k) plan are prohibited from trading interests in the Company’s equity securities under such plan. The “blackout period” is defined for purposes of this rule as any period of more than three consecutive business days during which the ability of 50 percent or more of the participants or beneficiaries located in the United States under all individual account plans of the Company to purchase or sell any equity securities of the Company under any such plan is suspended by action of the Company or a fiduciary of the plan. The Sarbanes-Oxley Act requires the Company to timely notify affected directors and executive officers and the SEC of any such blackout period. If you are a director or executive officer of the Company, the Compliance Officer will disapprove any requested transaction involving equity securities of the Company that would occur during a blackout period for participants in the Company’s 401(k) plan.

 

(e) Hardship Trading Exceptions. The Compliance Officer may, on a case-by-case basis, authorize trading in Company securities during a trading blackout period due to financial or other hardship. Any person wanting to rely on this exception must first notify the Compliance Officer in writing of the circumstance of the hardship and the amount and nature of the proposed trade. Such person will also be required to certify to the Compliance Officer in writing no earlier than two business days prior to the proposed trade that he or she is not in possession of material nonpublic information concerning the Company or its securities. Upon authorization from the Compliance Officer, the person may trade, although such person will be responsible for ensuring that any such trade complies in all other respects with this Policy.

 

15

 

 

8.Inquiries

 

If you have any questions regarding any of the provisions of this Policy, please contact _____________at _______________.

 

9.Acknowledgment and Certification

 

The undersigned does hereby acknowledge receipt of the Company’s Policy On Insider Trading regarding trading on material non-public information. The undersigned has read and understands (or has had explained to them by someone who understands) such Policy and agrees to be governed by such Policy at all times in connection with the purchase and sale of securities and the confidentiality of non-public information. The undersigned understands that if the undersigned is a Covered Person, the entire policy applies to them. The undersigned understands that if the undersigned is not a Covered Person, Sections 1 through 3 and Section 5 applies to them.

 

________________________________________

(Signature)

 

________________________________________   ________________________________________
(Please print name)   Title/Relationship to the Company

 

Date: ____________________________ 

 

16

 

 

ATTACHMENT A

 

SHORT-SWING PROFIT RULE SECTION 16(B) CHECKLIST

 

Note: ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six months of each other by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities) results in a violation of Section 16(b), and the “profit” must be recovered by Quantum Computing, Inc. (the “Company”). It makes no difference how long the shares being sold have been held or, for officers and directors, that you were an insider for only one of the two matching transactions. The highest priced sale will be matched with the lowest priced purchase within the six-month period.

 

Sales

 

If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated entities):

 

1.Have there been any purchases by the insider (or family members living in the same household or certain affiliated entities) within the past six months?

 

2.Have there been any option grants or exercises not exempt under Rule 16b-3 within the past six months?

 

3.Are any purchases (or non-exempt option exercises) anticipated or required within the next six months?

 

4.Has a Form 4 been prepared?

 

Note: If a sale is to be made by an affiliate of the Company, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144?

 

Purchases and Option Exercises

 

If a purchase or option exercise for Company stock is to be made:

 

1.Have there been any sales by the insider (or family members living in the same household or certain affiliated entities) within the past six months?

 

2.Are any sales anticipated or required within the next six months (such as tax-related or year-end transactions)?

 

3.Has a Form 4 been prepared?

 

Before proceeding with a purchase or sale, consider whether you are aware of material, non-public information which could affect the price of the Company stock. All transactions in the Company’s securities by officers and directors must be pre-cleared by contacting the Company’s Compliance Officer.

 

17

 

Exhibit 21.1

 

SUBSIDIARIES OF THE REGISTRANT

 

Name of Subsidiary   Jurisdiction of Incorporation or Organization
     
Qubittech, Inc.   Delaware
     
Qubittech International, Inc.   Delaware
     
QI Solutions, Inc.   Delaware
     
QPhoton, LLC   Delaware

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-269063, 333-268064 and 333-264518) of Quantum Computing Inc. of our report dated March 20, 2025 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K.

 

/s/ BPM LLP

 

San Jose, California

March 20, 2025

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Dr. William McGann, certify that:

 

1.I have reviewed this Annual Report on Form 10-K of Quantum Computing Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.[Omitted]; and

 

5.[Omitted].

 

Date: March 20, 2025 By: /s/ Dr. William McGann
    Dr. William McGann
    Principal Executive Officer
Quantum Computing Inc.

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Christopher Boehmler, certify that:

 

1.I have reviewed this Annual Report on Form 10-K of Quantum Computing Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.[Omitted]; and

 

5.[Omitted].

 

Date: March 20, 2025 By: /s/ Christopher Boehmler
    Christopher Boehmler
    Principal Financial Officer
Quantum Computing Inc.

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Annual Report of Quantum Computing Inc. (the “Company”) on Form 10-K for the period ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. William McGann, Principal Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 20, 2025 By: /s/ Dr. William McGann
    Dr. William McGann
    Principal Executive Officer
Quantum Computing Inc.

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Annual Report of Quantum Computing, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher Boehmler, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 20, 2025 By: /s/ Christopher Boehmler
    Christopher Boehmler
    Principal Financial Officer
Quantum Computing Inc.

 

v3.25.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2024
Mar. 18, 2025
Jun. 30, 2024
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Financial Statement Error Correction [Flag] false    
Entity Interactive Data Current Yes    
ICFR Auditor Attestation Flag false    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Documents Incorporated by Reference [Text Block]

None

   
Entity Information [Line Items]      
Entity Registrant Name QUANTUM COMPUTING INC.    
Entity Central Index Key 0001758009    
Entity File Number 001-40615    
Entity Tax Identification Number 82-4533053    
Entity Incorporation, State or Country Code DE    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Public Float     $ 34,743,396
Entity Incorporation, Date of Incorporation Jul. 20, 2018    
Entity Contact Personnel [Line Items]      
Entity Address, Address Line One 5 Marine View Plaza    
Entity Address, Address Line Two Suite 214    
Entity Address, City or Town Hoboken    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07030    
Entity Phone Fax Numbers [Line Items]      
City Area Code (703)    
Local Phone Number 436-2121    
Entity Listings [Line Items]      
Title of 12(b) Security Common Stock, par value $.0001    
Trading Symbol QUBT    
Security Exchange Name NASDAQ    
Entity Common Stock, Shares Outstanding   137,244,545  
v3.25.1
Audit Information
12 Months Ended
Dec. 31, 2024
Auditor [Table]  
Auditor Name BPM LLP
Auditor Firm ID 207
Auditor Location San Jose, California
Auditor Opinion [Text Block]

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Quantum Computing Inc. (a Delaware Corporation) and its subsidiaries (collectively, the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, mezzanine and stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 78,945 $ 2,059
Accounts receivable, net 27 65
Inventory 18 73
Loans receivable, net 279
Prepaid expenses and other current assets 161 180
Total current assets 79,151 2,656
Property and equipment, net 8,212 2,870
Operating lease right-of-use assets 1,522 1,051
Intangible assets, net 8,972 12,076
Goodwill 55,573 55,573
Other non-current assets 129 129
Total assets 153,559 74,355
Current liabilities:    
Accounts payable 1,372 1,462
Accrued expenses 2,134 639
Financial liabilities, net of issuance costs 1,925
Deferred revenue 79
Other current liabilities 974 786
Total current liabilities 4,559 4,812
Derivative liability 40,532
Operating lease liabilities 1,181 840
Total liabilities 46,272 5,652
Contingencies (see Note 8)
Stockholders’ equity:    
Preferred stock, $0.0001 par value, 1,550 shares Series A Preferred authorized; no shares and 1,490 thousand shares issued and outstanding as of December 31, 2024 and 2023, respectively; 3,080 thousand shares of Series B Preferred Stock authorized; no shares issued and outstanding as of December 31, 2024 and 2023
Common stock, $0.0001 par value, 250,000 thousand shares authorized; 129,012 thousand and 77,451 thousand shares issued and outstanding as of December 31, 2024 and 2023, respectively 13 8
Additional paid-in capital 307,756 200,635
Accumulated deficit (200,482) (131,940)
Total stockholders’ equity 107,287 68,703
Total liabilities and stockholders’ equity $ 153,559 $ 74,355
v3.25.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 129,012,000 77,451,000
Common stock, shares outstanding 129,012,000 77,451,000
Series A Preferred Stock    
Preferred stock par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,550,000 1,550,000
Preferred stock, shares issued 1,490,004
Preferred stock, shares outstanding 1,490,004
Series B Preferred Stock    
Preferred stock, shares authorized 3,080,000 3,080,000
Preferred stock, shares issued
Preferred stock, shares outstanding
v3.25.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Total revenue $ 373 $ 358
Cost of revenue 261 196
Gross profit 112 162
Operating expenses    
Research and development 11,318 8,891
Sales and marketing 1,818 1,806
General and administrative 12,913 15,708
Total operating expenses 26,049 26,405
Loss from operations (25,937) (26,243)
Non-operating income (expense)    
Interest and other income 423 295
Interest expense, net (2,496) (1,602)
Change in fair value of warrant liabilities (40,532) 528
Loss before income tax provision (68,542) (27,022)
Income tax provision
Net loss (68,542) (27,022)
Less: Series A convertible preferred stock dividends 861
Net loss attributable to common stockholders $ (68,542) $ (27,883)
Loss per share – basic (in Dollars per share) $ (0.73) $ (0.42)
Loss per share – diluted (in Dollars per share) $ (0.73) $ (0.42)
Weighted average shares used in computing net loss per common share – basic (in Shares) 93,881 66,611
Weighted average shares used in computing net loss per common share –dilutive (in Shares) 93,881 66,611
v3.25.1
Consolidated Statements of Mezzanine and Stockholders’ Equity - USD ($)
shares in Thousands, $ in Thousands
Mezzanine Equity
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2022 $ 6 $ 169,175 $ (104,057) $ 65,124
Balance (in Shares) at Dec. 31, 2022   1,500 55,963      
Issuance of shares for cash $ 2 24,728 24,730
Issuance of shares for cash (in Shares)     17,572      
Conversion of preferred stock 1 1
Conversion of preferred stock (in Shares)   (10) 11      
Preferred stock dividends (861) (861)
Stock-based compensation 4,238 4,238
Stock-based compensation (in Shares)     2,330      
Stock-based compensation for services 2,493 2,493
Stock-based compensation for services (in Shares)     1,575      
Net loss (27,022) (27,022)
Balance at Dec. 31, 2023 $ 8 200,635 (131,940) 68,703
Balance (in Shares) at Dec. 31, 2023   1,490 77,451      
Issuance of shares for cash $ 5 106,761 106,766
Issuance of shares for cash (in Shares)     49,679      
Conversion of Series A preferred stock to common stock (4,097) 4,097 4,097
Conversion of Series A preferred stock to common stock (in Shares)   (745) 745      
Reclassification of Series A preferred stock to mezzanine equity 8,195 (8,195) (8,195)
Repurchase of redeemable shares (4,098)
Repurchase of redeemable shares (in Shares)   (745)      
Preferred stock dividends          
Stock-based compensation 4,322 4,322
Stock-based compensation (in Shares)     995      
Stock-based compensation for services 136 136
Stock-based compensation for services (in Shares)     142      
Net loss (68,542) (68,542)
Balance at Dec. 31, 2024 $ 13 $ 307,756 $ (200,482) $ 107,287
Balance (in Shares) at Dec. 31, 2024   129,012      
v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (68,542) $ (27,022)
Adjustments to reconcile net loss to net cash used in operations    
Depreciation and intangibles amortization 3,798 3,307
Amortization of issuance costs 2,059 925
Change in fair value of warrant liability 40,532 (528)
Change in value of derivative (666)
Provision for credit losses 279 279
Other recognized losses (gains) 4 5
Stock-based compensation expense 5,782 4,271
Stock-based compensation expense for services 23 284
Changes in operating assets and liabilities    
Accounts receivable 38 (52)
Inventories 55 (70)
Prepaid expenses and other current assets 16 (110)
Other non-current assets (69)
Accounts payable (90) 596
Deferred revenue 79
Accrued expenses and other current liabilities 550 110
Other long-term liabilities (130) (241)
Net cash used in operating activities (16,213) (18,315)
Cash flows from investing activities:    
Purchase of property and equipment (6,036) (2,112)
Issuance of loan receivable (500)
Net cash used in investing activities (6,036) (2,612)
Cash flows from financing activities:    
Proceeds raised from financial liabilities, net of issuance costs 6,995
Payments of financial liabilities (10,313) (6,187)
Series A Preferred stock dividend payments (215) (865)
Repurchase of Series A preferred stock (4,098)
Proceeds from issuance of common stock 106,766 24,730
Net cash provided by financing activities 99,135 17,678
Net increase (decrease) in cash 76,886 (3,249)
Cash and cash equivalents, beginning of period 2,059 5,308
Cash and cash equivalents, end of period 78,945 2,059
Supplemental disclosures of cash flow information:    
Cash paid for interest 268 813
Non-cash investing and financing activities:    
Reclassification of Series A preferred stock to mezzanine equity 8,195
Valuation of derivative associated with convertible financial liability 666
Conversion of Series A preferred to common stock 4,097  
Operating lease right-of-use assets obtained in exchange for operating lease liabilities $ 765  
v3.25.1
Nature of the Organization and Business
12 Months Ended
Dec. 31, 2024
Nature of the Organization and Business [Abstract]  
Nature of the Organization and Business

Note 1 – Nature of the Organization and Business

 

Corporate History

 

Quantum Computing Inc. (“QCi” or the “Company”) was formed in the State of Nevada on July 25, 2001, under its original name, Ticketcart, Inc., which was changed to Innovative Beverage Group Holdings, Inc. in 2009. The Company redomiciled to Delaware on February 22, 2018 and changed its name to Quantum Computing Inc. Effective July 20, 2018, the trading symbol for the Company’s common stock, par value $0.0001, on the OTC Market changed from “IBGH” to “QUBT”. On July 15, 2021 the Company uplisted to The Nasdaq Stock Market LLC. On June 16, 2022, the Company merged with QPhoton, Inc. (“QPhoton”), a developer of quantum photonic systems and related technologies and applications. The QPhoton Merger enabled us to develop hardware applications integrated with the Company’s software platform, Qatalyst, that existed before the QPhoton Merger.

 

Nature of Business

 

QCi is an American company utilizing integrated photonics and non-linear quantum optics to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging and cybersecurity applications based on patented and proprietary photonics technology. QCi’s products are designed to operate at room temperature and at very low power levels compared to other quantum systems currently available in the market, such as superconducting, ion-trap, or annealing architectures. Our core photonics technology enables the execution of a go-to-market strategy which emphasizes scalability, accessibility and affordability. Our quantum machines, supported by professional services through our “Quantum Solutions” offering, enable subject matter experts (SMEs) and end users to deliver critical business solutions involving highly complex optimization problems.

 

The leading application of our quantum offerings today is our Entropy Quantum Computing. Our longer-term product development plan is to migrate the EQC’s current design, as well as other product designs based on discrete components, to a set of optical integrated circuits (TFLN Optical Chips) built on TFLN wafers.

 

Liquidity

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, the realization of assets, and the satisfaction of liabilities in the normal course of business. We have not achieved a level of sales adequate to support the Company’s cost structure. The Company has historically incurred losses and negative cash flows from operations. During the year ended December 31, 2024, the Company issued 49,679 shares of common stock for net proceeds of $106.8 million. Cash and cash equivalents on hand were $78.9 million as of December 31, 2024. As of December 31, 2024, the Company also had an accumulated deficit of $200.5 million and working capital of $74.6 million. In January 2025, the Company issued 8,163,266 shares of common stock for net proceeds of $93.3 million. As a result, the Company has adequate cash and cash equivalents on hand to meet its obligations over the next 12 months.

v3.25.1
Significant Accounting Policies
12 Months Ended
Dec. 31, 2024
Significant Accounting Policies [Abstract]  
Significant Accounting Policies

Note 2 – Significant Accounting Policies:

 

Basis of Presentation and Principles of Consolidation:

 

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (the “FASB”), including ASC 810, Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is December 31.

Risk and Uncertainties

 

The Company is subject to certain risks and uncertainties and believes changes in any of the following areas could have a material adverse effect on the Company’s future consolidated financial position or consolidated results of operations or cash flows: new product development, including market receptivity; litigation or claims against the Company based on intellectual property, patent, product regulation or other factors; competition from other products; general economic conditions; the ability to attract and retain qualified employees; and, ultimately, to sustain profitable operations.

 

Reclassifications

 

Certain reclassifications have been made to the fiscal year 2023 consolidated financial statements to conform ot the fiscal year 2024 presentation. The reclassifications had no impact on net loss, total assets, total liabilities, or stockholders’ equity.

 

Use of Estimates

 

These consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of goodwill and intangible assets, deferred tax assets, equity-based transactions and liquidity assessment. Actual results may differ from these estimates.

 

Segments

 

Our Chief Operating Decision Maker (“CODM”), the Chief Executive Officer, manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources and assess performance. Further, the CODM reviews and utilizes natural expenses, such as employee wages and benefits at a consolidated level, to manage the Company’s operations and strategic growth initiatives. Other segment items include interest income, interest expense, deferred offering costs, changes in fair value of derivative warrant liabilities and other operational expenses which are reflected in the consolidated statements of operations.

 

Cash and Cash Equivalents

 

Highly liquid investments with a maturity of three months or less when purchased are considered to be cash equivalents. The Company maintains its cash in mutual funds and deposit and money market accounts with high quality financial institutions which, at times, may exceed federally insured limits. As of December 31, 2024 and December 31, 2023, the Company had $78.9 million and $960 thousand, respectively, in cash equivalents invested in mutual funds. The Company has not experienced any losses on these deposits and believes it is not exposed to significant credit risk on cash. 

 

Revenue

 

The Company recognizes revenue in accordance with ASC 606 – Revenue from Contracts with Customers, by analyzing contracts with its customers using a five-step approach:

 

  1. Identify the contract;
     
  2. Identify the performance obligations;
     
  3. Determine the transaction price;

 

  4. Allocate the transaction price to the performance obligations; and
     
  5. Recognize revenue when performance obligations are satisfied.

The revenue the Company has recognized in the years ended December 31, 2024 and 2023 were primarily derived from contracts to perform professional services. Revenue from time and materials-based contracts is recognized as the direct hours worked during the period times the contractual hourly rate, plus direct materials and other direct costs as appropriate, plus negotiated materials handling burdens, if any. Revenue from units-based contracts is recognized as the number of units delivered or performed during the period times the contractual unit price. Revenue from fixed price contracts is recognized as work is performed with estimated profits recorded on a percentage of completion basis. The Company has no cost-plus type contracts at this time.

 

The Company includes depreciation and amortization expenses in manufacturing overhead, which is a component of cost of revenue. However, at the present time manufacturing overhead, including depreciation and amortization expense related to production equipment, is not material and the primary components of cost of revenue are direct labor and direct materials, with a small amount of shipping expenses.

 

The Company’s revenues consist of (in thousands):

 

   Year Ended December 31, 
   2024   2023   % Change 
Services  $346   $353    (2)%
Products   27    5    440%
Total  $373   $358    4%

 

The Company disaggregates revenue from contracts with customers based on the timing of transfer of goods or services to customers (point-in-time or over time) and geographic region based on the shipping location of the customer. The geographic regions that are tracked for the years ended December 31, 2024 and 2025 are the Americas and Europe.

 

Total net sales based on the disaggregation criteria described above are as follows (in thousands):

 

   Year Ended December 31, 
   2024   2023 
   Point-in-Time   Over Time   Total   Point-in-Time   Over Time   Total 
Americas  $27   $346   $373   $          5   $337   $342 
Europe   
-
    
-
    
-
    
-
    16    16 
Total  $27   $346   $373   $5   $353   $358 

 

Accounts Receivable

 

Accounts receivable consists of amounts due from customers for work performed on contracts. The Company records accounts receivable at their net realizable value. Periodically, the Company evaluates its accounts receivable to establish a provision for credit losses, when deemed necessary, based on the history of past write-offs, collections and current credit conditions. The customer accounts receivable as of December 31, 2024 are considered not fully collectible and thus the Company has recorded a provision for credit losses of $3.5 thousand; the customer accounts receivable as of December 31, 2023 were considered fully collectible.

Provision for Credit Losses

 

The Company estimates losses on loans and other financial instruments in accordance with Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 introduces the current expected credit losses (“CECL”) methodology for estimating allowances for credit losses. The CECL framework requires the Company to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supporting forecasts. Under CECL, the allowance for credit losses is measured as the difference between the financial asset’s cost basis and the net amount expected to be collected on the financial asset. CECL allows us to use information about past events including historical loan loss experience, current conditions, and reasonable and supportable forecasts to assess the collectability of the financial assets. The receivables for financial assets as of December 31, 2024 and 2023 are not considered fully collectible and thus management has recorded a provision for credit losses. See Note 9, Loan Receivable, for additional information.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis which approximates actual cost on a first in-first out method. Lower of cost or net realizable value is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory and are charged to cost of revenue. Once the cost of the inventory is reduced, a new lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Factors influencing these adjustments include changes in demand, product life cycle and development plans, component cost trends, product pricing, physical deterioration and quality issues. Revisions to these adjustments would be required if these factors differ from our estimates.

 

Operating Leases

 

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets are included in right-of-use assets, net on the consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current operating lease liabilities and non-current operating lease liabilities, respectively, on the consolidated balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. All of our operating leases are comprised of office space leases, and as of December 31, 2024 and 2023, we had no finance leases.

 

Business Combinations and Valuation of Goodwill

 

We account for business combinations under the acquisition method of accounting. This method requires the recording of acquired assets and assumed liabilities at their acquisition date fair values. The excess of the purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded withing general and administrative expenses.

 

The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company performs an annual impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to assess impairment, its common stock price is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit and can lead to potential impairment in future periods. The Company performed its annual impairment test during the second quarter of fiscal 2024 and 2023 and determined that its goodwill was not impaired. As of December 31, 2024 and 2023, we had not identified any factors that indicated there was an impairment of our goodwill and determined that no additional impairment analysis was then required.

Property and Equipment

 

Property and equipment are stated at cost or contributed value. Depreciation of furniture, software and equipment is calculated using the straight-line method over their estimated useful lives, and leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the lease term. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as a gain or loss on sale of equipment. Maintenance and repairs are charged against expense as incurred.

 

Impairment of Long-Lived Assets

 

The Company has long-lived assets such as tangible property and equipment, identified intangible assets consisting of acquired patents and core technology. When events or changes in circumstances occur that could indicate the carrying value of long-lived assets may not be recoverable, the Company assesses recoverability by determining whether the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. If the undiscounted cash flow is less, an impairment charge is recognized for the excess of the carrying amounts of these assets over the fair values. Fair values are determined by discounted future cash flows, appraisals or other methods.

 

During years ended December 31, 2024 and 2023, the Company did not record any impairment from long-lived assets.

 

Fair Value of Financial Instruments

 

The carrying amount of certain financial instruments held by the Company, such as cash equivalents, accounts receivable, contract assets and liabilities, accounts payable, and accrued and other current liabilities, approximate fair value due to their short maturities. The carrying amount of the liabilities for the convertible preferred stock warrants represent their fair value. The carrying amounts of the Company’s borrowings and lease liabilities approximate fair value due to the market interest rates that these obligations bear and interest rates currently available to the Company.

 

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

 

  Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;

 

  Level 2 Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

 

  Level 3 Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

 

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2024 and 2023, the Company had $78.9 million of the $78.9 million cash and cash equivalents and $960 thousand of the $2.1 million cash and cash equivalents, respectively, in Level 1 assets, comprised of U.S. Government mutual funds, and $40.5 million and no carrying value, respectively, for Level 3 liabilities, which are comprised of derivative and warrant liabilities. See Note 10, Capital Stock, for a full discussion of the warrant liability.

Research and Development Costs

 

Research and development costs include costs directly attributable to the conduct of research and development programs, including the cost of services provided by outside contractors, acquiring work-in-progress intellectual property, development, and mandatory compliance fees and contractual obligations. All costs associated with research and development are expensed as incurred.

 

Software Development Costs

 

Software development costs incurred subsequent to the establishment of technological feasibility for software intended to be sold, licensed or otherwise marketed to customers will be capitalized, but development costs not meeting the criteria for capitalization are expensed as incurred. With respect to internal use software, the Company will capitalize such development costs incurred during the application development stage, but development costs incurred prior to that stage will be expensed as incurred. No amortization expense will be recorded until the software is ready for its intended use. To date, the Company has not incurred any material capitalizable software development costs.

 

Stock-based Compensation

 

Stock-based compensation expense for expected-to-vest awards is valued under the single-option approach and amortized on a straight-line basis, accounting for actual forfeitures as they occur. We utilize the Black Scholes pricing model in order to determine the fair value of stock-based option awards. The Black Scholes pricing model requires various highly subjective assumptions including volatility, expected option life, and risk-free interest rate. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, management concludes that it is more-likely-than-not that the deferred tax assets will not be realized. Realization of deferred tax assets is also dependent upon future earnings, if any, the timing and amount of which are uncertain.

 

The Company records a liability for the uncertain tax positions taken or expected to be taken on the Company’s tax return when it is more-likely-than-not that the tax position might be challenged despite the Company’s belief that the tax return positions are fully supportable, and additional taxes will be due as a result. To the extent that the assessment of such tax positions changes, for example, based on the outcome of a tax audit, the change in estimate is recorded in the period in which the determination is made. The provision for income taxes includes the impact of provisions for uncertain tax positions.

 

Net Loss Per Share

 

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus the number of additional common shares that would have been outstanding if the common share equivalents had been issued (computed using the “If-Converted” method), unless the effect of such issuances would have been anti-dilutive.

The following table sets forth the computation of basic and diluted loss per share (in thousands, except for per share data):

 

   Year Ended
December 31,
 
   2024   2023 
Numerator:        
Net loss  $(68,542)  $(27,022)
Less: Series A convertible preferred stock dividends   
-
    861 
Net loss attributable to common stockholders – basic and diluted  $(68,542)  $(27,883)
Denominator:          
Weighted average shares used in computing net loss per common share – basic and diluted   93,881    66,611 
Net loss per common share – basic and diluted  $(0.73)  $(0.42)

 

Net loss per share is based on the weighted average number of common shares and common share equivalents outstanding during the period.

 

In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted common stock and warrants are excluded and diluted loss per share is equal to basic loss per share. Due to a net loss in the years ended December 31, 2024 and 2023, there were therefore no dilutive securities and hence basic and diluted loss per share were the same. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive (in thousands):

 

   Year Ended December 31, 
   2024   2023 
Warrants   2,583    6,053 
Options   12,907    12,280 
Unvested restricted common stock   2,997    1,192 
Total potentially dilutive shares   18,487    19,525 

 

As all potentially dilutive securities are anti-dilutive as of December 31, 2024 and 2023, diluted net loss per share is the same as basic net loss per share for each period.

 

Recently Adopted Accounting Standards

 

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which amends reportable segment requirements, primarily through enhanced disclosures about significant segment expenses, including for public entities that have a single reportable segment. The standard is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024 and have made the necessary reportable segment disclosures (See Note 3, Segment Reporting).

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

 

On December 14, 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under ASU 2023-09, entities are required to uniformly classify and present greater disaggregation of information in the rate reconciliation and income taxes paid. ASU 2023-09 is intended to benefit users of our consolidated financial statements by improving transparency and decision usefulness of income tax disclosures. The new standard is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this new guidance to have a material impact on our consolidated financial statements and have decided not to early adopt ASU 2023-09.

v3.25.1
Segment Reporting
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting

Note 3 - Segment Reporting

 

The Company operates as one operating segment as its CODM reviews financial information on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. In addition to consolidated net loss, our CODM reviews and utilizes natural expenses, such as employee wages and benefits at a consolidated level, to manage the Company’s operations and strategic growth initiatives. The following table presents segment information of revenue, significant expenses and net loss (in thousands):

 

   Year Ended December 31, 
   2024   2023 
Revenue  $373   $358 
Less:          
Salaries and employee related costs   9,534    9,745 
Stock-based compensation   5,805    4,555 
Rent and facilities   751    575 
Professional services and legal fees   2,959    3,963 
Technology & IT costs   1,062    1,198 
Other sales and marketing costs   734    1,471 
Direct and indirect materials   99    39 
Depreciation and amortization expense   3,798    3,307 
Other operational expenses   1,568    1,748 
Operating loss   (25,937)   (26,243)
Other income (expense)          
Interest expense   (254)   (602)
Interest and other income (expense) (1)   (1,819)   (705)
(Gain) loss on change in fair value of warrant liabilities   (40,532)   528 
Segment and net loss  $(68,542)  $(27,022)

 

(1)Includes interest income of $423 thousand and $295 thousand for the years ended December 31, 2024 and 2023, respectively.
v3.25.1
Intangible Assets, Net
12 Months Ended
Dec. 31, 2024
Intangible Assets, Net [Abstract]  
Intangible Assets, net

Note 4 – Intangible Assets, net

 

As a result of the merger with QPhoton in June 2022, the Company has the following amounts related to intangible assets, net (in thousands):

 

   December 31, 2024   December 31, 2023 
   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount 
Non-compete agreement with founder  $3,251   $(2,800)  $451   $3,251   $(1,715)  $1,536 
Website domain name and trademark   1,009    (521)   488    1,009    (320)   689 
Technology and licensed patents   12,731    (4,698)   8,033    12,731    (2,880)   9,851 
Total  $16,991   $(8,019)  $8,972   $16,991   $(4,915)  $12,076 

The amortization expense of the Company’s intangible assets for both the years ended December 31, 2024 and 2023 was approximately $3.1 million. The Company expects future amortization expense to be the following (in thousands):

 

   Amortization 
2025  $2,472 
2026   2,021 
2027   1,903 
2028   1,819 
2029   757 
Thereafter   
-
 
Total  $8,972 
v3.25.1
Income Taxes
12 Months Ended
Dec. 31, 2024
Income Taxes [Abstract]  
Income Taxes

Note 5 – Income Taxes

 

The Company’s provision for income taxes differs from the amount determined by applying the applicable federal statutory tax rate to the loss before income taxes due to the valuation allowance for the net deferred income tax assets. A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:

 

   Year Ended December, 31 
   2024   2023   2022 
Federal statutory income tax rate   21.0%   21.0%   21.0%
State income taxes, net of federal benefit   (3.1)%   0.0%   0.0%
Warrant mark-to-market adjustments   (12.4)%   2.0%   2.7%
Change in business credits   0.5%   0.0%   0.0%
Other permanent differences   (0.1)%   (0.3)%   (0.1)%
True-ups   0.0%   0.0%   0.0%
Change in deferred tax asset valuation allowance   (6.0)%   (22.3)%   (23.7)%
Effective income tax rate   0.0%   0.4%   0.0%

 

Income tax expense attributable to pretax loss from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax loss from continuing operations as a result of both temporary and permanent differences in the U.S. GAAP vs tax treatment of certain types of expenses, including stock-based compensation, depreciation and amortization, research and development and meals and entertainment. Additionally, the Company’s policy is to account for interest and penalties as income tax expense. As of December 31, 2024, the Company had no interest related to unrecognized tax benefits, and no amounts for penalties related to unrecognized tax benefits were recognized in the provision for income taxes. We do not anticipate any significant change within twelve months of this reporting date.

 

As of December 31, 2024, the Company had federal and state net operating loss carryforwards of approximately $89 million and $7 million, respectively. All of the federal NOL carryforwards were generated during 2018 or later and will carryforward indefinitely but will be subject to 80% taxable income limitation beginning tax years after December 31, 2021, as provided by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act (PL 116-136). State net operating loss will begin to expire in 2043 for state tax purposes. Furthermore, the utilization of NOLs and tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, a corporation that undergoes an ownership change may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has determined that ownership changes have occurred, primarily driven by the Transactions, and hence the Company’s ability to use its NOLs or tax credit carryforwards may be restricted.

 

As of December 31, 2024, in addition to the $89.4 million in tax-effected NOL carryforwards, at an assumed tax rate of 30%, the significant components of the Company’s net deferred tax assets included stock-based compensation of $14 million, capitalized research and development expenditures of approximately $3 million. As of December 31, 2023, in addition to the $13 million in tax-effected NOL carryforwards, also at an assumed tax rate of 26%, the significant components of the Company’s net deferred tax assets included stock-based compensation of $11 million and capitalized research and development expenditures of approximately $2 million. The Company believes that it is more likely than not that the benefit from the net deferred tax assets will not be realized. Accordingly, it has provided a full valuation allowance on any potential deferred tax assets The valuation allowance increased by approximately $16 million for the period ended December 31, 2024. The provision for income taxes is not material in the years presented due to there being no taxable income.

The Company has federal R&D credit carryforwards of approximately $878 thousand. The Company has no state R&D credit carryforwards.

 

The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions, with varying statutes of limitations. The tax years from inception through 2024 remain open to examination due to the carryover of unused net operating losses that are being carried forward for tax purposes. 

 

Uncertain Tax Positions

 

The Company has unrecognized tax benefits related to research and development credit carryforwards. A full valuation allowance has been provided against the Company’s research and development credits. Therefore, any adjustments to these unrecognized tax benefits would be offset by corresponding adjustments to the valuation allowance, resulting in no impact on the consolidated balance sheet or statement of operations.

 

   December 31,
2024
 
Beginning balance as of December 31, 2023  $
-
 
Changes related to tax positions taken in the prior year   96,767 
Changes related to tax positions taken in the current year   167,774 
Ending balance as of December 31, 2024  $263,541 
v3.25.1
Property and Equipment, Net
12 Months Ended
Dec. 31, 2024
Property and Equipment, Net [Abstract]  
Property and Equipment, net

Note 6 – Property and Equipment, net

 

The Company’s property and equipment, net are primarily located at the Company’s leased facilities in Hoboken, NJ and Tempe, AZ and consist of (in thousands):

 

   December 31, 
Classification  2024   2023 
Computer and laboratory equipment  $8,438   $2,999 
Network equipment   29    29 
Furniture and fixtures   37    32 
Software   77    49 
Leasehold improvements   597    33 
Total cost of property and equipment   9,178    3,142 
Accumulated depreciation   966    272 
Property and equipment, net  $8,212   $2,870 

 

The approximate $6.0 million increase in property and equipment is primarily driven by purchases of laboratory equipment, as well as leasehold improvements, in establishing the AZ Chips Facility.

 

The Company began depreciating select property and equipment at the AZ Chips Facility as they were put in service during the year ended December 31, 2024, and recorded total depreciation expense of $694 thousand and $203 thousand during the years ended December 31, 2024 and 2023, respectively, using useful lives of the Company’s long-lived assets as follows:

 

   Estimated
Useful Life
(Years)
 
Computer and laboratory equipment   5 
Network equipment   4 
Furniture and fixtures   7 
Software   3 
Leasehold improvements   Lessor of lease term or 5 

 

$5.4 million of property and equipment have yet to be placed in service and have not started depreciating.

 

Maintenance and repairs are charged to operations when incurred. When property and equipment are sold or otherwise disposed, the asset account and related accumulated depreciation and amortization accounts are relieved, and any gain or loss is included in other income or expense. There were no significant gains or losses in the year ended December 31, 2024 and 2023, respectively.

v3.25.1
Financial Liabilities
12 Months Ended
Dec. 31, 2024
Financial Liabilities [Abstract]  
Financial Liabilities

Note 7 – Financial Liabilities

 

 The Company has the following amounts related to financial liabilities (in thousands):

 

   December 31, 
   2024   2023 
Remaining loan balances  $
         -
   $2,063 
Remaining unamortized debt issuance costs   
-
    (138)
Financial liabilities, net  $
-
   $1,925 

 

Additionally, the Company has no and $14 thousand of accrued interest as of December 31, 2024 and 2023, respectively, which is included in Other Current Liabilities.

 

Secured Promissory Note

 

On August 6, 2024, the Company entered into a Securities Purchase Agreement (the “Secured SPA”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which the Company issued and sold to Streeterville a Secured Convertible Promissory Note (the “Streeterville Convertible Note”) in the original principal amount of $8.25 million. The principal amount includes an original issue discount of $750 thousand. Streeterville paid $7.5 million in cash for the Streeterville Convertible Note. The Streeterville Convertible Note accrues interest at a rate of 10% per annum and has a maturity date of February 6, 2026, unless earlier prepaid, redeemed or accelerated in accordance with its terms prior to such date. The Company intends to use the net proceeds from the sale of the Streeterville Convertible Note primarily for general working capital purposes, including for (i) operations as the Company increases its sales and marketing efforts; (ii) capital expenditures in outfitting its chip fabrication facility in Tempe, AZ; and (iii) for any other planned or unplanned expenditures that might arise in support of the Company’s business plan. Ascendiant Capital Markets, LLC served as the placement agent on the transaction and received a fee of $450 thousand, and the Company recognized $55 thousand in other issuance costs, primarily for legal services. The Company repaid the Streeterville Convertible Note on November 18, 2024. As of December 31, 2024, there was no outstanding balance and the Company has no further obligations with respect to the Secured SPA or Streeterville Convertible Note.

 

Unsecured Promissory Note

 

On September 23, 2022, the Company entered into a note purchase agreement (the “Unsecured NPA”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which Streeterville purchased an unsecured promissory note (the “Note” or the “Streeterville Unsecured Note”) in the initial principal amount of $8.25 million. The Streeterville Unsecured Note bore interest at 10% per annum. The maturity date of the Note was defined as 18 months from the date of its issuance (the “Maturity Date”). The Streeterville Unsecured Note carried an original issue discount of $750 thousand, which was included in the principal balance of the Note. If the Company had elected to prepay the Streeterville Unsecured Note prior to the Maturity Date, it would have paid to Streeterville 120% of the portion of the Outstanding Balance the Company would have elected to prepay. As of December 31, 2024, Streeterville has redeemed the full principal amount of the Unsecured NPA. There was an outstanding balance of $1.9 million as of December 31, 2023. As of December 31, 2024, there was no outstanding balance and the Company has no further obligations with respect to the Unsecured NPA or Streeterville Unsecured Note.

 

Note Purchase Agreement – the Company and Wholly-Owned Subsidiary QPhoton

 

On February 18, 2022, the Company entered into a Note Purchase Agreement (the “QCi Note Purchase Agreement”) with QPhoton, pursuant to which the Company agreed to loan money to QPhoton using two unsecured promissory notes (each, a “QCi Note”), each in the principal amount of $1.25 million, subject to the terms and conditions of the QCi Note Purchase Agreement. Also, on February 18, 2022, pursuant to the terms of the QCi Note Purchase Agreement, the Company loaned the principal amount of $1.25 million to QPhoton. On April 1, 2022, pursuant to the terms of the QCi Note Purchase Agreement, the Company loaned the principal amount of $1.25 million to QPhoton, for a total loan under the two QCi Notes of $2.5 million.

 

The QCi Note Purchase Agreement contains customary representations and warranties by QPhoton and the Company, as well as a “most favored nations” provision for the benefit of the Company. The QCi Notes issued under the QCi Note Purchase Agreement, including the QCi Notes issued on February 18, 2022 and April 1, 2022, provide that the indebtedness evidenced by the applicable QCi Note bears simple interest at the rate of 6% per annum (or 15% per annum during the occurrence of an event of default, as defined in the QCi Notes), and becomes due and payable in full on the earlier of (i) March 1, 2023, subject to extension by one year at the option of QPhoton, (ii) a change of control (as defined in the QCi Notes) of QPhoton or (iii) an event of default. As a result of the merger, the QCi Note and accrued interest is eliminated through consolidation. However, the two QCi Notes were not forgiven or converted to equity, remain outstanding under the terms and conditions of the QCi Note Purchase Agreement, and are eliminated for presentation purposes in these consolidated financial statements.

v3.25.1
Contingencies
12 Months Ended
Dec. 31, 2024
Contingencies [Abstract]  
Contingencies

Note 8 – Contingencies 

 

Indemnification Arrangements

 

We enter into standard indemnification arrangements in our ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties (generally our business partners or customers) in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to our products. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these agreements is minimal.

 

We have entered into indemnification agreements with our directors and officers that may require us to indemnify our directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of a culpable nature. These agreements also require us to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified and to make good faith determination whether or not it is practicable for us to obtain directors and officers insurance. We currently have directors and officers liability insurance.

 

Legal Proceedings

 

From time to time, we may be involved in legal proceedings arising in the ordinary course of business. In general, management believes that ordinary course of business matters will not have a material adverse effect on our consolidated financial position or consolidated results of operations and are adequately covered by our liability insurance. However, it is possible that consolidated cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one of more of these contingencies or because of the diversion of management’s attention and the incurrence of significant expenses.

 

See Part I, Item 3, Legal Proceedings, in this Form 10-K for additional details on the status of the following proceedings.

 

BV Advisory v. QCi Breach Lawsuit

 

At the time of the QPhoton Merger in June 2022, QPhoton had an outstanding balance of principal and interest due to BV Advisory based on a note purchase agreement that QPhoton had entered into with BV Advisory on March 1, 2021 (the “BV Note Purchase Agreement”). Accordingly, the Company has recorded an estimated payable (the “BV Advisory Payable”), recognized as other current liabilities on the consolidated financial statements, based on best available information in the amount of $536 thousand as of December 31, 2024 and 2023.

 

On August 16, 2022, BV Advisory filed a complaint Delaware Chancery Court naming the Company and certain of its directors and officers (among others) as defendants seeking, among other relief, monetary damages for an alleged breach of the BV Note Purchase Agreement. During the year ended December 31, 2024, BV Advisory’s other claims were dismissed by the Delaware Chancery Court and BV Advisory transferred its claim for breach of the BV Note Purchase Agreement to the Delaware Superior Court. The Company believes that BV Advisory’s claims have no merit and intends to defend itself vigorously. BV Advisory’s claims are not covered by the Company’s liability insurance, nor does the Company believe it is necessary to accrue an amount in addition to the BV Advisory Payable at this time.

 

BV Advisory v. QCi Appraisal Action

 

BV Advisory was purportedly a shareholder of QPhoton, Inc., the predecessor in interest to QPhoton, LLC, a wholly owned subsidiary of the Company (both referred to as “QPhoton” in this Legal Proceedings discussion). BV Advisory rejected the Merger Consideration (as defined below) and on October 13, 2022 filed a petition in the Delaware Chancery Court seeking appraisal of the shares of QPhoton it allegedly owned (which shares represented 10% of the shares of QPhoton outstanding immediately prior to the Company’s acquisition of QPhoton). The Appraisal Petition is currently pending in Delaware Chancery Court. The Company included BV Advisory’s purported ownership of QPhoton in the purchase price accounting for the QPhoton Merger.

The Company’s total purchase price of QPhoton was approximately $71.0 million, or $69.9 million net of cash acquired, consisting of Company common stock, Series B Preferred Stock and QPhoton Warrants (as defined below). While the total shares of the Company’s common stock on an as-converted basis offered in the QPhoton Merger was 36,600,823 (the “Merger Consideration”), the fair market valuation contemplated 31,299,417 of the shares, which assumed full conversion of the 2,377,028 shares of Series B Preferred Stock to common stock at the 10:1 ratio, and that only 1,726,931 of the warrants to purchase up to 7,028,337 shares of the Company’s common stock (the “QPhoton Warrants”) would eventually be exercised (specifically only the QPhoton Warrants for which the associated Company options and/or warrants had an exercise price at or below $2.27 at the time of the QPhoton Merger).

 

Accordingly, as of December 31, 2024 and 2023, the Company has neither issued 2,957,251 shares of the Company’s common stock on an as converted basis (the “Unissued QPhoton Shares”) nor 702,834 warrants to purchase shares of the Company’s common stock (the “Unissued QPhoton Warrants”) that were included in the Merger Consideration. The Unissued QPhoton Shares are included in the statement of stockholder’s equity as additional paid in capital as of as of December 31, 2024 and 2023, and the Unissued QPhoton Warrants have a carrying value of $40.5 million as a liability on the Company’s consolidated balance sheet as of December 31, 2024, and no carrying value as a liability on the Company’s consolidated balance sheet as of December 31, 2023.

 

QCi v. BV Advisory Injunction Lawsuit

 

On January 31, 2025, the Company filed a complaint in Delaware Chancery Court against BV Defendants (BV Advisory and its principal Keith Barksdale) asserting claims for defamation, breach of contract, conversion, aiding and abetting conversion, and misappropriation of trade secrets based on the BV Defendants’ unauthorized possession and dissemination of certain of the Company’s confidential and privileged documents. The Company seeks, among other relief, injunctive relief and damages. On February 11, 2025, the Court granted the Company’s motion for temporary restraining order and instructed the parties to negotiate an expedited case schedule. On February 13, 2025, the Court entered a stipulated case schedule that set a trial for April 8 and 9, 2025 on the Company’s claims for conversion, aiding and abetting conversion, and misappropriation of trade secrets. The parties are currently engaged in discovery. The Company does not believe it is necessary to accrue a litigation reserve at this time.

 

Securities Class Action Lawsuit

 

On February 25, 2025, a class action lawsuit was filed against the Company and certain of its current and past officers in the New Jersey District Court, by a plaintiff seeking to represent a class of all persons who purchased the Company’s securities between March 30, 2020 and January 15, 2025, alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose material information about the Company’s customers, contracts and business operations. To date, the New Jersey District Court has not certified a class or designated a lead plaintiff. The Company disputes the allegations in the complaint, intends to vigorously defend against the claims asserted, and does not believe it is necessary to accrue a litigation reserve at this time.

 

Arbitration over Stock Options

 

In February 2025, the Company entered into arbitrations with Former Consultants (two individuals) regarding forfeiture of stock options. The Company had issued stock options to the consultants in 2020 and 2021 and terminated the Former Consultants’ agreements in March 2024, at which time the Company informed the Former Consultants that any vested options had to be exercised within three months of the termination date, per the Company’s Equity and Incentive Plans. The Former Consultants did not exercise their vested options, and the options were duly forfeited. In December 2024, the Former Consultants claim that they still retain the right to exercise the options, which the Company has rejected. The Company believes these claims are without merit, intends to defend itself vigorously, and does not believe it is necessary to accrue a litigation reserve at this time.

v3.25.1
Loan Receivable
12 Months Ended
Dec. 31, 2024
Loan Receivable [Abstract]  
Loan Receivable

Note 9 – Loan Receivable

 

On May 16, 2023, the Company entered into a Summary of Proposed Terms (the “Letter of Intent”) with millionways, Inc (“millionways”) to provide bridge loans to millionways and enter into due diligence to acquire up to 100% of the AI firm. On June 6, 2023, the Company entered into a note purchase agreement (the “MW Agreement”) with millionways, pursuant to which the Company agreed to purchase from millionways up to three unsecured promissory notes (each, a “MW Note”), in an aggregate principal amount of up to $2.0 million, subject to the terms and conditions of the MW Agreement. Also on June 6, 2023, pursuant to the terms of the MW Agreement, the Company purchased the MW Notes from millionways and loaned an aggregate principal amount of $500 thousand to millionways.

 

The MW Agreement contains customary representations and warranties by millionways and the Company, as well as a “most favored nations” provision for the benefit of the Company. The MW Notes issued under the MW Agreement, including the MW Notes issued on June 6, 2023, provide that the indebtedness evidenced by the applicable MW Note bears simple interest at the rate of 10% per annum (or 15% per annum during the occurrence of an event of default, as defined in the MW Notes), and becomes due and payable in full on the earlier of (i) May 16, 2024, (ii) a change of control (as defined in the MW Notes) of millionways, (iii) dollar-for-dollar prepayment for additional capital received through any vehicle from a third party or (iv) an event of default.

 

The Company reserved $558 thousand of the outstanding $558 thousand receivable as uncollectible based on credit risk in the consolidated financial statements as of December 31, 2024, however, as of March 18, 2025, is actively seeking collection of $658 thousand, including principal and interest.

v3.25.1
Capital Stock
12 Months Ended
Dec. 31, 2024
Capital Stock [Abstract]  
Capital Stock

Note 10 – Capital Stock

 

Authorized Classes of Stock

 

As of December, 2024, the Company’s Board of Directors has authorized two classes of preferred stock. The Board has authorized 1,550,000 shares of preferred stock as Series A preferred stock, par value $0.0001 per share, none of which are issued and outstanding at December 31, 2024, and 1,490,004 of which were issued and outstanding as of December 31, 2023. The Board has also authorized 3,079,864 shares of preferred stock as Series B preferred stock, par value $0.0001 per share, none of which are issued and outstanding at December 31, 2024 and 2023.

 

Series A Convertible Preferred Offering

 

From November 10, 2021 through November 17, 2021, the Company conducted a private placement offering (the “Private Placement”) pursuant to securities purchase agreements with 7 accredited investors (the “Series A Investors”), whereby the Series A Investors purchased from the Company an aggregate of 1,545,459 shares of the Company’s newly created Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”) and warrants to purchase 1,545,459 shares of the Company’s common stock (the “Preferred Warrants”) for an aggregate purchase price of $8.5 million. The Private Placement was completed and closed to further investment on November 17, 2021.

 

The Series A Preferred Stock ranks senior to common stock with respect to the payment of dividends and liquidation rights. Each holder of Series A Preferred Stock is entitled to receive, with respect to each share of Series A Preferred Stock then outstanding and held by such holder, dividends at the rate of 10% per annum (the “Preferred Dividends.”) The Company is obligated to pay the Preferred Dividends quarterly, in arrears, within 15 days of the end of each quarter. The Company has the option to pay the Preferred Dividends in cash or in common stock, at a price per share of common stock equal to the average of the closing sale price of the common stock for the 5 trading days preceding the applicable dividend payment date. The Preferred Dividends are accrued monthly, but not compounded, and are recorded as interest expense, because the Preferred Dividends are mandatory and not declared at the discretion of the Board of Directors.

 

The number of shares of the Company’s common stock issuable upon conversion of any share of Series A Preferred Stock shall be determined by dividing (x) the Conversion Amount of such share of Series A Preferred Stock by (y) the Conversion Price. “Conversion Amount” means, with respect to each share of Series A Preferred Stock, as of the applicable date of determination, the sum of (1) the stated value thereof plus (2) any accrued dividends. “Conversion Price” means, with respect to each share of Series A Preferred Stock, as of any optional conversion date, Mandatory Conversion Date or other date of determination, $5.50, subject to adjustment for stock splits, dividends, recapitalizations and similar corporate events.

The Preferred Warrants were two-year warrants to purchase shares of the Company’s common stock at an exercise price of $7.00 per share, subject to adjustment, were exercisable at any time on or after the date that was six months following the issuance date, and provided for cashless exercise in the event the underlying shares of the Company’s common stock are not registered. As of December 31, 2023, all of the Preferred Warrants had expired unexercised.

 

In connection with the Purchase Agreement, the Company and the Series A Investors entered into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company agreed to file a registration statement to register the shares of the Company’s common stock underlying the Series A Preferred Stock and warrants within 180 days. Pursuant to the Registration Rights Agreement, the Series A Investors received certain rights, including but not limited to piggyback registration rights, providing that the holder be given notice of any proposed registration of securities by the Company, and requiring that the Company register all or any portion of the registrable securities that the holders request to be registered, in each case, subject to the terms and conditions of the Registration Rights Agreement. On April 27, 2022 the Company filed a Registration Statement on Form S-3 to register the resale of the shares of common stock as required by the Registration Rights Agreement. The Form S-3 went effective on June 2, 2022.

 

On June 13, 2022, one of the Series A Investors, Falcon Capital Partners, converted 45,455 shares of Series A Preferred Stock into 47,728 shares of the Company’s common stock.

 

On February 9, 2023, one of the Series A Investors, Greenfield Children, LLC, converted 10,000 shares of Series A Preferred Stock plus accrued dividends into 11,096 shares of the Company’s common stock.

 

On March 19, 2024, the Company entered into a Redemption and Waiver Agreement (the “Series A Redemption Agreement”) with the current holders (the “Series A Holders”) of its Series A Preferred Stock. Accordingly, $8.125 million of additional paid in capital was reclassified from shareholders’ equity to mezzanine equity (the “Mezzanine Equity”) on the Company’s consolidated balance sheet in accordance with Accounting Series Release No. 268, Presentation in Financial Statements of “Redeemable Preferred Stocks”. The Mezzanine Equity was valued at the date of the Private Placement issuance. Pursuant to the Series A Redemption Agreement, the Company agreed to redeem all outstanding shares of the Series A Preferred Stock for an aggregate cash purchase price of $8,195,000, or $5.50 per share, at its sole discretion, in 18 monthly payments (each a “Monthly Redemption Threshold” payment), which may be accelerated at the Company’s sole discretion and which does not prevent the Series A Holders from converting outstanding shares of Series A Preferred Stock at a conversion price of $5.50 per share. In addition, the Series A Holders agreed to waive (the “Waivers”), on a month-by-month basis following each monthly payment, certain rights granted to them in (i) the Preferred Stock Certificate of Designation (the “Preferred Stock COD”), including for the accrual and payment of accrued and future dividends; and (ii) the Preferred Stock Securities Purchase Agreement (the “Preferred Stock SPA”). In the event the Company opts to not make a Monthly Redemption Threshold payment, the Waivers are forfeited and the terms revert to those detailed in the Preferred Stock COD and Preferred Stock SPA. During the year ended December 31, 2024, the Company redeemed 745,047 shares of Series A Preferred Stock for approximately $4.1 million in cash paid to the Series A Holders.

 

During November 2024 and December 2024, the Series A Holders converted 744,957 shares of Series A Preferred Stock into 744,957 shares of the Company’s common stock. As of December 31, 2024, there were no shares of Series A Preferred Stock issued and outstanding and the Mezzanine Equity valuation was reduced to zero.

 

At-the-Market Facility

 

During the years ended December 31, 2024 and 2023, the Company sold 23,679,391 and 17,571,926 shares of common stock, respectively, through its At-The-Market (ATM) facility, managed by Ascendiant Capital Markets, LLC, at an average price of $1.21. The Company received net aggregate proceeds of $48.5 million, of which $23.8 million and $24.7 million, respectively, was received during the years ended December 31, 2024 and 2023.

Registered Direct Offering

 

On November 14, 2024, the Company entered into securities purchase agreements (the “November RDO SPAs”) for a registered direct offering (the “November RDO”) to sell an aggregate of 16 million shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $2.50 per share (the “November RDO Shares”), resulting in gross proceeds of $40 million, before deducting placement agent commissions and other offering expenses. On November 18, 2024, the Company completed the sale of the November RDO Shares and announced its intention to use the net proceeds from the November RDO for the repayment of debt, working capital, and general corporate purposes. Specifically, the Company used approximately $9.3 million of the gross proceeds to pay in full the Streeterville Convertible Note.

 

In conjunction with the November RDO SPAs, the Company also entered into a placement agency agreement with Titan Partners Group LLC (“Titan”), a division of American Capital Partners, LLC (the “November Placement Agent”) dated November 14, 2024, pursuant to which the November Placement Agent will act as the exclusive placement agent for the Company in connection with the November RDO. The Company agreed to pay the November Placement Agent a cash fee of 7.25% of the gross proceeds from the November RDO and to issue to the November Placement Agent (or its designees) 800,000 five-year warrants representing 5% of the securities sold in the November RDO, which will be exercisable beginning on May 13, 2025, and have an initial exercise price per share of the Company’s common stock of $2.875. In addition, the Company agreed to reimburse the November Placement Agent for up to $100,000 of its fees and expenses in connection with the November RDO.

 

Registered Direct and Private Placement Offerings

 

On December 10, 2024, the Company entered into securities purchase agreements (the “December RDO SPAs”) for a registered direct offering (the “December RDO”), an aggregate of 1,540,000 shares of the Company’s common stock, par value $0.0001 per share, at a purchase price of $5.00 per share. Also on December 10, 2024, the Company entered into securities purchase agreements, pursuant to which the Company agreed to issue in a concurrent private placement (the “December Private Placement” and together with the December RDO, the “December SPAs”), an aggregate of 8,460,000 shares (the “December Placement Shares”) of common stock at a purchase price of $5.00 per share. The December SPAs closed on December 12, 2024. The December RDO resulted in gross proceeds of $7.7 million and the December Private Placement resulted in gross proceeds of $42.3 million, in each case before deducting placement agent commissions and other offering expenses. Furthermore, the Company filed a registration statement registering the resale of the December Placement Shares on December 20, 2024, which went effective January 6, 2025.

 

In conjunction with the December SPAs, the Company also entered into a placement agency agreement with Titan (the “December Placement Agent”), dated December 10, 2024, pursuant to which the December Placement Agent will act as the exclusive placement agent for the Company in connection with the December SPAs. The Company agreed to pay the December Placement Agent a cash fee of 7% of the gross proceeds from the December SPAs and to issue to the December Placement Agent (or its designees) 500,000 five-year warrants (representing 5% of the securities sold in the Offerings), which will be exercisable beginning on June 8, 2025, and have an initial exercise price per share of the Company’s common stock of $5.75. In addition, the Company agreed to reimburse the December Placement Agent for up to $100,000 of its fees and expenses in connection with the December SPAs.

 

The combined amount of net proceeds raised from the ATM and RDOs was $106.8 million and $24.7 million for the years ended December 31, 2024 and 2023, respectively.

 

Warrants

 

The table below summarizes the warrants outstanding at December 31, 2024 (in thousands, except exercise prices):

 

Issuance Date  Expiration Date  Exercise Price   Issued   Exercised   Forfeited /
Canceled
   Warrants
Outstanding
 
August 18, 2020  August 18, 2025  $2.00    171    (150)   
-
    21 
June 16, 2022  May 9, 2027  $0.0001    6,325    
-
    (4,121)   2,204 
November 18, 2024  November 18, 2029  $2.875    800    
-
    
-
    800 
December 12, 2024  December 12, 2029  $5.75    500    
-
    
-
    500 

In connection with a restricted stock units offering in June 2020, the Company issued warrants in August 2020 to purchase 171,000 shares of the Company’s common stock, at an exercise price of $2.00. Those warrants are exercisable for five years from the date of issuance.

 

In connection with the QPhoton Merger on June 16, 2022, the Company issued 6.3 million warrants to purchase shares of the Company’s common stock at an exercise price of $0.0001. Those warrants are exercisable when and if stock options and warrants issued by the Company and outstanding as of June 15, 2022 (the “Underlying Options”) are exercised. As of December 31, 2024, all of the QPhoton Warrants linked to the outstanding Underlying Options are expected to be exercised as the exercise prices of all the Underlying Options are below the closing stock price as of December 31, 2024. The 6.3 million issued warrants represent a portion of the 7.0 million warrants included in the Merger Consideration, having been received by two QPhoton shareholders. A third alleged shareholder rejected the Merger Consideration and commenced litigation, and to date that litigation has not been resolved and the associated 702,834 warrants have not been issued, of which 457,926 would have been canceled to date due to forfeitures of Underlying Options. See Part I, Item 3, Legal Proceedings, for additional information on the status of the litigation.

 

As of December 31, 2024, of the 6.3 million QPhoton Warrants issued, approximately 65% have been forfeited because the corresponding Underlying Options had expired or been forfeited. Further, as discussed in Note 2, Significant Accounting Policies – Fair Value of Financial Instruments, the QPhoton Warrants issued on June 16, 2022, are considered Level 3 liabilities for fair value measurement on the valuation hierarchy. In determining the fair market value of the QPhoton Warrants, the Company determines which underlying options and warrants are in-the-money or out-of-the-money at period end by comparing to the bid price of the Company’s common stock, then accounts for changes period-over-period by realizing a mark-to-market gain or loss for the period. Due to the difference between the exercise price and the market value of the Company's stock as of the balance sheet dates, the market value of the stock and the probability of the underlying options and warrants being exercised are the only significant inputs in the valuation of the warrant liability. Accordingly, the Company recognized a mark-to-market loss of $40.5 million and a mark-to-market gain of $528 thousand during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the QPhoton Warrants have a carrying value of $40.5 million as a liability on the Company’s consolidated balance sheet, an increase of $40.5 million as compared to the Company’s December 31, 2023 consolidated balance sheet, where the QPhoton Warrants had no carrying value as a liability on the Company’s consolidated balance sheet.

v3.25.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2024
Stock-Based Compensation [Abstract]  
Stock-based Compensation

Note 11 – Stock-based Compensation

 

Incentive Plans

 

The Quantum Computing Inc. 2019 Equity and Incentive Plan, as amended in 2021 (the “2019 Plan”) enabled the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company up to a total of 3.0 million shares of common stock, all of which have been issued.

 

On July 5, 2022, the Board of Directors adopted the Quantum Computing Inc. 2022 Equity and Incentive Plan (the “2022 Plan”), which was approved by a majority of the shareholders in September 2022. The 2022 Plan initially provided for the issuance of up to 16 million shares of the Company’s common stock and includes provisions for annual automatic evergreen increases of 1,000,000 shares of common stock. As of December 31, 2024, the total number of shares of our common stock reserved for issuance under the 2022 Plan is 18 million and a total of 13 million shares and options were issued and outstanding under the 2022 Plan.

 

Options

 

The following table summarizes the Company’s option activity for the year ended December 31, 2024 (in thousands, except exercise price and contractual life data):

 

   Number
Outstanding
   Weighted
Average
Exercise
Price per
Share
   Weighted
Average
Remaining
Contractual
Life (Years)
 
Balance as of January 1, 2023   9,165    3.51    4.2 
Granted   5,340    1.38    5.0 
Forfeited   (662)   4.41    - 
Balance as of December 31, 2023   13,843   $2.64    3.7 
Granted   830    0.92    5.0 
Forfeited   (1,690)   4.14    - 
Balance as of December 31, 2024   12,983   $2.34    2.9 
                
Vested and exercisable as of December 31, 2023   8,803    3.21    3.4 
Vested and exercisable as of December 31, 2024   9,646   $2.66    2.7 

The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December 31, 2024 and 2023:

 

   Year Ended 
   December 31, 
   2024   2023 
Exercise price  $0.46 – 1.12   $0.85 – 1.84 
Risk-free interest rate   4.2 – 5.2 %    4.7 – 5.0 % 
Expected volatility   90 – 105 %    98 – 137 % 
Expected dividend yield   0%   0%
Expected life of options (in years)   5.0    5.0 

 

The following table summarizes the exercise price range as of December 31, 2024 (in thousands):

 

Exercise Price  Outstanding
Options
   Exercisable
Options
 
$ 0.00 – 1.00   230    122 
$ 1.00 – 2.00   5,803    2,928 
$ 2.00 – 3.00   5,879    5,525 
$ 3.00 – 6.00   38    38 
$ 6.00 – 8.00   683    683 
$ 8.00 – 12.00   350    350 
    12,983    9,646 

 

The weighted average grant-date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $0.92 per share and $1.38 per share, respectively. As of December 31, 2024, total unrecognized compensation cost related to common stock options was $3.1 million, which is expected to be recognized over a period of 3.0 years.

 

Restricted Stock

 

As of December 31, 2024, there were 1.3 million shares of the Company’s common stock issued and unvested that had been awarded as stock-based compensation under the 2022 Plan. The following table summarizes the Company’s activity for restricted stock tied to vesting schedules for the year ended December 31, 2024 (in thousands):

 

   Number
Outstanding
   Weighted
Average Fair
Value
 
Unvested as of January 1, 2023   50   $5.70 
Granted   2,429    1.36 
Vested   (1,046)   1.48 
Forfeited   (24)   1.28 
Unvested as of December 31, 2023   1,409   $1.42 
Granted   904    1.58 
Vested   (1,049)   1.82 
Unvested as of December 31, 2024   1,264   $1.20 

Stock-based compensation

 

The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):

 

   Year Ended 
   December 31, 
   2024   2023 
Research and development  $4,024   $2,080 
Selling and marketing   301    (279)
General and administrative   1,457    2,470 
Total stock-based compensation  $5,782   $4,271 

 

For the years ended December 31, 2024 and 2023, the consolidated statement of stockholders’ equity was lower by $1.5 million and $33 thousand, respectively, as compared to the consolidated statement of cash flows for timing differences between award dates and the realization of stock-based compensation expense.

 

In terms of new issuances, the Company issued 995 thousand shares of the Company’s common stock to employees in the year ended December 31, 2024 (the “2024 SBC Awards), as compared to 2.3 million in the year ended December 31, 2023 (the “2023 SBC Awards”).

 

The 2024 SBC Awards included 218 thousand such shares issued to former executives per their respective employment and separation agreements (the “Separation Agreement Shares”) and 777 thousand such shares issued as performance and incentive awards, which included 727 thousand shares of the Company’s common stock issued to 30 employees as payment in lieu of cash for 2023 performance bonuses (the “2024 Performance Incentive Shares”) and 50 thousand shares of common stock as retention bonuses to five employees identified as key technical staff (the “2024 Retention Incentive Shares”). The 2024 Performance Incentive Shares are restricted with the following vesting schedule: one-half vested on December 31, 2024 and one-half will vest on December 31, 2025. The 2024 Retention Incentive Shares are restricted and vested on December 31, 2024.

 

The Company recognized $197 thousand and $815 thousand, respectively, of stock-based compensation expense during the year ended December 31, 2024 in conjunction with the Separation Agreement Shares and 2024 Retention Incentive Shares, and does not expect future expense related to these issuances as they are fully vested. In conjunction with the 2024 Performance Incentive Shares, the Company recognized $244 thousand of stock-based compensation expense during the year ended December 31, 2024, and expects future expense related to these offerings to total $244 thousand in the year ending December 31, 2025.

 

The 2023 SBC Awards included 854 thousand shares of the Company’s common stock issued to 35 employees as payment in lieu of cash for 2022 performance bonuses (the “2023 Performance Incentive Shares”) and 1.5 million shares of the Company’s common stock as long-term incentive bonuses to five employees identified as key technical staff (the “2023 Retention Incentive Shares”). The 2023 Performance Incentive Shares are restricted and vested in equal halves on each of December 31, 2023 and 2024. As of December 31, 2024, the Company canceled 23,600 of the issued shares that were forfeited by employees no longer with the Company and does not expect future expense related to these offerings as they are fully vested. The 2023 Retention Incentive Shares are restricted and vest annually in equal amounts over a five-year period as follows: 20% vested or will vest on each December 31 of 2023, 2024, 2025, 2026 and 2027, subject to the grantee continuing to perform services for the Company in the capacity in which the grant was received on each applicable vesting date. In conjunction with the 2023 Performance Incentive Shares, the Company recognized $462 thousand of stock-based compensation expense during the year ended December 31, 2024 and does not expect future expense related to these offerings as they are fully vested. In conjunction with the 2023 Retention Incentive Shares, the Company recognized $533 thousand and $320 thousand, respectively, of stock-based compensation expense during the years ended December 31, 2024 and 2023, and expects future expense related to these offerings to total $1.3 million over the remaining vesting periods. 

Stock-based compensation for services

 

The Company recognized $23 thousand and $284 thousand, respectively, during the years ended December 31, 2024 and 2023 in stock-based compensation for services in lieu of cash payments to certain consultants, including expenses for both shares issued and stock option awards granted. For the years ended December 31, 2024 and 2023, the statement of stockholders’ equity was higher by $114 thousand and $2.2 million, respectively, as compared to the statement of cash flows for timing differences between award dates and the realization of stock-based compensation for services expense.

 

In terms of issuances, the Company issued 142 thousand shares of the Company’s common stock to various consultants for market and media advisory services in the year ending December 31, 2024, as compared to 1.6 million shares of the Company’s common stock in the year ending December 31, 2023 (the “2023 Advisor Shares”). The Company issued 1.5 million of the 2023 Advisor Shares to a consultant who served as an advisor on the QPhoton Merger (the “QPhoton Advisor Shares”), comprised of 750 thousand such shares to Draper, Inc. and 750 thousand such shares to Carriage House Capital, Inc, and issued 75 thousand of the 2023 Advisor Shares to FMW Media Works as compensation for services rendered in support of marketing and communications. For the QPhoton Advisor Shares, the expense was recognized in 2022 at the time of the merger, though the shares were not awarded and issued until 2023.

v3.25.1
Related Party Transactions
12 Months Ended
Dec. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions

Note 12 – Related Party Transactions

 

There were no related party transactions during the years ended December 31, 2024 and 2023. 

v3.25.1
Operating Leases
12 Months Ended
Dec. 31, 2024
Operating Leases [Abstract]  
Operating Leases

Note 13 – Operating Leases

 

As of December 31, 2024, the Company has use of space in three different locations, Hoboken, NJ, Tempe, AZ, and Arlington, VA, under lease or membership agreements, which expire at various dates through November 30, 2028. The Company’s leases do not provide an implicit rate, and the rates implicit in our leases are not readily determinable. Therefore, the Company uses its incremental borrowing rate as the discount rate when measuring operating lease assets and liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company’s leases all contain options to extend or renew the lease or membership term.

 

The table below reconciles the undiscounted future minimum lease payments under these operating leases to the total operating lease liabilities recognized on the consolidated balance sheet as of December 31, 2024 (in thousands):

 

Year  Lease Payments
Due
 
2025  $437 
2026   591 
2027   515 
2028   212 
Total minimum payments   1,755 
Less: imputed interest   (136)
Present value of operating lease liabilities   1,619 
Less: current portion included in other current liabilities   (438)
Long-term operating lease liabilities  $1,181 

Other information related to operating lease liabilities consists of the following:

 

   Year Ended December 31, 
   2024   2023 
         
Cash paid for operating lease liabilities  $385   $411 
Weighted average remaining lease term in years   3.3    3.7 
Weighted average discount rate   10%   10%
v3.25.1
License Agreement – Stevens Institute of Technology
12 Months Ended
Dec. 31, 2024
License Agreement – Stevens Institute of Technology [Abstract]  
License Agreement – Stevens Institute of Technology

Note 14 – License Agreement – Stevens Institute of Technology

 

Effective December 17th, 2020, QPhoton signed a License Agreement with the Stevens Institute. The License Agreement enables the Company to commercially use technology such as licensed patents, licensed patent applications and licensed “Know-How”. QPhoton is also able to issue sublicenses for the technology under the agreement. The agreement is effective until the later of: (i) the 30-year anniversary of the effective date, or (ii) the expiration of the licensed patent or licensed patent application that is last to expire. As part of the merger of the Company and QPhoton, the Stevens License Agreement was assigned to the Company.

 

During the term of the agreement and prior to any commercialization or sublicensing of the technology by the Company, the Company shall be required to submit annual reports to the Stevens Institute reporting on all research, development, and efforts toward commercialization and/or sublicensing made during the year. Once any commercialization and/or sublicensing has been initiated, the Company shall deliver quarterly reports to the Stevens Institute reporting on the revenue received by the Company, all sublicenses derived from the sale of licensed products, and the net sales price associated with each transaction. The Company will be responsible for reimbursing Stevens for any costs associated with the prosecution and maintenance of the licensed patents and licensed patent applications moving forward.

 

Consideration for the agreement

 

As consideration for the license and other rights granted under the agreement, QPhoton agreed to pay the following: (i) $35 thousand within 30 days of execution of the agreement, (ii) $28 thousand within 30 days of each annual anniversary of the effective date, (iii) equity in the Company equivalent to 9.0% of the membership units of the Company within 30 days of the execution of the agreement, and (iv) royalties of 3.5% of the Net Sales Price of each licensed product sold or licensed by the Company during the quarter then-ended, for which it also received payment, concurrent with the delivery of the relevant quarterly report.

 

As of December 31, 2024, the Company has begun to commercialize some of the licensed technology, though the Company has not recorded any related revenue and hence has not incurred any royalty expenses payable to the Stevens Institute.

v3.25.1
Subsequent Events
12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events

Note 15 – Subsequent Events:

 

On January 7, 2025, the Company entered into securities purchase agreements (the “January SPAs”) pursuant to which the Company agreed to issue, in a private placement (the “January Private Placement”), an aggregate of 8,163,266 shares (the “January Placement Shares”) of the Company’s common stock, par value $0.0001 per share, at a purchase price of $12.25 per share. The January SPAs required the Company to file a registration statement registering the resale of the January Placement Shares by January 24, 2025. The Company’s Registration Statement on Form S-1 (File No. 333-284416), to register resale of the the shares sold in this offering was filed on January 22, 2025 and became effective on February 3, 2025. The January Private Placement resulted in gross proceeds of approximately $100 million before deducting placement agent commissions and other offering expenses. The closing of the January Private Placement took place on January 9, 2025, following the satisfaction of customary closing conditions.

 

Pursuant to the January SPAs, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents, or file any registration statement or any amendment or supplement thereto, for a period of 75 days after the closing date of the January Private Placement, subject to certain customary exceptions, without the consent of the January SPAs purchasers and the January Placement Agent, as defined below.

The Company also entered into a placement agency agreement with Titan (the “January Placement Agent”), dated January 7, 2025, pursuant to which the January Placement Agent will act as the exclusive placement agent for the Company in connection with the January SPAs. The Company agreed to pay the January Placement Agent a cash fee of 6% of the gross proceeds from the January SPAs and to issue to the January Placement Agent (or its designees) 326,531 five-year warrants (representing 4% of the securities sold in the Placement), which will be exercisable beginning on July 6, 2025, and have an initial exercise price per share of the Company’s common Stock of $14.0875. In addition, the Company agreed to reimburse the January Placement Agent for up to $100,000 of its fees and expenses in connection with the January SPAs.

 

As a condition of the January SPAs, the Company’s directors and executive officers entered into Lock-Up Agreements with the Company pursuant to which they agreed for a period of 60 days after the closing date of the January SPAs, subject to certain exceptions, not to directly or indirectly offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position with respect to, any shares of the Company’s common stock or securities convertible, exchangeable or exercisable into the Company’s common stock, that they beneficially own, hold, or thereafter acquire, or make any demand for or exercise any right or cause to be filed a registration, including any amendments thereto, with respect to the registration of any the Company’s common stock or common stock equivalents or publicly disclose the intention to do any of the foregoing.

 

On January 28, 2025, the Delaware Chancery Court reassigned the BV Advisory appraisal action from Vice Chancellor Glasscock (following his retirement on January 15, 2025) to Vice Chancellor Bonnie David, effective as of that date.

 

On January 31, 2025, the Company filed a complaint in Delaware Chancery Court against BV Defendants (BV Advisory and its principal Keith Barksdale) asserting claims for defamation, breach of contract, conversion, aiding and abetting conversion, and misappropriation of trade secrets based on the BV Defendants’ unauthorized possession and dissemination of certain of the Company’s confidential and privileged documents. The Company seeks, among other relief, injunctive relief and damages. On February 11, 2025, the Court granted the Company’s motion for temporary restraining order and instructed the parties to negotiate an expedited case schedule. On February 13, 2025, the Court entered a stipulated case schedule that set a trial for April 8 and 9, 2025 on the Company’s claims for conversion, aiding and abetting conversion, and misappropriation of trade secrets.

 

On February 25, 2025, a class action lawsuit was filed against the Company and certain of its current and past officers in the New Jersey District Court, by a plaintiff seeking to represent a class of all persons who purchased the Company’s securities between March 30, 2020 and January 15, 2025, alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose material information about the Company’s customers, contracts and business operations. To date the New Jersey District Court has not certified a class or designated a lead plaintiff. The Company disputes the allegations in the complaint and intends to vigorously defend against the claims asserted.

 

In February 2025, the Company entered into arbitrations with two former consultants (two individuals) regarding forfeiture of stock options. The Company had issued stock options to the consultants in 2020 and 2021 and terminated the former consultants’ agreements in March 2024, at which time the Company informed the former consultants that any vested options had to be exercised within three months of the termination date, per the 2019 Plan and the 2022 Plan. The former consultants did not exercise their vested options, and the options were duly forfeited. In December 2024, the former consultants claimed that they still retained the right to exercise the options, which the Company rejected. The Company believes these claims are without merit and intends to defend itself vigorously.

 

There are no other events of a subsequent nature that in management’s opinion are reportable.

v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) $ (68,542) $ (27,022)
v3.25.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Rule 10b5-1Arr Modified Flag false
Non-Rule 10b5-1Arr Modified Flag false
v3.25.1
Insider Trading Policies and Procedures
3 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted false
v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

A robust and consistent approach to cybersecurity is critical to achieving our strategic business objectives and protecting our intellectual property. As an advanced technology company developing quantum photonic products, we face a wide range of cybersecurity threats such as ransomware and denial-of-service attacks that affect most industry sectors, to attacks from highly sophisticated adversaries, including nation state actors, that target dual-use advanced technologies such as quantum computing. Our customers, suppliers and other business partners face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially adversely affect our operations, performance and results of operations. We are continually evaluating best practices and methods to protect the Company from a wide range of potential threats. Due to the risks that these cybersecurity threats pose to our business, we are investing in cyber defense systems and training programs.

Cybersecurity Risk Board of Directors Oversight [Text Block] The Board, through the Risk Committee, oversees the Company’s processes for identifying and mitigating risks, including cybersecurity risks. Company management periodically briefs the Board on our cybersecurity and information security policies and plans, and the Board is apprised of cybersecurity incidents deemed to have a moderate or higher business impact. In the event of an incident, the Company has developed an incident response plan, which sets forth the steps to be followed from incident detection and assessment to mitigation, recovery and notification and reporting, including notifying functional areas (e.g. legal), as well as senior leadership and the Board, as appropriate
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Although we take cybersecurity risks seriously, we may not be successful in preventing or mitigating a cybersecurity incident that could have a material adverse effect on the Company.
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] true
Cybersecurity Risk Role of Management [Text Block]

We continue to evaluate our cybersecurity requirements to address the evolving cybersecurity risks that the Company faces in an increasingly technically capable environment. The Company has implemented policies for its personnel, including awareness programs, travel security programs and other related cybersecurity best practices. The information technology team manages the Company’s cybersecurity policies, including employee training, with the ultimate goal of preventing cybersecurity incidents, if possible, while also maintaining IT system performance and data integrity to minimize the business impact should an incident occur. The Company is coordinating closely with the Board’s Risk Committee to ensure that the Company will implement the appropriate cybersecurity technologies to protect the Company and its intellectual property.

Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Company management periodically briefs the Board on our cybersecurity and information security policies and plans, and the Board is apprised of cybersecurity incidents deemed to have a moderate or higher business impact.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
v3.25.1
Accounting Policies, by Policy (Policies)
12 Months Ended
Dec. 31, 2024
Significant Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation:

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (the “FASB”), including ASC 810, Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year end is December 31.

Risk and Uncertainties

Risk and Uncertainties

The Company is subject to certain risks and uncertainties and believes changes in any of the following areas could have a material adverse effect on the Company’s future consolidated financial position or consolidated results of operations or cash flows: new product development, including market receptivity; litigation or claims against the Company based on intellectual property, patent, product regulation or other factors; competition from other products; general economic conditions; the ability to attract and retain qualified employees; and, ultimately, to sustain profitable operations.

Reclassifications

Reclassifications

Certain reclassifications have been made to the fiscal year 2023 consolidated financial statements to conform ot the fiscal year 2024 presentation. The reclassifications had no impact on net loss, total assets, total liabilities, or stockholders’ equity.

Use of Estimates

Use of Estimates

These consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of goodwill and intangible assets, deferred tax assets, equity-based transactions and liquidity assessment. Actual results may differ from these estimates.

Segments

Segments

Our Chief Operating Decision Maker (“CODM”), the Chief Executive Officer, manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources and assess performance. Further, the CODM reviews and utilizes natural expenses, such as employee wages and benefits at a consolidated level, to manage the Company’s operations and strategic growth initiatives. Other segment items include interest income, interest expense, deferred offering costs, changes in fair value of derivative warrant liabilities and other operational expenses which are reflected in the consolidated statements of operations.

Cash and Cash Equivalents

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are considered to be cash equivalents. The Company maintains its cash in mutual funds and deposit and money market accounts with high quality financial institutions which, at times, may exceed federally insured limits. As of December 31, 2024 and December 31, 2023, the Company had $78.9 million and $960 thousand, respectively, in cash equivalents invested in mutual funds. The Company has not experienced any losses on these deposits and believes it is not exposed to significant credit risk on cash. 

Revenue

Revenue

The Company recognizes revenue in accordance with ASC 606 – Revenue from Contracts with Customers, by analyzing contracts with its customers using a five-step approach:

  1. Identify the contract;
     
  2. Identify the performance obligations;
     
  3. Determine the transaction price;
  4. Allocate the transaction price to the performance obligations; and
     
  5. Recognize revenue when performance obligations are satisfied.

The revenue the Company has recognized in the years ended December 31, 2024 and 2023 were primarily derived from contracts to perform professional services. Revenue from time and materials-based contracts is recognized as the direct hours worked during the period times the contractual hourly rate, plus direct materials and other direct costs as appropriate, plus negotiated materials handling burdens, if any. Revenue from units-based contracts is recognized as the number of units delivered or performed during the period times the contractual unit price. Revenue from fixed price contracts is recognized as work is performed with estimated profits recorded on a percentage of completion basis. The Company has no cost-plus type contracts at this time.

The Company includes depreciation and amortization expenses in manufacturing overhead, which is a component of cost of revenue. However, at the present time manufacturing overhead, including depreciation and amortization expense related to production equipment, is not material and the primary components of cost of revenue are direct labor and direct materials, with a small amount of shipping expenses.

The Company’s revenues consist of (in thousands):

   Year Ended December 31, 
   2024   2023   % Change 
Services  $346   $353    (2)%
Products   27    5    440%
Total  $373   $358    4%

The Company disaggregates revenue from contracts with customers based on the timing of transfer of goods or services to customers (point-in-time or over time) and geographic region based on the shipping location of the customer. The geographic regions that are tracked for the years ended December 31, 2024 and 2025 are the Americas and Europe.

Total net sales based on the disaggregation criteria described above are as follows (in thousands):

   Year Ended December 31, 
   2024   2023 
   Point-in-Time   Over Time   Total   Point-in-Time   Over Time   Total 
Americas  $27   $346   $373   $          5   $337   $342 
Europe   
-
    
-
    
-
    
-
    16    16 
Total  $27   $346   $373   $5   $353   $358 
Accounts Receivable

Accounts Receivable

Accounts receivable consists of amounts due from customers for work performed on contracts. The Company records accounts receivable at their net realizable value. Periodically, the Company evaluates its accounts receivable to establish a provision for credit losses, when deemed necessary, based on the history of past write-offs, collections and current credit conditions. The customer accounts receivable as of December 31, 2024 are considered not fully collectible and thus the Company has recorded a provision for credit losses of $3.5 thousand; the customer accounts receivable as of December 31, 2023 were considered fully collectible.

Provision for Credit Losses

Provision for Credit Losses

The Company estimates losses on loans and other financial instruments in accordance with Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 introduces the current expected credit losses (“CECL”) methodology for estimating allowances for credit losses. The CECL framework requires the Company to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supporting forecasts. Under CECL, the allowance for credit losses is measured as the difference between the financial asset’s cost basis and the net amount expected to be collected on the financial asset. CECL allows us to use information about past events including historical loan loss experience, current conditions, and reasonable and supportable forecasts to assess the collectability of the financial assets. The receivables for financial assets as of December 31, 2024 and 2023 are not considered fully collectible and thus management has recorded a provision for credit losses. See Note 9, Loan Receivable, for additional information.

Inventory

Inventory

Inventory is stated at the lower of cost or net realizable value. Cost is determined on a standard cost basis which approximates actual cost on a first in-first out method. Lower of cost or net realizable value is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory and are charged to cost of revenue. Once the cost of the inventory is reduced, a new lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Factors influencing these adjustments include changes in demand, product life cycle and development plans, component cost trends, product pricing, physical deterioration and quality issues. Revisions to these adjustments would be required if these factors differ from our estimates.

Operating Leases

Operating Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets are included in right-of-use assets, net on the consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current operating lease liabilities and non-current operating lease liabilities, respectively, on the consolidated balance sheets.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. All of our operating leases are comprised of office space leases, and as of December 31, 2024 and 2023, we had no finance leases.

Business Combinations and Valuation of Goodwill

Business Combinations and Valuation of Goodwill

We account for business combinations under the acquisition method of accounting. This method requires the recording of acquired assets and assumed liabilities at their acquisition date fair values. The excess of the purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Results of operations related to business combinations are included prospectively beginning with the date of acquisition and transaction costs related to business combinations are recorded withing general and administrative expenses.

The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company performs an annual impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to assess impairment, its common stock price is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit and can lead to potential impairment in future periods. The Company performed its annual impairment test during the second quarter of fiscal 2024 and 2023 and determined that its goodwill was not impaired. As of December 31, 2024 and 2023, we had not identified any factors that indicated there was an impairment of our goodwill and determined that no additional impairment analysis was then required.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost or contributed value. Depreciation of furniture, software and equipment is calculated using the straight-line method over their estimated useful lives, and leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the lease term. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as a gain or loss on sale of equipment. Maintenance and repairs are charged against expense as incurred.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company has long-lived assets such as tangible property and equipment, identified intangible assets consisting of acquired patents and core technology. When events or changes in circumstances occur that could indicate the carrying value of long-lived assets may not be recoverable, the Company assesses recoverability by determining whether the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. If the undiscounted cash flow is less, an impairment charge is recognized for the excess of the carrying amounts of these assets over the fair values. Fair values are determined by discounted future cash flows, appraisals or other methods.

During years ended December 31, 2024 and 2023, the Company did not record any impairment from long-lived assets.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying amount of certain financial instruments held by the Company, such as cash equivalents, accounts receivable, contract assets and liabilities, accounts payable, and accrued and other current liabilities, approximate fair value due to their short maturities. The carrying amount of the liabilities for the convertible preferred stock warrants represent their fair value. The carrying amounts of the Company’s borrowings and lease liabilities approximate fair value due to the market interest rates that these obligations bear and interest rates currently available to the Company.

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

  Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
  Level 2 Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
  Level 3 Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2024 and 2023, the Company had $78.9 million of the $78.9 million cash and cash equivalents and $960 thousand of the $2.1 million cash and cash equivalents, respectively, in Level 1 assets, comprised of U.S. Government mutual funds, and $40.5 million and no carrying value, respectively, for Level 3 liabilities, which are comprised of derivative and warrant liabilities. See Note 10, Capital Stock, for a full discussion of the warrant liability.

Research and Development Costs

Research and Development Costs

Research and development costs include costs directly attributable to the conduct of research and development programs, including the cost of services provided by outside contractors, acquiring work-in-progress intellectual property, development, and mandatory compliance fees and contractual obligations. All costs associated with research and development are expensed as incurred.

Software Development Costs

Software Development Costs

Software development costs incurred subsequent to the establishment of technological feasibility for software intended to be sold, licensed or otherwise marketed to customers will be capitalized, but development costs not meeting the criteria for capitalization are expensed as incurred. With respect to internal use software, the Company will capitalize such development costs incurred during the application development stage, but development costs incurred prior to that stage will be expensed as incurred. No amortization expense will be recorded until the software is ready for its intended use. To date, the Company has not incurred any material capitalizable software development costs.

Stock-based Compensation

Stock-based Compensation

Stock-based compensation expense for expected-to-vest awards is valued under the single-option approach and amortized on a straight-line basis, accounting for actual forfeitures as they occur. We utilize the Black Scholes pricing model in order to determine the fair value of stock-based option awards. The Black Scholes pricing model requires various highly subjective assumptions including volatility, expected option life, and risk-free interest rate. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future.

Income Taxes

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, management concludes that it is more-likely-than-not that the deferred tax assets will not be realized. Realization of deferred tax assets is also dependent upon future earnings, if any, the timing and amount of which are uncertain.

The Company records a liability for the uncertain tax positions taken or expected to be taken on the Company’s tax return when it is more-likely-than-not that the tax position might be challenged despite the Company’s belief that the tax return positions are fully supportable, and additional taxes will be due as a result. To the extent that the assessment of such tax positions changes, for example, based on the outcome of a tax audit, the change in estimate is recorded in the period in which the determination is made. The provision for income taxes includes the impact of provisions for uncertain tax positions.

Net Loss Per Share

Net Loss Per Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus the number of additional common shares that would have been outstanding if the common share equivalents had been issued (computed using the “If-Converted” method), unless the effect of such issuances would have been anti-dilutive.

The following table sets forth the computation of basic and diluted loss per share (in thousands, except for per share data):

   Year Ended
December 31,
 
   2024   2023 
Numerator:        
Net loss  $(68,542)  $(27,022)
Less: Series A convertible preferred stock dividends   
-
    861 
Net loss attributable to common stockholders – basic and diluted  $(68,542)  $(27,883)
Denominator:          
Weighted average shares used in computing net loss per common share – basic and diluted   93,881    66,611 
Net loss per common share – basic and diluted  $(0.73)  $(0.42)

Net loss per share is based on the weighted average number of common shares and common share equivalents outstanding during the period.

In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted common stock and warrants are excluded and diluted loss per share is equal to basic loss per share. Due to a net loss in the years ended December 31, 2024 and 2023, there were therefore no dilutive securities and hence basic and diluted loss per share were the same. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive (in thousands):

   Year Ended December 31, 
   2024   2023 
Warrants   2,583    6,053 
Options   12,907    12,280 
Unvested restricted common stock   2,997    1,192 
Total potentially dilutive shares   18,487    19,525 

As all potentially dilutive securities are anti-dilutive as of December 31, 2024 and 2023, diluted net loss per share is the same as basic net loss per share for each period.

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which amends reportable segment requirements, primarily through enhanced disclosures about significant segment expenses, including for public entities that have a single reportable segment. The standard is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning December 15, 2024. The Company adopted ASU 2023-07 on January 1, 2024 and have made the necessary reportable segment disclosures (See Note 3, Segment Reporting).

Recently Issued Accounting Pronouncements Not Yet Adopted

Recently Issued Accounting Pronouncements Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

On December 14, 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under ASU 2023-09, entities are required to uniformly classify and present greater disaggregation of information in the rate reconciliation and income taxes paid. ASU 2023-09 is intended to benefit users of our consolidated financial statements by improving transparency and decision usefulness of income tax disclosures. The new standard is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this new guidance to have a material impact on our consolidated financial statements and have decided not to early adopt ASU 2023-09.

v3.25.1
Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Significant Accounting Policies [Abstract]  
Schedule of Revenues

The Company’s revenues consist of (in thousands):

 

   Year Ended December 31, 
   2024   2023   % Change 
Services  $346   $353    (2)%
Products   27    5    440%
Total  $373   $358    4%
Schedule of Net Sales Based on the Disaggregation Criteria

Total net sales based on the disaggregation criteria described above are as follows (in thousands):

 

   Year Ended December 31, 
   2024   2023 
   Point-in-Time   Over Time   Total   Point-in-Time   Over Time   Total 
Americas  $27   $346   $373   $          5   $337   $342 
Europe   
-
    
-
    
-
    
-
    16    16 
Total  $27   $346   $373   $5   $353   $358 
Schedule of Computation of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per share (in thousands, except for per share data):

 

   Year Ended
December 31,
 
   2024   2023 
Numerator:        
Net loss  $(68,542)  $(27,022)
Less: Series A convertible preferred stock dividends   
-
    861 
Net loss attributable to common stockholders – basic and diluted  $(68,542)  $(27,883)
Denominator:          
Weighted average shares used in computing net loss per common share – basic and diluted   93,881    66,611 
Net loss per common share – basic and diluted  $(0.73)  $(0.42)
Schedule of Computation of Diluted Net Loss Per Common Share, as their Effect Would be Anti-Dilutive The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive (in thousands):
   Year Ended December 31, 
   2024   2023 
Warrants   2,583    6,053 
Options   12,907    12,280 
Unvested restricted common stock   2,997    1,192 
Total potentially dilutive shares   18,487    19,525 
v3.25.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Information of Revenue, Significant Expenses and Net Loss The following table presents segment information of revenue, significant expenses and net loss (in thousands):
   Year Ended December 31, 
   2024   2023 
Revenue  $373   $358 
Less:          
Salaries and employee related costs   9,534    9,745 
Stock-based compensation   5,805    4,555 
Rent and facilities   751    575 
Professional services and legal fees   2,959    3,963 
Technology & IT costs   1,062    1,198 
Other sales and marketing costs   734    1,471 
Direct and indirect materials   99    39 
Depreciation and amortization expense   3,798    3,307 
Other operational expenses   1,568    1,748 
Operating loss   (25,937)   (26,243)
Other income (expense)          
Interest expense   (254)   (602)
Interest and other income (expense) (1)   (1,819)   (705)
(Gain) loss on change in fair value of warrant liabilities   (40,532)   528 
Segment and net loss  $(68,542)  $(27,022)

 

(1)Includes interest income of $423 thousand and $295 thousand for the years ended December 31, 2024 and 2023, respectively.
v3.25.1
Intangible Assets, Net (Tables)
12 Months Ended
Dec. 31, 2024
Intangible Assets, Net [Abstract]  
Schedule of Amounts Related to Intangible Assets

As a result of the merger with QPhoton in June 2022, the Company has the following amounts related to intangible assets, net (in thousands):

 

   December 31, 2024   December 31, 2023 
   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount   Gross Carrying Amount   Accumulated Amortization   Net Carrying Amount 
Non-compete agreement with founder  $3,251   $(2,800)  $451   $3,251   $(1,715)  $1,536 
Website domain name and trademark   1,009    (521)   488    1,009    (320)   689 
Technology and licensed patents   12,731    (4,698)   8,033    12,731    (2,880)   9,851 
Total  $16,991   $(8,019)  $8,972   $16,991   $(4,915)  $12,076 
Schedule of Future Amortization Expense

The amortization expense of the Company’s intangible assets for both the years ended December 31, 2024 and 2023 was approximately $3.1 million. The Company expects future amortization expense to be the following (in thousands):

 

   Amortization 
2025  $2,472 
2026   2,021 
2027   1,903 
2028   1,819 
2029   757 
Thereafter   
-
 
Total  $8,972 
v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Taxes [Abstract]  
Schedule of U.S. Statutory Tax Rate to Effective Tax Rate A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:
   Year Ended December, 31 
   2024   2023   2022 
Federal statutory income tax rate   21.0%   21.0%   21.0%
State income taxes, net of federal benefit   (3.1)%   0.0%   0.0%
Warrant mark-to-market adjustments   (12.4)%   2.0%   2.7%
Change in business credits   0.5%   0.0%   0.0%
Other permanent differences   (0.1)%   (0.3)%   (0.1)%
True-ups   0.0%   0.0%   0.0%
Change in deferred tax asset valuation allowance   (6.0)%   (22.3)%   (23.7)%
Effective income tax rate   0.0%   0.4%   0.0%
Schedule of Unrecognized Tax Benefits Related to Research and Development Credit Carry forwards Therefore, any adjustments to these unrecognized tax benefits would be offset by corresponding adjustments to the valuation allowance, resulting in no impact on the consolidated balance sheet or statement of operations.
   December 31,
2024
 
Beginning balance as of December 31, 2023  $
-
 
Changes related to tax positions taken in the prior year   96,767 
Changes related to tax positions taken in the current year   167,774 
Ending balance as of December 31, 2024  $263,541 
v3.25.1
Property and Equipment, Net (Tables)
12 Months Ended
Dec. 31, 2024
Property and Equipment, Net [Abstract]  
Schedule of Property and Equipment

The Company’s property and equipment, net are primarily located at the Company’s leased facilities in Hoboken, NJ and Tempe, AZ and consist of (in thousands):

 

   December 31, 
Classification  2024   2023 
Computer and laboratory equipment  $8,438   $2,999 
Network equipment   29    29 
Furniture and fixtures   37    32 
Software   77    49 
Leasehold improvements   597    33 
Total cost of property and equipment   9,178    3,142 
Accumulated depreciation   966    272 
Property and equipment, net  $8,212   $2,870 

The Company began depreciating select property and equipment at the AZ Chips Facility as they were put in service during the year ended December 31, 2024, and recorded total depreciation expense of $694 thousand and $203 thousand during the years ended December 31, 2024 and 2023, respectively, using useful lives of the Company’s long-lived assets as follows:

 

   Estimated
Useful Life
(Years)
 
Computer and laboratory equipment   5 
Network equipment   4 
Furniture and fixtures   7 
Software   3 
Leasehold improvements   Lessor of lease term or 5 
v3.25.1
Financial Liabilities (Tables)
12 Months Ended
Dec. 31, 2024
Financial Liabilities [Abstract]  
Schedule of Outstanding Promissory Notes Payable to Financial Liabilities

 The Company has the following amounts related to financial liabilities (in thousands):

 

   December 31, 
   2024   2023 
Remaining loan balances  $
         -
   $2,063 
Remaining unamortized debt issuance costs   
-
    (138)
Financial liabilities, net  $
-
   $1,925 
v3.25.1
Capital Stock (Tables)
12 Months Ended
Dec. 31, 2024
Capital Stock [Abstract]  
Schedule of Warrants Outstanding

The table below summarizes the warrants outstanding at December 31, 2024 (in thousands, except exercise prices):

 

Issuance Date  Expiration Date  Exercise Price   Issued   Exercised   Forfeited /
Canceled
   Warrants
Outstanding
 
August 18, 2020  August 18, 2025  $2.00    171    (150)   
-
    21 
June 16, 2022  May 9, 2027  $0.0001    6,325    
-
    (4,121)   2,204 
November 18, 2024  November 18, 2029  $2.875    800    
-
    
-
    800 
December 12, 2024  December 12, 2029  $5.75    500    
-
    
-
    500 
v3.25.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Stock-Based Compensation [Abstract]  
Schedule of Option Activity

The following table summarizes the Company’s option activity for the year ended December 31, 2024 (in thousands, except exercise price and contractual life data):

 

   Number
Outstanding
   Weighted
Average
Exercise
Price per
Share
   Weighted
Average
Remaining
Contractual
Life (Years)
 
Balance as of January 1, 2023   9,165    3.51    4.2 
Granted   5,340    1.38    5.0 
Forfeited   (662)   4.41    - 
Balance as of December 31, 2023   13,843   $2.64    3.7 
Granted   830    0.92    5.0 
Forfeited   (1,690)   4.14    - 
Balance as of December 31, 2024   12,983   $2.34    2.9 
                
Vested and exercisable as of December 31, 2023   8,803    3.21    3.4 
Vested and exercisable as of December 31, 2024   9,646   $2.66    2.7 
Schedule of Grant-Date Fair Value of Stock Options Granted

The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December 31, 2024 and 2023:

 

   Year Ended 
   December 31, 
   2024   2023 
Exercise price  $0.46 – 1.12   $0.85 – 1.84 
Risk-free interest rate   4.2 – 5.2 %    4.7 – 5.0 % 
Expected volatility   90 – 105 %    98 – 137 % 
Expected dividend yield   0%   0%
Expected life of options (in years)   5.0    5.0 
Schedule of Exercise Price Range

The following table summarizes the exercise price range as of December 31, 2024 (in thousands):

 

Exercise Price  Outstanding
Options
   Exercisable
Options
 
$ 0.00 – 1.00   230    122 
$ 1.00 – 2.00   5,803    2,928 
$ 2.00 – 3.00   5,879    5,525 
$ 3.00 – 6.00   38    38 
$ 6.00 – 8.00   683    683 
$ 8.00 – 12.00   350    350 
    12,983    9,646 
Schedule of Activity for Restricted Stock The following table summarizes the Company’s activity for restricted stock tied to vesting schedules for the year ended December 31, 2024 (in thousands):
   Number
Outstanding
   Weighted
Average Fair
Value
 
Unvested as of January 1, 2023   50   $5.70 
Granted   2,429    1.36 
Vested   (1,046)   1.48 
Forfeited   (24)   1.28 
Unvested as of December 31, 2023   1,409   $1.42 
Granted   904    1.58 
Vested   (1,049)   1.82 
Unvested as of December 31, 2024   1,264   $1.20 
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock

The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):

 

   Year Ended 
   December 31, 
   2024   2023 
Research and development  $4,024   $2,080 
Selling and marketing   301    (279)
General and administrative   1,457    2,470 
Total stock-based compensation  $5,782   $4,271 
v3.25.1
Operating Leases (Tables)
12 Months Ended
Dec. 31, 2024
Operating Leases [Abstract]  
Schedule of Undiscounted Future Minimum Lease Payments Under Operating Leases

The table below reconciles the undiscounted future minimum lease payments under these operating leases to the total operating lease liabilities recognized on the consolidated balance sheet as of December 31, 2024 (in thousands):

 

Year  Lease Payments
Due
 
2025  $437 
2026   591 
2027   515 
2028   212 
Total minimum payments   1,755 
Less: imputed interest   (136)
Present value of operating lease liabilities   1,619 
Less: current portion included in other current liabilities   (438)
Long-term operating lease liabilities  $1,181 
Schedule of Other Information Related to Operating Lease Liabilities

Other information related to operating lease liabilities consists of the following:

 

   Year Ended December 31, 
   2024   2023 
         
Cash paid for operating lease liabilities  $385   $411 
Weighted average remaining lease term in years   3.3    3.7 
Weighted average discount rate   10%   10%
v3.25.1
Nature of the Organization and Business (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jan. 07, 2025
Jan. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Jul. 20, 2018
Nature of the Organization and Business [Line Items]          
Incorporation date     Jul. 20, 2018    
Common stock, par value (in Dollars per share)     $ 0.0001 $ 0.0001 $ 0.0001
Net proceeds     $ 106,766 $ 24,730  
Cash and cash equivalents     78,945 2,059  
Accumulated deficit     (200,482) $ (131,940)  
Working capital     $ 74,600    
Common Stock [Member]          
Nature of the Organization and Business [Line Items]          
Issuance of common shares (in Shares)     49,679,000 17,572,000  
Subsequent Event [Member]          
Nature of the Organization and Business [Line Items]          
Common stock, par value (in Dollars per share) $ 0.0001        
Issuance of common shares (in Shares) 8,163,266 8,163,266,000      
Net proceeds   $ 93,300      
v3.25.1
Significant Accounting Policies (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Significant Accounting Policies [Line Items]    
Cash equivalents invested in mutual funds $ 78,900,000 $ 960,000
Provision for credit losses 3,500  
Cash and cash equivalent 78,900,000 78,900,000
Level 1 Asset [Member]    
Significant Accounting Policies [Line Items]    
Cash and cash equivalent 960,000 2,100,000
Level 3 Liabilities [Member]    
Significant Accounting Policies [Line Items]    
Cash and cash equivalent $ 40,500,000
v3.25.1
Significant Accounting Policies - Schedule of Revenues (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Revenues [Line Items]    
Percentage of change 4.00%  
Total revenue $ 373 $ 358
Services [Member]    
Schedule of Revenues [Line Items]    
Revenue $ 346 353
Percentage of change (2.00%)  
Products [Member]    
Schedule of Revenues [Line Items]    
Revenue $ 27 $ 5
Percentage of change 440.00%  
v3.25.1
Significant Accounting Policies - Schedule of Net Sales Based on the Disaggregation Criteria (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Total net sales $ 373 $ 358
Americas [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Net sales 373 342
Europe [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Net sales 16
Point-in-Time [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Total net sales 27 5
Point-in-Time [Member] | Americas [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Net sales 27 5
Point-in-Time [Member] | Europe [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Net sales
Over Time [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Total net sales 346 353
Over Time [Member] | Americas [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Net sales 346 337
Over Time [Member] | Europe [Member]    
Schedule of Net Sales Based on the Disaggregation Criteria [Line Items]    
Net sales $ 16
v3.25.1
Significant Accounting Policies - Schedule of Computation of Basic and Diluted Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Numerator:    
Net loss $ (68,542) $ (27,022)
Less: Series A convertible preferred stock dividends 861
Net loss attributable to common stockholders – basic (68,542) (27,883)
Net loss attributable to common stockholders – Diluted $ (68,542) $ (27,883)
Denominator:    
Weighted average shares used in computing net loss per common share – basic (in Shares) 93,881 66,611
Weighted average shares used in computing net loss per common share – Diluted (in Shares) 93,881 66,611
Net loss per common share – basic (in Dollars per share) $ (0.73) $ (0.42)
Net loss per common share – Diluted (in Dollars per share) $ (0.73) $ (0.42)
v3.25.1
Significant Accounting Policies - Schedule of Computation of Diluted Net Loss Per Common Share, as their Effect Would be Anti-Dilutive (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Computation of Diluted Net Loss Per Common Share, as Their Effect Would be Anti-Dilutive [Line Items]    
Weighted average common stock on anti-dilutive securities 18,487 19,525
Warrants [Member]    
Schedule of Computation of Diluted Net Loss Per Common Share, as Their Effect Would be Anti-Dilutive [Line Items]    
Weighted average common stock on anti-dilutive securities 2,583 6,053
Options [Member]    
Schedule of Computation of Diluted Net Loss Per Common Share, as Their Effect Would be Anti-Dilutive [Line Items]    
Weighted average common stock on anti-dilutive securities 12,907 12,280
Unvested restricted common stock [Member]    
Schedule of Computation of Diluted Net Loss Per Common Share, as Their Effect Would be Anti-Dilutive [Line Items]    
Weighted average common stock on anti-dilutive securities 2,997 1,192
v3.25.1
Segment Reporting (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Segment Reporting [Abstract]    
Number of operating segment 1  
Interest income $ 423 $ 295
v3.25.1
Segment Reporting - Schedule of Segment Information of Revenue, Significant Expenses and Net Loss (Details) - Chief Operating Decision Maker [Member] - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Segment Information of Revenue, Significant Expenses and Net Loss [Line Items]    
Revenue $ 373 $ 358
Less:    
Salaries and employee related costs 9,534 9,745
Stock-based compensation 5,805 4,555
Rent and facilities 751 575
Professional services and legal fees 2,959 3,963
Technology & IT costs 1,062 1,198
Other sales and marketing costs 734 1,471
Direct and indirect materials 99 39
Depreciation and amortization expense 3,798 3,307
Other operational expenses 1,568 1,748
Loss from operations (25,937) (26,243)
Other income (expense)    
Interest expense (254) (602)
Interest and other income (expense) [1] (1,819) (705)
(Gain) loss on change in fair value of warrant liabilities (40,532) 528
Net loss $ (68,542) $ (27,022)
[1] Includes interest income of $423 thousand and $295 thousand for the years ended December 31, 2024 and 2023, respectively.
v3.25.1
Intangible Assets, Net (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Intangible Assets, Net [Abstract]    
Amortization expense of intangible assets $ 3.1 $ 3.1
v3.25.1
Intangible Assets, Net - Schedule of Amounts Related to Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Schedule of Amounts Related to Intangible Assets [Line Items]    
Gross Carrying Amount $ 16,991 $ 16,991
Accumulated Amortization (8,019) (4,915)
Net Carrying Amount 8,972 12,076
Non-compete agreement with founder [Member]    
Schedule of Amounts Related to Intangible Assets [Line Items]    
Gross Carrying Amount 3,251 3,251
Accumulated Amortization (2,800) (1,715)
Net Carrying Amount 451 1,536
Website domain name and trademark [Member]    
Schedule of Amounts Related to Intangible Assets [Line Items]    
Gross Carrying Amount 1,009 1,009
Accumulated Amortization (521) (320)
Net Carrying Amount 488 689
Technology and licensed patents [Member]    
Schedule of Amounts Related to Intangible Assets [Line Items]    
Gross Carrying Amount 12,731 12,731
Accumulated Amortization (4,698) (2,880)
Net Carrying Amount $ 8,033 $ 9,851
v3.25.1
Intangible Assets, Net - Schedule of Future Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Schedule of Future Amortization Expense [Abstract]    
2025 $ 2,472  
2026 2,021  
2027 1,903  
2028 1,819  
2029 757  
Thereafter  
Total $ 8,972 $ 12,076
v3.25.1
Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Taxes [Abstract]        
Federal income tax rate 21.00% 21.00% 21.00%  
Federal operating loss carryforwards $ 89,000      
State net operating loss carryforwards $ 7,000      
Taxable income rate       80.00%
Cumulative change percentage 50.00%      
Tax-effected carryforwards $ 89,400 $ 13,000    
Carryforwards assumed tax rate 30.00% 26.00%    
Deferred tax assets included stock-based compensation $ 14,000 $ 11,000    
Capitalized research and development expenditures 3,000 $ 2,000    
Valuation allowance increased 16,000      
Federal R&D credit carryforwards $ 878      
v3.25.1
Income Taxes - Schedule of U.S. Statutory Tax Rate to Effective Tax Rate (Details)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Schedule of U.S. Statutory Tax Rate to Effective Tax Rate [Abstract]      
Federal statutory income tax rate 21.00% 21.00% 21.00%
State income taxes, net of federal benefit (3.10%) 0.00% 0.00%
Warrant mark-to-market adjustments (12.40%) 2.00% 2.70%
Change in business credits 0.50% 0.00% 0.00%
Other permanent differences (0.10%) (0.30%) (0.10%)
True-ups 0.00% 0.00% 0.00%
Change in deferred tax asset valuation allowance (6.00%) (22.30%) (23.70%)
Effective income tax rate 0.00% 0.40% 0.00%
v3.25.1
Income Taxes - Schedule of Unrecognized Tax Benefits Related to Research and Development Credit Carry forwards (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2024
USD ($)
Schedule of Unrecognized Tax Benefits Related to Research and Development Credit Carry forwards [Abstract]  
Beginning balance as of December 31, 2023
Changes related to tax positions taken in the prior year 96,767
Changes related to tax positions taken in the current year 167,774
Ending balance as of December 31, 2024 $ 263,541
v3.25.1
Property and Equipment, Net (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Property and Equipment [Abstract]    
Increase in property and equipment $ 6,000  
Depreciation expense 694 $ 203
Property and equipment service $ 5,400  
v3.25.1
Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Schedule of Property and Equipment [Line Items]    
Total cost of property and equipment $ 9,178 $ 3,142
Accumulated depreciation 966 272
Property and equipment, net 8,212 2,870
Computer and laboratory equipment [Member]    
Schedule of Property and Equipment [Line Items]    
Total cost of property and equipment $ 8,438 2,999
Estimated Useful Life 5 years  
Network equipment [Member]    
Schedule of Property and Equipment [Line Items]    
Total cost of property and equipment $ 29 29
Estimated Useful Life 4 years  
Furniture and fixtures [Member]    
Schedule of Property and Equipment [Line Items]    
Total cost of property and equipment $ 37 32
Estimated Useful Life 7 years  
Software [Member]    
Schedule of Property and Equipment [Line Items]    
Total cost of property and equipment $ 77 49
Estimated Useful Life 3 years  
Leasehold improvements [Member]    
Schedule of Property and Equipment [Line Items]    
Total cost of property and equipment $ 597 $ 33
Estimated Useful Life (Years) Lessor of lease term or 5  
v3.25.1
Financial Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Aug. 06, 2024
Sep. 23, 2022
Apr. 01, 2022
Dec. 31, 2024
Dec. 31, 2023
Feb. 18, 2022
Financial Liabilities [Line Items]            
Accrued interest payable       $ 14  
Received fee $ 450          
Other issuance costs 55          
Principal balance     $ 1,250     $ 1,250
Loans assumed     $ 2,500      
Percentage of interest rate     15.00%     15.00%
Secured SPA [Member]            
Financial Liabilities [Line Items]            
Principal amount 8,250          
Original issue discount 750          
Payment in cash $ 7,500          
Maturity date Feb. 06, 2026          
Streeterville [Member]            
Financial Liabilities [Line Items]            
Interest percentage 10.00%          
Streeterville Unsecured Note [Member]            
Financial Liabilities [Line Items]            
Interest percentage   10.00%        
Initial principal amount   $ 8,250        
Maturity date   18 months        
Original issue discount   $ 750        
Elected to prepay   120.00%        
Outstanding balance       $ 1,900  
QCi Note Purchase Agreement [Member]            
Financial Liabilities [Line Items]            
Initial principal amount           $ 1,250
Percentage of interest rate     6.00%     6.00%
v3.25.1
Financial Liabilities - Schedule of Outstanding Promissory Notes Payable to Financial Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Schedule of Outstanding Promissory Notes Payable to Financial Liabilities [Abstract]    
Remaining loan balances $ 2,063
Remaining unamortized debt issuance costs (138)
Financial liabilities, net $ 1,925
v3.25.1
Contingencies (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Nov. 18, 2024
Oct. 13, 2022
Contingencies [Line Items]        
Other current liabilities (in Dollars) $ 974 $ 786    
Fair market valuation contemplated shares 31,299,417      
Conversion shares 2,377,028      
Warrants to purchase shares 7,028,337      
Exercise price per share (in Dollars per share)     $ 2.875  
Warrant liability (in Dollars) $ 40,500    
BV Advisory [Member]        
Contingencies [Line Items]        
Other current liabilities (in Dollars) $ 536 $ 536    
QPhoton Warrants [Member]        
Contingencies [Line Items]        
Converted shares 36,600,823      
Warrants [Member]        
Contingencies [Line Items]        
Warrants to purchase shares 1,726,931      
Exercise price per share (in Dollars per share) $ 2.27      
QPhoton Warrants [Member]        
Contingencies [Line Items]        
Warrants to purchase shares 702,834      
BV Advisory Partners, LLC [Member]        
Contingencies [Line Items]        
Purchase price percentage       10.00%
Series B Preferred Stock [Member]        
Contingencies [Line Items]        
Total purchase price (in Dollars) $ 69,900      
Unissued QPhoton Shares [Member]        
Contingencies [Line Items]        
Converted shares 2,957,251 2,957,251    
Common Stock [Member]        
Contingencies [Line Items]        
Total purchase price (in Dollars) $ 71,000      
Converted shares 745,000      
v3.25.1
Loan Receivable (Details) - USD ($)
$ in Thousands
Jun. 06, 2023
Mar. 18, 2025
Dec. 31, 2024
May 16, 2023
Loan Receivable [Line Items]        
Outstanding reserve     $ 558  
Uncollected receivables     $ 558  
Millionways [Member]        
Loan Receivable [Line Items]        
Acquire, percentage of AI firm       100.00%
Unsecured Promissory Notes [Member]        
Loan Receivable [Line Items]        
Aggregate principal amount $ 2,000      
MW Agreement [Member]        
Loan Receivable [Line Items]        
Aggregate principal amount $ 500      
MW Note [Member]        
Loan Receivable [Line Items]        
Bears simple interest 10.00%      
Annual interest rate 15.00%      
Subsequent Event [Member]        
Loan Receivable [Line Items]        
Uncollected receivables   $ 658    
v3.25.1
Capital Stock (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 10, 2024
Nov. 30, 2024
Nov. 18, 2024
Nov. 14, 2024
Mar. 19, 2024
Feb. 09, 2023
Jun. 16, 2022
Jun. 13, 2022
Nov. 17, 2021
Dec. 31, 2024
Dec. 31, 2023
Jul. 05, 2022
Jul. 20, 2018
Capital Stock [Line Items]                            
Purchase of warrants 7,028,337                   7,028,337      
Aggregate purchase price (in Dollars)   $ 500,000                        
Conversion price per share (in Dollars per share) $ 5.5         $ 5.5         $ 5.5      
Warrants term 2 years                   2 years      
Exercise price (in Dollars per share)       $ 2.875                    
Aggregate cash purchase (in Dollars)                     $ (8,195,000)      
Price of per share (in Dollars per share)         $ 2.5                  
Shares of common stock   1,540,000     16,000,000                  
Common stock par value per share (in Dollars per share) $ 0.0001                   $ 0.0001 $ 0.0001   $ 0.0001
Other offering expenses (in Dollars)         $ 40,000,000                  
Convertible note (in Dollars)       $ 9,300,000                    
Cash fee percentage       7.25%                    
Securities sold percentage       5.00%                    
Fee and expenses (in Dollars)   $ 100,000   $ 100,000                    
Placement shares   8,460,000                        
Common stock exercise price (in Dollars per share)   $ 5                        
Gross proceeds from placement (in Dollars)   $ 42,300,000                        
Percentage of cash fee   7.00%                        
Percentage of securities sold offerings   5.00%                        
Issued warrants shares               6,300,000            
Exercise price per share (in Dollars per share)               $ 0.0001            
Issued warrants price (in Dollars)                     $ 6,300,000      
Warrants (in Dollars)                     $ 7,000,000      
Due to forfeitures                     457,926      
Forfeited percentage                     65.00%      
Recognized mark-to-market gains (in Dollars)                     $ 40,532,000 $ (528,000)    
Warrant liability (in Dollars) $ 40,500,000                   $ 40,500,000    
December Placement Agent [Member]                            
Capital Stock [Line Items]                            
Exercise price (in Dollars per share)   $ 5.75                        
QPhoton Warrants [Member]                            
Capital Stock [Line Items]                            
Shares converted                     36,600,823      
Issued warrants price (in Dollars)                     $ 6,300,000      
Preferred Stock [Member]                            
Capital Stock [Line Items]                            
Shares converted                     (745,000)      
Aggregate cash purchase (in Dollars)                          
Redeemed, shares                     745,000      
Common Stock [Member]                            
Capital Stock [Line Items]                            
Shares converted                     745,000      
Aggregate cash purchase (in Dollars)                          
Redeemed, shares                          
Shares of common stock                         1,000,000  
Restricted Stock Units (RSUs) [Member]                            
Capital Stock [Line Items]                            
Purchase of warrants                       171,000    
Warrants term                       5 years    
Exercise price (in Dollars per share)                       $ 2    
Ascendiant Capital Markets [Member]                            
Capital Stock [Line Items]                            
Average price per share (in Dollars per share) $ 1.21                   $ 1.21      
Proceeds from market facility (in Dollars)                     $ 48,500,000      
Ascendiant Capital Markets [Member] | Common Stock [Member]                            
Capital Stock [Line Items]                            
Sale of common stock                     23,679,391 17,571,926    
QPhoton Merger [Member]                            
Capital Stock [Line Items]                            
Issuance of warrant 702,834                   702,834      
Series A Preferred Stock [Member]                            
Capital Stock [Line Items]                            
Preferred stock, share authorized 1,550,000                   1,550,000 1,550,000    
Preferred stock, par value (in Dollars per share) $ 0.0001                 $ 0.0001 $ 0.0001 $ 0.0001    
Preferred stock, shares issued                   1,490,004    
Preferred stock, shares outstanding                   1,490,004    
Purchased shares                   1,545,459        
Aggregate purchase price (in Dollars)                   $ 8,500,000        
Preferred dividends percentage                     10.00%      
Shares converted 744,957   744,957                      
Additional paid in capital (in Dollars)           $ 8,125,000                
Aggregate cash purchase (in Dollars)           $ 8,195,000                
Price of per share (in Dollars per share)           $ 5.5                
Redeemed, shares                     745,047      
Cash paid (in Dollars)                     $ 4,100,000      
Series A Preferred Stock [Member] | Preferred Warrants [Member]                            
Capital Stock [Line Items]                            
Purchase of warrants                   1,545,459        
Series A Preferred Stock [Member] | Preferred Stock [Member]                            
Capital Stock [Line Items]                            
Preferred stock, shares issued                        
Preferred stock, shares outstanding                        
Series A Preferred Stock [Member] | Falcon Capital Partners [Member]                            
Capital Stock [Line Items]                            
Shares converted                 45,455          
Series A Preferred Stock [Member] | Greenfield Children, LLC, [Member]                            
Capital Stock [Line Items]                            
Shares converted             10,000              
Series B Preferred Stock [Member]                            
Capital Stock [Line Items]                            
Preferred stock, share authorized 3,080,000                   3,080,000 3,080,000    
Preferred stock, shares issued                      
Preferred stock, shares outstanding                      
Series B Preferred Stock [Member] | Preferred Stock [Member]                            
Capital Stock [Line Items]                            
Preferred stock, share authorized 3,079,864                   3,079,864 3,079,864    
Preferred stock, par value (in Dollars per share) $ 0.0001                   $ 0.0001 $ 0.0001    
Preferred stock, shares issued                      
Preferred stock, shares outstanding                      
Common Stock [Member]                            
Capital Stock [Line Items]                            
Exercise price (in Dollars per share) $ 7                   $ 7      
Common stock par value per share (in Dollars per share)   0.0001     $ 0.0001                  
Common Stock [Member] | Falcon Capital Partners [Member]                            
Capital Stock [Line Items]                            
Shares converted                 47,728          
Common Stock [Member] | Greenfield Children, LLC, [Member]                            
Capital Stock [Line Items]                            
Shares converted             11,096              
At-the-Market Facility [Member]                            
Capital Stock [Line Items]                            
Proceeds from market facility (in Dollars)                     $ 23,800,000 $ 24,700,000    
Sales of equity (in Dollars)                     106,800,000      
Warrant [Member]                            
Capital Stock [Line Items]                            
Aggregate purchase price (in Dollars)       $ 800,000                    
Warrant liability (in Dollars) $ 40,500,000                   $ 40,500,000 40,500,000    
Private Placement [Member]                            
Capital Stock [Line Items]                            
Price of per share (in Dollars per share)   $ 5                        
Registered Direct Offering [Member]                            
Capital Stock [Line Items]                            
Gross proceeds from placement (in Dollars)   $ 7,700,000                        
Sales of equity (in Dollars)                       $ 24,700,000    
v3.25.1
Capital Stock - Schedule of Warrants Outstanding (Details) - Warrant [Member]
shares in Thousands
12 Months Ended
Dec. 31, 2024
$ / shares
shares
August 18, 2020 [Member]  
Schedule of Warrants Outstanding [Line Items]  
Expiration Date Aug. 18, 2025
Exercise Price (in Dollars per share) | $ / shares $ 2
Issued 171
Exercised (150)
Forfeited / Canceled
Warrants Outstanding 21
June 16, 2022 [Member]  
Schedule of Warrants Outstanding [Line Items]  
Expiration Date May 09, 2027
Exercise Price (in Dollars per share) | $ / shares $ 0.0001
Issued 6,325
Exercised
Forfeited / Canceled (4,121)
Warrants Outstanding 2,204
November 18, 2024 [Member]  
Schedule of Warrants Outstanding [Line Items]  
Expiration Date Nov. 18, 2029
Exercise Price (in Dollars per share) | $ / shares $ 2.875
Issued 800
Exercised
Forfeited / Canceled
Warrants Outstanding 800
December 12, 2024 [Member]  
Schedule of Warrants Outstanding [Line Items]  
Expiration Date Dec. 12, 2029
Exercise Price (in Dollars per share) | $ / shares $ 5.75
Issued 500
Exercised
Forfeited / Canceled
Warrants Outstanding 500
v3.25.1
Stock-Based Compensation (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Jul. 05, 2022
shares
Dec. 31, 2027
Dec. 31, 2026
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Employees
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 10, 2024
shares
Nov. 14, 2024
shares
Stock-based Compensation [Line Items]                
Reserved for issuance             1,540,000 16,000,000
Common stock shares outstanding         129,012,000 77,451,000    
Common stock shares issued         129,012,000 77,451,000    
Weighted average grant-date fair value of stock options granted (in Dollars per share) | $ / shares         $ 0.92 $ 1.38    
Stock-based compensation (in Dollars) | $         $ 1,500 $ 33    
Stock-based compensation expense (in Dollars) | $         $ 5,782 4,271    
Issued shares forfeited         457,926      
Stock-based compensation for services (in Dollars) | $         $ 23 $ 284    
Number of shares issued for services         142,000 1,600,000    
2023 Retention Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Vesting percentage         20.00% 20.00%    
Options [Member]                
Stock-based Compensation [Line Items]                
Weighted average grant-date fair value of stock options granted (in Dollars per share) | $ / shares         $ 0.92 $ 1.38    
Unrecognized compensation (in Dollars) | $           $ 3,100    
Recognized period         3 years      
Separation Agreement Shares [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         218,000      
Common Stock [Member]                
Stock-based Compensation [Line Items]                
Reserved for issuance 1,000,000              
Number of shares issued         49,679,000 17,572,000    
Realization of stock-based compensation expense (in Dollars) | $         $ 114 $ 2,200    
2019 Equity and Incentive Plan [Member]                
Stock-based Compensation [Line Items]                
Grant incentive stock options         3,000,000      
2022 Equity and Incentive Plan [Member]                
Stock-based Compensation [Line Items]                
Shares issued 16,000,000              
Reserved for issuance         18,000,000      
Common stock shares outstanding         13,000,000      
Common stock shares issued         13,000,000      
QPhoton Merger [Member]                
Stock-based Compensation [Line Items]                
Shares issued           750,000    
Carriage House Capital, Inc [Member]                
Stock-based Compensation [Line Items]                
Shares issued           750,000    
F M W Media Work [Member]                
Stock-based Compensation [Line Items]                
Shares issued           75,000    
QPhoton Merger [Member]                
Stock-based Compensation [Line Items]                
Shares issued           1,500,000    
Restricted Stock [Member] | 2022 Equity and Incentive Plan [Member]                
Stock-based Compensation [Line Items]                
Shares issued         1,300,000      
2024 SBC Awards [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         995,000 2,300,000    
2024 SBC Awards [Member] | Common Stock [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         727,000      
Performance and Incentive Awards [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         777,000      
2023 Performance Bonuses [Member]                
Stock-based Compensation [Line Items]                
Number of employees (in Employees) | Employees         30      
2024 Retention Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         50,000      
Number of employees (in Employees) | Employees         5      
2024 Retention Incentive Shares [Member] | Separation Agreement Shares [Member]                
Stock-based Compensation [Line Items]                
Stock-based compensation expense (in Dollars) | $         $ 197 $ 815    
2024 Performance Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Stock-based compensation expense (in Dollars) | $         $ 244      
2023 SBC Awards [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         854,000      
Number of employees (in Employees) | Employees         35      
Stock-based compensation expense (in Dollars) | $           1,300    
Issued shares forfeited         23,600      
2023 Retention Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Number of shares issued         1,500,000      
Number of employees (in Employees) | Employees         5      
Stock-based compensation expense (in Dollars) | $         $ 533 $ 320    
2023 Performance Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Stock-based compensation expense (in Dollars) | $         $ 462      
Forecast [Member] | 2023 Retention Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Vesting percentage   20.00% 20.00% 20.00%        
Forecast [Member] | 2024 Performance Incentive Shares [Member]                
Stock-based Compensation [Line Items]                
Stock-based compensation expense (in Dollars) | $       $ 244        
v3.25.1
Stock-Based Compensation - Schedule of Option Activity (Details) - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Schedule Of Option Activity [Abstract]      
Number Outstanding, Balance 9,165 12,983 13,843
Weighted Average Exercise Price per Share, Balance $ 3.51 $ 2.34 $ 2.64
Weighted Average Remaining Contractual Life (Years), Balance 4 years 2 months 12 days 2 years 10 months 24 days 3 years 8 months 12 days
Number Outstanding, Vested and exercisable   9,646 8,803
Weighted Average Exercise Price per Share, Vested and exercisable   $ 2.66 $ 3.21
Weighted Average Remaining Contractual Life (Years), Vested and exercisable   2 years 8 months 12 days 3 years 4 months 24 days
Number Outstanding, Granted   830 5,340
Weighted Average Exercise Price per Share, Granted   $ 0.92 $ 1.38
Weighted Average Remaining Contractual Life (Years), Granted   5 years 5 years
Number Outstanding, Forfeited   (1,690) (662)
Weighted Average Exercise Price per Share, Forfeited   $ 4.14 $ 4.41
v3.25.1
Stock-Based Compensation - Schedule of Grant-Date Fair Value of Stock Options Granted (Details) - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Grant-Date Fair Value of Stock Options Granted [Line Items]    
Expected dividend yield 0.00% 0.00%
Expected life of options (in years) 5 years 5 years
Minimum [Member]    
Schedule of Grant-Date Fair Value of Stock Options Granted [Line Items]    
Exercise price (in Dollars per share) $ 0.46 $ 0.85
Risk-free interest rate 4.20% 4.70%
Expected volatility 90.00% 98.00%
Maximum [Member]    
Schedule of Grant-Date Fair Value of Stock Options Granted [Line Items]    
Exercise price (in Dollars per share) $ 1.12 $ 1.84
Risk-free interest rate 5.20% 5.00%
Expected volatility 105.00% 137.00%
v3.25.1
Stock-Based Compensation - Schedule of Exercise Price Range (Details) - shares
shares in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 12,983 13,843 9,165
Exercisable Options 9,646 8,803  
0.00 – 1.00 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 230    
Exercisable Options 122    
1.00 – 2.00 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 5,803    
Exercisable Options 2,928    
2.00 – 3.00 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 5,879    
Exercisable Options 5,525    
3.00 – 6.00 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 38    
Exercisable Options 38    
6.00 – 8.00 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 683    
Exercisable Options 683    
8.00 – 12.00 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Outstanding Options 350    
Exercisable Options 350    
v3.25.1
Stock-Based Compensation - Schedule of Activity for Restricted Stock (Details) - Restricted Stock [Member] - $ / shares
shares in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Activity for Restricted Stock [Abstract]    
Number Outstanding, Balance 1,409 50
Weighted Average Fair Value, Balance $ 1.42 $ 5.7
Number Outstanding, Granted 904 2,429
Weighted Average Fair Value, Granted $ 1.58 $ 1.36
Number Outstanding, Vested (1,049) (1,046)
Weighted Average Fair Value, Vested $ 1.82 $ 1.48
Number Outstanding, Forfeited   (24)
Weighted Average Fair Value, Forfeited   $ 1.28
Number Outstanding, Balance 1,264 1,409
Weighted Average Fair Value, Balance $ 1.2 $ 1.42
v3.25.1
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock [Line Items]    
Total stock-based compensation $ 5,782 $ 4,271
Research and Development [Member]    
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock [Line Items]    
Total stock-based compensation 4,024 2,080
Selling and Marketing [Member]    
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock [Line Items]    
Total stock-based compensation 301 (279)
General and Administrative [Member]    
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock [Line Items]    
Total stock-based compensation $ 1,457 $ 2,470
v3.25.1
Operating Leases (Details)
Dec. 31, 2024
Operating Leases [Abstract]  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating lease liabilities
v3.25.1
Operating Leases - Schedule of Undiscounted Future Minimum Lease Payments Under Operating Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Schedule of Undiscounted Future Minimum Lease Payments Under Operating Leases [Abstract]    
2025 $ 437  
2026 591  
2027 515  
2028 212  
Total minimum payments 1,755  
Less: imputed interest (136)  
Present value of operating lease liabilities 1,619  
Less: current portion included in other current liabilities (438)  
Long-term operating lease liabilities $ 1,181 $ 840
v3.25.1
Operating Leases - Schedule of Other Information Related to Operating Lease Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Schedule of Other Information Related Operating Lease Liabilities [Abstract]    
Cash paid for operating lease liabilities $ 385 $ 411
Weighted average remaining lease term in years 3 years 3 months 18 days 3 years 8 months 12 days
Weighted average discount rate 10.00% 10.00%
v3.25.1
License Agreement – Stevens Institute of Technology (Details)
12 Months Ended
Dec. 31, 2024
License Agreement – Stevens Institute of Technology [Abstract]  
Consideration agreement, description As consideration for the license and other rights granted under the agreement, QPhoton agreed to pay the following: (i) $35 thousand within 30 days of execution of the agreement, (ii) $28 thousand within 30 days of each annual anniversary of the effective date, (iii) equity in the Company equivalent to 9.0% of the membership units of the Company within 30 days of the execution of the agreement, and (iv) royalties of 3.5% of the Net Sales Price of each licensed product sold or licensed by the Company during the quarter then-ended, for which it also received payment, concurrent with the delivery of the relevant quarterly report.
v3.25.1
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
1 Months Ended
Jan. 07, 2025
Jan. 31, 2025
Subsequent Events [Line Items]    
Issuance of common shares (in Shares) 8,163,266 8,163,266,000
Common share par value $ 0.0001  
Price per share $ 12.25  
Gross proceeds (in Dollars) $ 100,000,000  
Cash fee percentage 6.00%  
Number of warrants issued (in Shares) 326,531  
Warrant outstanding term term 5 years  
Securities sold 4.00%  
Exercise price $ 14.0875  
Fees and expenses (in Dollars) $ 100,000  

Grafico Azioni Quantum Computing (NASDAQ:QUBT)
Storico
Da Mar 2025 a Mar 2025 Clicca qui per i Grafici di Quantum Computing
Grafico Azioni Quantum Computing (NASDAQ:QUBT)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Quantum Computing